(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Concomitant) (NN drug2) (NN administration)) (VP (VBD decreased) (NP (NP (DT the) (JJ mean) (NN AUC)) (PP (IN of) (NP (NN total))) (PP (IN drug3) (NP (QP (RB approximately) (CD 55)) (NN %)))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ incremental) (NN LDL-C) (NN reduction)) (ADJP (JJ due) (PP (TO to) (S (VP (VBG adding) (NP (NN drug1)) (PP (TO to) (NP (NN drug2)))))))) (VP (MD may) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (DT this) (NN interaction))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NP (NN safety)) (CC and) (NP (NN effectiveness))) (PP (IN of) (NP (NP (NNS drug2)) (VP (VBN administered) (PP (IN with) (NP (NN drug3))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN established))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NN cholesterol) (NN excretion)) (PP (IN into) (NP (DT the) (NN bile))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NN cholelithiasis)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (JJ preclinical) (NN study)) (PP (IN in) (NP (NNS dogs))))) (, ,) (NP (NN drug1)) (VP (VBD increased) (NP (NN cholesterol)) (PP (IN in) (NP (DT the) (NN gallbladder) (NN bile))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (SBAR (IN until) (S (NP (NP (NN use)) (PP (IN in) (NP (NNS patients)))) (VP (VBZ is) (VP (VBN studied)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (DT a) (JJ pharmacokinetic) (NN study))) (, ,) (NP (JJ concomitant) (NN drug2) (NN administration)) (VP (VBD increased) (NP (NN total) (NN drug3) (NNS concentrations)) (ADVP (RB approximately) (RB 1.5-fold)))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (DT a) (JJ pharmacokinetic) (NN study))) (, ,) (NP (JJ concomitant) (NN drug2) (NN administration)) (VP (VBD increased) (NP (NN total) (NN drug3) (NNS concentrations)) (ADVP (RB approximately) (RB 1.7-fold)))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT No) (ADJP (RB clinically) (JJ significant)) (JJ pharmacokinetic) (NNS interactions)) (VP (VBD were) (VP (VBN seen) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN co-administered) (PP (IN with) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC or) (NP (NN drug7))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (DT The) (JJ total) (NN drug2) (NN level)) (VP (VBD increased) (ADVP (RB 12-fold)) (PP (IN in) (NP (NP (CD one) (JJ renal) (NN transplant) (NN patient)) (VP (VBG receiving) (NP (NP (JJ multiple) (NNS medications)) (, ,) (PP (VBG including) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP take) (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (NN Carcinogenesis)) (, ,) (NP (NN Mutagenesis)) (, ,) (NP (NP (NN Impairment)) (PP (IN of) (NP (NN Fertility))) (S (NP (NP (DT A) (JJ 104-week) (JJ dietary) (NN carcinogenicity) (NN study)) (PP (IN with) (NP (NN drug1)))) (VP (VBD was) (VP (VBN conducted) (PP (IN in) (NP (NNS rats))) (PP (IN at) (NP (NP (NNS doses)) (NP (NP (NP (QP (RB up) (TO to) (CD 1500)) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (NP (NNS males)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (CD 500) (NN mg/kg/day)) (PRN (-LRB- -LRB-) (NP (NNS females)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (CD ~20) (NNS times)) (NP (NP (DT the) (JJ human) (NN exposure)) (PP (IN at) (NP (NP (CD 10) (NN mg) (RB daily)) (VP (VBN based) (PP (IN on) (NP (NP (NN AUC0-24hr)) (PP (IN for) (NP (JJ total) (NN drug2)))))))))) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (S (NP (NP (DT A) (JJ 104-week) (JJ dietary) (NN carcinogenicity) (NN study)) (PP (IN with) (NP (NN drug1)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN conducted) (PP (IN in) (NP (NNS mice))) (PP (IN at) (NP (NP (NNS doses)) (ADJP (QP (RB up) (TO to) (CD 500)) (NN mg/kg/day)))) (PRN (-LRB- -LRB-) (NP (NP (CD >150) (NNS times)) (NP (NP (DT the) (JJ human) (NN exposure)) (PP (IN at) (NP (NP (CD 10) (NN mg) (RB daily)) (VP (VBN based) (PP (IN on) (NP (NN AUC0-24hr)))))) (PP (IN for) (NP (JJ total) (NN drug2))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (ADJP (RB statistically) (JJ significant)) (NNS increases)) (PP (IN in) (NP (NN tumor) (NNS incidences))) (PP (IN in) (NP (NP (JJ drug-treated) (NNS rats)) (CC or) (NP (NNS mice))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN evidence)) (PP (IN of) (NP (NN mutagenicity)))) (VP (VBD was) (VP (VBN observed) (ADVP (FW in) (FW vitro)) (PP (IN in) (NP (DT a) (JJ microbial) (NN mutagenicity) (-LRB- -LRB-) (NN Ames) (-RRB- -RRB-) (NN test))) (PP (PP (IN with) (NP (NP (FW Salmonella) (FW typhimurium)) (CC and) (NP (FW Escherichia) (FW coli)))) (PP (IN with)) (CC or) (PP (IN without) (NP (JJ metabolic) (NN activation))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN evidence)) (PP (IN of) (NP (NN clastogenicity)))) (VP (VBD was) (VP (VBN observed) (ADVP (FW in) (FW vitro)) (PP (IN in) (NP (NP (NP (DT a) (JJ chromosomal) (NN aberration)) (NN assay)) (PP (IN in) (NP (JJ human) (JJ peripheral) (NN blood) (NNS lymphocytes))) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ metabolic) (NN activation))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NN genotoxicity)))) (PP (IN in) (NP (DT the) (ADJP (FW in) (FW vivo)) (NN mouse) (NN micronucleus) (NN test))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (JJ oral) (-LRB- -LRB-) (NN gavage) (-RRB- -RRB-) (NN fertility) (NNS studies)) (PP (IN of) (NP (NN drug1))) (VP (VBN conducted) (PP (IN in) (NP (NNS rats)))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (JJ reproductive) (NN toxicity)))) (PP (IN at) (NP (NP (NNS doses)) (NP (NP (QP (RB up) (TO to) (CD 1000)) (NN mg/kg/day)) (PP (IN in) (NP (NP (ADJP (ADJP (JJ male)) (CC or) (ADJP (JJ female))) (NNS rats)) (PRN (-LRB- -LRB-) (NP (NP (CD ~7) (NNS times)) (NP (NP (DT the) (JJ human) (NN exposure)) (PP (IN at) (NP (NP (CD 10) (NN mg) (RB daily)) (VP (VBN based) (PP (IN on) (NP (NN AUC0-24hr)))))) (PP (IN for) (NP (JJ total) (NN drug2))))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NN Pregnancy) (NN Pregnancy) (NN Category)) (: :) (S (LST (LS C)) (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (ADJP (ADJP (JJ adequate)) (CC and) (ADJP (JJ well-controlled))) (NNS studies)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ pregnant) (NNS women)))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN during) (NP (NN pregnancy))) (SBAR (RB only) (IN if) (S (NP (DT the) (JJ potential) (NN benefit)) (VP (VBZ justifies) (NP (NP (DT the) (NN risk)) (PP (TO to) (NP (DT the) (NN fetus))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (JJ oral) (PRN (-LRB- -LRB-) (NP (NN gavage)) (-RRB- -RRB-)) (JJ embryo-fetal) (NN development) (NNS studies)) (PP (IN of) (NP (NN drug1))) (VP (VBN conducted) (PP (IN in) (NP (NP (NNS rats)) (CC and) (NP (NNS rabbits)))) (PP (IN during) (NP (NN organogenesis)))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (NP (JJ embryolethal) (NNS effects)) (PP (IN at) (NP (NP (NP (DT the) (NNS doses)) (VP (VBN tested))) (PRN (-LRB- -LRB-) (NP (QP (CD 250) (, ,) (CD 500) (, ,) (CD 1000)) (NN mg/kg/day)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NNS rats))) (, ,) (NP (NP (VBN increased) (NNS incidences)) (PP (IN of) (NP (NP (JJ common) (JJ fetal) (JJ skeletal) (NNS findings)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ extra) (NN pair)) (PP (IN of) (NP (JJ thoracic) (NNS ribs)))) (, ,) (NP (JJ unossified) (JJ cervical) (NN vertebral) (NN centra))) (, ,) (NP (VBD shortened) (NNS ribs)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN observed) (PP (IN at) (NP (CD 1000) (NN mg/kg/day))) (PRN (-LRB- -LRB-) (NP (NP (CD ~10) (NNS times)) (NP (NP (DT the) (JJ human) (NN exposure)) (PP (IN at) (NP (NP (CD 10) (NN mg) (RB daily)) (VP (VBN based) (PP (IN on) (NP (NN AUC0-24hr)))))) (PP (IN for) (NP (JJ total) (NN drug1))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NNS rabbits)) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))) (, ,) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (JJ extra) (JJ thoracic) (NNS ribs)))) (VP (VBD was) (VP (VBN observed) (PP (IN at) (NP (CD 1000) (NN mg/kg/day))) (PRN (-LRB- -LRB-) (NP (NP (CD 150) (NNS times)) (NP (NP (DT the) (JJ human) (NN exposure)) (PP (IN at) (NP (NP (CD 10) (NN mg) (RB daily)) (VP (VBN based) (PP (IN on) (NP (NN AUC0-24hr)))))) (PP (IN for) (NP (JJ total) (NN drug2))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD crossed) (NP (DT the) (NN placenta)) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ pregnant) (NNS rats)) (CC and) (NP (NNS rabbits))) (VP (VBD were) (PP (IN given) (NP (JJ multiple) (JJ oral) (NNS doses)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Multiple) (NN dose) (NNS studies)) (PP (IN of) (NP (NP (NN drug1)) (VP (VBN given) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS rats)) (CC and) (NP (NNS rabbits)))))))) (PP (IN during) (NP (NN organogenesis))))))) (VP (VBP result) (PP (IN in) (NP (NP (JJR higher) (NN drug4)) (CC and) (NP (NN statin) (NNS exposures)))))) (. .)))
(S1 (S (S (NP (JJ Reproductive) (NNS findings)) (VP (VBP occur) (PP (IN at) (NP (JJR lower) (NNS doses))) (PP (IN in) (NP (NP (NN combination) (NN therapy)) (VP (VBD compared) (PP (TO to) (NP (NN monotherapy)))))))) (. .)))
(S1 (S (S (NP (DT All) (NNS drug1)) (VP (VBP are) (VP (VBN contraindicated) (PP (IN in) (NP (ADJP (ADJP (JJ pregnant)) (CC and) (ADJP (JJ nursing))) (NNS women)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (DT an) (NN drug2)) (PP (IN in) (NP (NP (DT a) (NN woman)) (PP (IN of) (NP (JJ childbearing) (NN potential))))))))))) (, ,) (VP (VP (VBP refer) (PP (TO to) (NP (DT the) (NN pregnancy) (NN category)))) (CC and) (VP (VBP package) (NP (NP (NN labeling)) (PP (IN for) (NP (DT the) (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN Labor)) (CC and) (NP (NN Delivery)) (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (NP (NN labor)) (CC and) (NP (NN delivery))) (PP (IN in) (NP (JJ pregnant) (NNS women))))))) (VP (VBP are) (ADJP (JJ unknown)))) (. .)))
(S1 (S (S (S (VP (VBG Nursing) (NP (NP (NNS Mothers)) (PP (IN In) (NP (NN rat) (NNS studies)))))) (, ,) (NP (NP (NN exposure)) (PP (TO to) (NP (JJ total) (NN drug1))) (PP (IN in) (NP (NN nursing) (NNS pups)))) (VP (VBD was) (PP (RB up) (TO to) (NP (NP (NN half)) (PP (IN of) (NP (NP (DT that)) (VP (VBN observed) (PP (IN in) (NP (JJ maternal) (NN plasma)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN excreted) (PP (IN into) (NP (JJ human) (NN breast) (NN milk)))))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (JJ nursing) (NNS mothers))) (SBAR (IN unless) (S (NP (DT the) (JJ potential) (NN benefit)) (VP (VBZ justifies) (NP (NP (DT the) (JJ potential) (NN risk)) (PP (TO to) (NP (DT the) (NN infant))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Pediatric) (NN Use)) (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS adolescents)) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (TO to) (CD 18)) (NNS years)) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (NNS adults))))))))))))))) (. .)))
(S1 (S (NP (NP (NN Treatment)) (VP (VBP experience) (PP (IN with) (NP (NN drug1))) (PP (IN in) (NP (DT the) (JJ pediatric) (NN population))))) (VP (VBZ is) (ADJP (JJ limited) (PP (TO to) (NP (NP (NP (NP (CD 4) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP (CD 9) (TO to) (CD 17)) (NNS years)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN sitosterolemia) (NN study)))) (CC and) (NP (NP (NP (CD 5) (NNS patients)) (PRN (-LRB- -LRB-) (NP (QP (CD 11) (TO to) (CD 17)) (NNS years)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN HoFH) (NN study)))))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS children)) (PRN (-LRB- -LRB-) (NP (NN &lt) (: ;) (CD 10) (NNS years)) (-RRB- -RRB-))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NP (JJ Geriatric) (NN Use)) (PP (IN Of) (NP (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NP (NN drug1)) (PP (IN in) (NP (JJ clinical) (NNS studies)))))))) (, ,) (NP (CD 948))))) (VP (VBD were) (NP (NP (CD 65)) (CC and) (NP (JJR older))) (PRN (-LRB- -LRB-) (S (NP (DT this)) (VP (VBD included) (NP (NP (CD 206)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (NP (NP (CD 75)) (CC and) (NP (JJR older))))))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NN effectiveness)) (CC and) (NP (NN safety))) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (ADJP (JJ similar) (PP (IN between) (NP (NP (DT these) (NNS patients)) (CC and) (NP (JJR younger) (NNS subjects))))))) (. .)))
(S1 (S (S (NP (NP (JJR Greater) (NN sensitivity)) (PP (IN of) (NP (DT some) (JJR older) (NNS individuals)))) (VP (MD cannot) (VP (VB be) (VP (VBN ruled) (PRT (RP out)))))) (. .)))
(S1 (S (S (NP (NP (NN Interaction)) (PP (IN with) (NP (NN drug1)))) (: :) (S (SBAR (IN Although) (S (NP (NN drug2)) (VP (VBZ does) (RB not) (NP (NP (PRP itself)) (VP (VBP cause) (NP (JJ orthostatic) (NN hypotension))))))) (, ,) (NP (NP (PRP$ its) (NN administration)) (PP (TO to) (NP (NP (NNS patients)) (VP (ADVP (RB already)) (VBG receiving) (NP (NN drug3)))))) (VP (MD can) (VP (VB result) (PP (IN in) (NP (JJ profound) (JJ orthostatic) (NNS effects))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (PP (IN at) (NP (DT all) (JJ possible) (NN drug1))) (VP (MD should) (VP (VB be) (VP (VBN discontinued) (ADVP (RB well)) (PP (IN before) (NP (NN drug2)))))))) (VP (VBZ is) (VP (VBN begun)))) (. .)))
(S1 (S (S (S (SBAR (WHADVP (WRB Where)) (S (NP (DT this)) (VP (VBZ is) (RB not) (ADJP (JJ possible))))) (, ,) (NP (NN drug1) (NN therapy)) (VP (MD should) (VP (VB be) (VP (VBN started) (PP (IN in) (NP (DT the) (NN hospital))))))) (CC and) (S (NP (DT the) (NN patient)) (VP (MD should) (VP (VB remain) (VP (VBN institutionalized) (SBAR (IN until) (S (S (NP (JJ severe) (JJ orthostatic) (NNS effects)) (VP (VBP are) (ADVP (RB no) (RBR longer)) (ADJP (JJ present)))) (CC or) (S (NP (DT the) (NN patient)) (VP (VBZ has) (VP (VBN learned) (S (VP (TO to) (VP (VB avoid) (NP (NP (NNS activities)) (SBAR (WHNP (WDT that)) (S (VP (VBP provoke) (NP (PRP them))))))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (CD 34) (JJ different) (NNS drugs)) (VP (VBD were) (VP (VBN tested))))))) (, ,) (NP (NP (ADJP (RB therapeutically) (JJ relevant)) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD displaced) (NP (JJ protein-bound) (NN drug4)) (PP (IN in) (NP (JJ fresh) (JJ human) (NN serum))) (PP (TO to) (NP (DT a) (ADJP (ADJP (JJ small)) (CC but) (ADJP (JJ significant))) (NN extent)))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (ADJP (RB extremely) (JJ high)) (NN binding)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NN plasma) (NNS proteins)))))) (, ,) (NP (NP (DT these) (JJ small) (NNS decreases)) (PP (IN in) (NP (NN binding)))) (VP (MD could) (VP (VB cause) (NP (NP (JJ substantial) (NNS increases)) (PP (IN in) (NP (NP (JJ free) (NN drug) (NNS levels)) (PP (IN in) (NP (NP (NN plasma)) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB result) (PP (IN in) (NP (NP (NN potentiation)) (PP (IN of) (NP (NN drug) (NN toxicity))))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN in) (S (VP (VBG administering) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2) (NN injection)) (-RRB- -RRB-))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT these) (JJ other) (NNS agents)))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (DT no) (NN change)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NNS kinetics)) (PP (IN of) (NP (NN drug1))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN plasma) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (ADVP (RB slightly)) (VP (VBN increased)))) (. .)))
(S1 (S (S (NP (NP (DT An) (NN increase)) (PP (IN in) (NP (NP (JJ intracellular) (NNS levels)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD was) (VP (VBN observed) (ADVP (FW in) (FW vitro)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP antagonize) (NP (NP (DT the) (JJ uricosuric) (NN action)) (PP (IN of) (NP (NP (. .) (NNS drugs)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN gout))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC AND) (NP (JJ OTHER) (NNS drug2))) (VP (VP (MD WILL) (VP (VB BE) (ADJP (JJ ADDITIVE) (PP (TO TO) (NP (NN drug3)))))) (CC AND) (VP (MD MAY) (VP (VB INCREASE) (NP (NP (NN PLASMA) (NNS CONCENTRATIONS)) (PP (IN OF) (NP (NN drug4)))) (PP (TO TO) (NP (JJ TOXIC) (NNS LEVELS))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Drugs)) (CC and) (NP (NNS foods))) (SBAR (WHNP (WDT that)) (S (VP (VBP raise) (NP (NN urine) (NN pH)))))) (VP (MD will) (VP (VB increase) (NP (NP (NP (JJ renal) (NN clearance)) (CC and) (NP (JJ urinary) (NN excretion))) (PP (IN of) (NP (NN drug1)))) (, ,) (S (ADVP (RB thus)) (VP (VBG lowering) (NP (NN plasma) (NNS levels))))))) (: ;)))
(S1 (S (S (NP (VBG acidifying) (NP (NP (NNS drugs)) (CC or) (NP (NNS foods)))) (VP (MD will) (VP (VP (VB decrease) (NP (JJ urinary) (NN excretion))) (CC and) (VP (VB increase) (NP (NN plasma) (NNS levels)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))) (VP (MD may) (VP (VB predispose) (PP (TO to) (NP (JJ systemic) (JJ bleeding)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ hypoglycemic) (NN effect)) (PP (IN of) (NP (NP (JJ oral) (NN drug2)) (PP (IN of) (NP (DT the) (NN sulfonylurea) (NN class))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ competes) (PP (IN with) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NNS drugs))))) (PP (IN for) (NP (NP (NN protein) (NN binding) (NNS sites)) (, ,) (ADVP (RB notably)) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC and) (RB possibly) (NP (NN drug11))))))) (. .)))
(S1 (S (S (VP (VBG Drug/) (NP (NN Laboratory) (NN Test) (NNS Interactions)))) (NP (NN drug1)) (VP (VBZ competes) (PP (IN with) (NP (NN thyroid) (NN hormone))) (PP (IN for) (S (VP (VBG binding) (PP (TO to) (NP (NP (NN plasma) (NNS proteins)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (VP (VBN reflected) (PP (IN in) (NP (NP (DT a) (JJ depressed) (NN plasma) (NN T4) (NN value)) (PP (IN in) (NP (DT some) (NNS patients)))))))))))))))) (: ;)))
(S1 (S (S (NP (NP (NN thyroid) (NN function)) (CC and) (NP (JJ basal) (NN metabolism))) (VP (VBP are) (ADJP (JJ unaffected)))) (. .)))
(S1 (S (PP (IN In) (NP (NP (NP (JJ elderly) (NNS patients)) (VP (ADVP (RB concurrently)) (VBG receiving) (NP (JJ certain) (NN drug1)))) (, ,) (NP (ADVP (RB primarily)) (NP (NN drug2))))) (, ,) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NN thrombopenia))) (PP (IN with) (NP (NN purpura)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported)))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB prolong) (NP (DT the) (NN prothrombin) (NN time)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (DT the) (NN drug2) (NN drug3)))))))))))))))) (. .)))
(S1 (S (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (TO to) (NP (NP (NNS patients)) (ADVP (RB already)))) (PP (IN on) (NP (JJ anticoagulant) (NN therapy))))))))))) (, ,) (CC and) (S (NP (DT the) (NN coagulation) (NN time)) (VP (MD should) (VP (VB be) (VP (VBN reassessed)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VBP inhibit) (NP (NP (DT the) (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (PP (IN At) (NP (DT a) (JJ 1.6-g) (NN dose))) (, ,) (NP (NN drug1)) (VP (VP (VBD produced) (NP (NP (DT a) (ADJP (ADJP (JJ slight)) (CC but) (ADJP (JJ significant))) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN drug2))))))) (CC but) (VP (VBD did) (RB not) (VP (VB produce) (NP (NP (DT a) (JJ corresponding) (NN decrease)) (PP (IN in) (NP (DT the) (JJ metabolic) (NN clearance) (NN rate)))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBG administering) (NP (DT these) (NNS drugs)) (ADVP (RB concurrently))))) (, ,) (NP (PRP one)) (VP (MD should) (VP (VB be) (ADJP (JJ alert) (PP (IN for) (NP (JJ possible) (JJ excessive) (NN drug1) (NN effect))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD can) (ADVP (RB also)) (VP (VB displace) (NP (NN drug2)) (PP (IN from) (NP (NN plasma) (JJ protein-binding) (NNS sites))) (, ,) (S (ADVP (RB thus)) (VP (VBG increasing) (NP (JJ free) (NN drug3) (NNS concentrations))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN Jaff) (NN alkaline) (NN picrate) (NN reaction) (NN assay)) (PP (IN for) (NP (NN creatinine))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NNS overestimations)) (PP (IN of) (NP (QP (RB about) (CD 10)) (NN %))))) (PP (IN in) (NP (NP (DT the) (NN range)) (PP (IN of) (NP (JJ normal) (NNS values)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pharmacokinetic) (NNS interactions)) (VP (VBN listed) (PP (IN below)))) (VP (VBP are) (ADJP (RB potentially) (RB clinically) (JJ important)))) (. .)))
(S1 (S (S (NP (NP (JJ Mutual) (NN inhibition)) (PP (IN of) (NP (NN metabolism)))) (VP (VBZ occurs) (PP (IN with) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (JJ adverse) (NNS events)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (JJ individual) (NN use)) (PP (IN of) (NP (DT either) (NN drug))))))) (VP (MD may) (VP (VB be) (S (NP (JJR more) (NNS apt)) (VP (TO to) (VP (VB occur)))))))))) (. .)))
(S1 (S (S (NP (NNS convulsions)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NP (JJ hepatic) (NNS enzymes)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))))))))) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NNS drug4)))))) (CC and) (VP (MD may) (VP (VB require) (VP (VBN increased) (PP (IN in) (NP (NN drug5) (NN dose))) (S (VP (TO to) (VP (VB achieve) (NP (DT the) (JJ desired) (NN response)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))) (CC and) (ADVP (RB thus)) (VP (VB decrease) (NP (PRP$ its) (NN clearance)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN titrated) (S (VP (TO to) (VP (VB avoid) (NP (NN steroid) (NN toxicity))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (JJ chronic) (JJ high) (NN dose) (NN drug2))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VP (MD could) (VP (VB lead) (PP (TO to) (NP (VBN decreased) (NN drug1) (NN serum) (NNS levels))))) (CC or) (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN toxicity)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN withdrawn)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NN hypoprothrombinemia)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ oral) (NNS drug2)))) (VP (VBZ is) (NP (NN variable)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (VBN enhanced)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (VBN diminished) (NNS effects)) (PP (IN of) (NP (NN drug1))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN coagulation) (NNS indices)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (S (VP (TO to) (VP (VB maintain) (NP (DT the) (JJ desired) (JJ anticoagulant) (NN effect))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (ADVP (RB generally)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN treated) (PP (IN with) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN action)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (NN anesthesia)) (, ,) (NP (JJ other) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (, ,) (NP (NP (DT the) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (DT the) (NN drug1) (NN inhaler)) (CC and) (NP (NP (JJ other) (NNS drugs)) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN asthma)))))))))) (VP (VBD was) (RB not) (VP (VBN associated) (PP (IN with) (NP (DT any) (JJ unusual) (JJ adverse) (NNS events)))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))) (, ,)) (VP (MD may) (VP (VB increase) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug2)))) (PP (IN during) (NP (JJ concomitant) (NN dosing)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs))))) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NN drug1)))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN release)) (PP (IN of) (NP (NNS neutrophils))))))) (: ;)))
(S1 (S (S (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD should) (VP (VB have) (NP (NP (ADJP (RBR more) (JJ frequent)) (NN monitoring)) (PP (IN of) (NP (NN neutrophil) (NNS counts))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS drug2)) (VP (MD may) (VP (VB increase) (NP (NP (NN sensitivity)) (PP (TO to) (NP (JJ oral) (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN Dosage)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD may) (VP (VB have) (S (VP (TO to) (VP (VB be) (VP (VBN decreased) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB maintain) (NP (JJ desired) (NN prothrombin) (NN time))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (JJ oral) (NN anticoagulant) (NN therapy)))) (VP (VBP require) (NP (JJ close) (NN monitoring)) (, ,) (SBAR (WHADVP (RB especially) (WRB when)) (S (NP (NN drug1)) (VP (VBP are) (VP (VP (VBN started)) (CC or) (VP (VBN stopped)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (JJ multidose) (NN study)) (PP (IN of) (NP (NN drug2))) (, ,) (VP (VBN given) (PP (IN as) (NP (ADJP (QP (CD 5) (CC or) (CD 10)) (NN mg)) (NN BID))) (PP (IN in) (NP (NP (CD 15) (JJ healthy) (NNS subjects)) (VP (ADVP (RB concurrently)) (VBN treated) (PP (IN with) (NP (NN drug3))))))) (, ,)) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ mean) (NN increase)) (PP (IN in) (NP (NP (NP (NN drug4) (NN half-life)) (PP (IN from) (NP (QP (CD 26) (TO to) (CD 48)) (NNS hours)))) (CC and) (NP (NP (NN AUC)) (PP (IN from) (NP (QP (CD 4.55) (TO to) (CD 12.08)) (NN ng) (NN *) (NN hr/mL)))))))))) (: :) (S (NP (NP (JJ similar) (NNS increases)) (PP (IN in) (NP (NP (NN drug5) (NN half-life)) (CC and) (NP (NN AUC))))) (VP (VBD were) (ADVP (RB also)) (VP (VBN detected)))) (. .))))
(S1 (S (S (NP (NP (NP (JJ Microscopic) (NN hematuria)) (PRN (-LRB- -LRB-) (NP (CD 9/15)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ gingival) (JJ bleeding)) (PRN (-LRB- -LRB-) (NP (NN 1/15)) (-RRB- -RRB-)))) (VP (VBD were) (ADVP (RB also)) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (NP (DT A) (ADJP (RB 5.5-fold)) (NN decrease)) (PP (IN in) (NP (NP (DT the) (JJ mean) (NN drug1) (NN dose)) (PP (IN from) (NP (NP (CD 6.13) (NN mg/day) (TO to) (CD 1.13) (NN mg/day)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (QP (RB approximately) (CD 80-85)) (NN %)) (NN reduction)) (PP (IN of) (NP (NN drug2) (NN dose)))) (-RRB- -RRB-)))))) (, ,)) (VP (VBD was) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB maintain) (NP (NP (DT a) (NN target) (NN INR)) (PP (IN of) (NP (CD 1.5)))))))))) (. .)))
(S1 (S (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1) (NN therapy)) (VP (VBZ is) (VP (VBN initiated) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (ADVP (RB already)) (VBG receiving) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2))))))))))) (, ,) (NP (NP (DT the) (NN INR)) (CC or) (NP (NP (NN prothrombin) (NN time)) (PRN (-LRB- -LRB-) (NP (NN PT)) (-RRB- -RRB-)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)))))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (NN drug3)) (VP (VBN adjusted) (PP (IN as) (ADJP (JJ necessary) (PP (IN until) (NP (NP (DT a) (JJ stable) (NN target) (NN INR)) (CC or) (NP (NN PT)))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN achieved)))))) (. .)))
(S1 (S (ADVP (RB Furthermore)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT both) (NNS drugs))))) (, ,) (NP (NP (NP (JJ careful) (NN monitoring)) (PP (IN of) (NP (DT the) (NP (NN INR)) (CC or) (NP (NN PT))))) (, ,) (CC and) (NP (NP (NN adjustment)) (PP (IN of) (NP (NP (DT the) (NN drug1) (NN dosage)) (SBAR (IN if) (S (VP (VBN indicated)))))))) (VP (VBP are) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN drug2) (NN dose)) (VP (VBZ is) (VP (VP (VBN changed)) (CC or) (VP (VBN discontinued)))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (PP (IN for) (NP (NP (NP (NNS signs)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (JJ occult) (JJ bleeding))))))))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1) (NN drug2)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ oral) (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (PP (IN In) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN edema)) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))))))))) (VP (MD may) (VP (VB increase) (NP (DT the) (NN edema))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN test) (NNS interactions) (NP (NN drug1))) (VP (MD may) (VP (VB decrease) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ thyroxine-binding) (NN globulin)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (VBN decreased) (JJ total) (NN T4) (NN serum) (NNS levels)) (CC and) (NP (NP (VBN increased) (NN resin) (NN uptake)) (PP (IN of) (NP (NP (NN T3)) (CC and) (NP (NN T4)))))))))))) (. .)))
(S1 (S (S (NP (JJ Free) (NN thyroid) (NN hormone) (NNS levels)) (VP (VBP remain) (ADJP (JJ unchanged)))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN PBI)))) (CC and) (NP (JJ radioactive) (NN iodine) (NN uptake))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (DT The) (VBG following) (NNS agents)) (VP (MD may) (VP (VB increase) (NP (NP (NP (NP (JJ certain) (NNS actions)) (CC or) (NP (JJ side) (NNS effects))) (PP (IN of) (NP (NN drug1)))) (: :) (NP (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug4)) (-RRB- -RRB-))) (, ,) (NP (NN drug5)) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NP (NP (CD drug10)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (CD drug11)) (-RRB- -RRB-))) (, ,) (NP (CD drug12) (CC and) (CD drug13)) (, ,) (NP (CD drug14)) (, ,) (NP (CD drug15))) (, ,) (CC and) (NP (NP (JJ other) (NNS drugs)) (VP (VBG having) (NP (JJ anticholinergic) (NN activity))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP antagonize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (VBN increased) (JJ intraocular) (NN pressure)))))) (VP (MD may) (VP (VB be) (ADJP (JJ hazardous))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NNS agents)) (PP (JJ such) (IN as) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB affect) (NP (NP (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NP (JJ various) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (ADJP (RB slowly) (VBG dissolving)) (NN dosage) (NNS forms)) (PP (IN of) (NP (NN drug2))))))))))) (: ;)))
(S1 (S (S (NP (VBN increased) (NN serum) (NN drug1) (NNS concentrations)) (VP (MD may) (VP (VB result)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (JJ gastrointestinal) (NN motility))))) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug2))))))))) (, ,) (NP (NP (JJ simultaneous) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN inhibiting) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ gastric) (JJ hydrochloric) (NN acid) (NN secretion)))) (VP (VBP are) (VP (VBN antagonized) (PP (IN by) (NP (NP (NP (NNS agents)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NN achlorhydria))))))) (CC and) (NP (NP (DT those)) (VP (VBN used) (S (VP (TO to) (VP (VB test) (NP (JJ gastric) (NN secretion)))))))))))) (. .)))
(S1 (S (SBAR (IN Since) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (ADJP (RB concurrently) (VBN administered)) (NN drug3))))))) (, ,) (NP (NP (JJ periodic) (NN serum) (NN level) (NNS determinations)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (JJ necessary)) (PRN (-LRB- -LRB-) (NP (NP (JJ eg) (NNS drug4)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug5)) (CC and) (NP (NN drug6)))))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN drug2) (CONJP (CC and) (RB probably)) (JJ other) (NNS drug3)) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug4))))) (VP (MD can) (VP (VB cause) (NP (NP (ADJP (RB unusually) (ADJP (JJ large)) (CC or) (ADJP (JJ prolonged))) (NNS losses)) (PP (IN of) (NP (NP (NN fluid)) (CC and) (NP (NNS electrolytes)))))))) (. .))))
(S1 (S (NP (NP (JJ Other) (NNS drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug2) (NNS Tablets)) (VP (VBP are) (VP (VBN used) (PP (IN with) (NP (JJ other) (NN drug3))))))) (, ,) (NP (NN care)) (VP (MD must) (VP (VB be) (VP (VBN taken) (, ,) (PP (ADVP (RB especially)) (IN during) (NP (JJ initial) (NN therapy))))))) (. .))))
(S1 (S (S (NP (NP (NN Dosage) (NNS adjustments)) (PP (IN of) (NP (JJ other) (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (: :) (S (NP (NP (DT The) (JJ hypotensive) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (DT the) (NN volume) (NN contraction)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NN drug4) (NN therapy)))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2) (JJ -induced) (NN hypokalemia))) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN sensitivity)) (PP (IN of) (NP (DT the) (NN myocardium))) (PP (TO to) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (JJ Serious) (NNS arrhythmias)) (VP (MD can) (VP (VB result)))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (: :) (S (VP (MD May) (VP (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hypokalemia))))) (CC and) (VP (VB increase) (NP (NP (NN salt)) (CC and) (NP (NN water)) (NP (NN retention))))))) (. .))))
(S1 (S (S (NP (NN drug1) (: :) (NN Serum) (NN drug2) (NNS levels)) (VP (MD may) (VP (VB increase)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NN drug2) (JJ -induced) (NN hypokalemia)) (VP (MD may) (VP (VB enhance) (NP (NP (NN neuromuscular) (NN blocking) (NNS effects)) (PP (IN of) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug4)))) (-RRB- -RRB-))))) (S (NP (DT the) (ADJP (RBS most) (JJ serious)) (NN effect)) (VP (MD would) (VP (VB be) (NP (NP (JJ respiratory) (NN depression)) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB proceed) (PP (TO to) (NP (NN apnea)))))))))))) (. .))))
(S1 (S (S (ADVP (RB Accordingly)) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ advisable) (PP (TO to) (NP (NP (NN discontinue) (NN drug1) (NNS Tablets)) (NP (NP (CD three) (NNS days)) (PP (IN before) (NP (JJ elective) (NN surgery)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NP (JJ Other) (NNS drug2)) (: :))) (VP (MD May) (VP (VB decrease) (NP (NP (DT the) (JJ antihypertensive) (NNS effects)) (PP (IN of) (NP (NN drug3) (NNS Tablets))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NN drug2)) (VP (MD may) (VP (VB decrease) (NP (NP (JJ arterial) (NN responsiveness)) (PP (TO to) (NP (NN drug3))))))) (, ,) (CC but) (S (NP (DT this) (NN diminution)) (VP (VBZ is) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB preclude) (NP (NP (NN effectiveness)) (PP (IN of) (NP (NP (DT the) (JJ pressor) (NN agent)) (PP (IN for) (NP (JJ therapeutic) (NN use))))))))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN Efficacy))) (VP (MD may) (VP (VB be) (VP (VBN decreased) (PP (JJ due) (TO to) (NP (NP (JJ urinary) (JJ alkalizing) (NN effect)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ other) (NN drug3)) (, ,)) (VP (MD may) (VP (VB affect) (NP (NP (DT the) (JJ hypoprothrombinemic) (NN response)) (PP (TO to) (NP (NN drug4))))))) (: ;)))
(S1 (S (S (NP (NN dosage) (NNS adjustments)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (VBN increased) (NN plasma) (NN drug3) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 57) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN increased) (NN plasma) (NN bismuth) (NN trough) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 48) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (VBN increased) (NN drug4) (NN plasma) (NNS concentrations)) (PRN (-LRB- -LRB-) (NP (CD 31) (NN %)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN with) (NP (NN drug1)))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJ slight) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN drug2) (NN absorption))))) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (RB clinically) (JJ unimportant))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN with) (NP (NP (NP (DT a) (JJ high) (NN dose)) (PP (IN of) (NP (NN drug1)))) (PRN (-LRB- -LRB-) (NP (CD 170) (NN mEq)) (-RRB- -RRB-))))) (VP (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (ADJP (CD 28) (NN %)) (NN decrease)) (PP (IN in) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))))))) (CC and) (VP (MD may) (VP (VB decrease) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN bismuth)))) (PP (IN from) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBP are) (ADJP (RB clinically) (JJ insignificant)))) (. .)))
(S1 (S (S (PP (IN For) (NP (NP (NN information)) (PP (IN on) (NP (NP (NN drug) (NNS interactions)) (VP (VBN associated) (PP (IN with) (NP (NN drug1)))))))) (, ,) (VP (VBP refer) (PP (TO to) (NP (DT the) (NN drug2) (NN package) (NN insert))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (JJ other) (JJ local) (NNS drug2)) (CC or) (NP (NNS agents))) (ADJP (RB structurally) (JJ related) (PP (TO to) (NP (NN drug3)))))))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (VBP are) (ADJP (JJ additive))))))))) (. .)))
(S1 (S (S (NP (NN Cytochrome) (NN P4501A2)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (DT the) (JJ major) (NN metabolite))))))))) (. .)))
(S1 (S (S (ADVP (FW In) (FW vivo)) (, ,) (NP (NP (DT the) (NN plasma) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (CD 70) (NN %))) (PP (IN during) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD 25) (NN mg)) (ADJP (JJ bid) (PP (IN for) (NP (CD 2) (NNS days))))) (-RRB- -RRB-))) (, ,) (NP (DT a) (ADJP (ADJP (JJ selective)) (CC and) (ADJP (JJ potent))) (NN CYP1A2) (NN inhibitor))))))))) (. .)))
(S1 (S (ADVP (RB Thus)) (NP (NP (JJ strong) (NNS inhibitors)) (PP (IN of) (NP (NN cytochrome) (NN P4501A2))) (, ,) (PP (JJ such) (IN as) (NP (NN drug1))) (, ,) (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN during) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug2)))))) (, ,)) (VP (MD can) (VP (VB interact) (PP (IN with) (NP (NP (NN drug3)) (VP (VBG leading) (PP (TO to) (NP (VBN increased) (NN drug4) (NN plasma) (NNS levels)))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN CYP1A2) (NNS inhibitors)) (VP (VBP are) (VP (VBN coadministered))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Possible) (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP1A2))) (PP (IN via) (NP (NP (JJ competitive) (NN inhibition)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))))))) (VP (MD may) (ADVP (RB also)) (VP (VB occur)))) (. .)))
(S1 (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NP (NP (DT a) (ADJP (ADJP (JJ selective)) (CC and) (ADJP (JJ potent))) (NN inhibitor)) (PP (IN of) (NP (NN CYP3A4)))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (ADJP (CD 100) (NN mg)) (NN bid)) (PP (IN for) (NP (CD 2) (NNS days))) (PP (IN with) (NP (NP (NN drug2) (NN infusion)) (VP (VBN administered) (PP (NP (CD 1) (NN hour)) (IN after) (NP (NN drug3))))))) (-RRB- -RRB-)))))) (VP (VBD caused) (NP (NP (DT a) (ADJP (CD 15) (NN %)) (NN reduction)) (PP (IN in) (NP (NP (JJ in-vivo) (NN plasma) (NN clearance)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NNS Additives)) (VP (MD may) (VP (VB be) (ADJP (JJ incompatible))))) (: ;)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (ADJP (JJ incompatible) (PP (IN with) (NP (NN drug3) (NN solution)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (JJ parenteral) (NNS solutions)) (VP (VBG containing) (NP (NN drug2)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (, ,) (PP (IN except) (SBAR (WHADVP (WRB where)) (S (NP (NN compatibility)) (VP (VBZ has) (VP (VBN been) (ADVP (RB previously)) (VP (VBN established))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Precipitation)) (CC or) (NP (NN haze))) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NN sodium) (NN bicarbonate-calcium) (NNS admixtures)))))) (. .)))
(S1 (S (NP (NP (NN NOTE)) (: :) (S (VP (VBP Do) (RB not) (VP (VB use) (NP (DT the) (NN injection)) (SBAR (IN if) (S (NP (PRP it)) (VP (VBZ contains) (NP (NN precipitate)))))))) (. .))))
(S1 (S (S (NP (NNS Additives)) (VP (MD may) (VP (VB be) (ADJP (JJ incompatible))))) (. .)))
(S1 (S (S (VP (VB Consult) (PP (IN with) (NP (NN pharmacist))) (, ,) (SBAR (IN if) (FRAG (JJ available))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBG introducing) (NP (NNS additives))))) (, ,) (VP (VP (VBP use) (NP (NP (JJ aseptic) (NN technique)) (, ,) (NP (NN mix))) (ADVP (RB thoroughly))) (CC and) (VP (VBP do) (RB not) (VP (VB store))))) (. .)))
(S1 (S (NP (NP (NP (JJ Drug-Drug) (NNS Interactions)) (NP (NP (NN Effect)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (NN Metabolism)) (PP (IN of) (NP (JJ Other) (NNS Drugs))))))) (: :) (S (NP (NN drug3)) (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN metabolized) (PP (IN through) (NP (NP (NN hydrolysis)) (PP (IN by) (NP (NNS esterases)))))))) (. .))))
(S1 (S (S (NP (JJ Minimal) (NN metabolism)) (VP (VBZ occurs) (PP (IN via) (NP (DT the) (JJ major) (NN cytochrome) (NN P450) (NNS isoenzymes))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (ADJP (FW in) (FW vitro)) (NNS studies)))) (, ,) (NP (NP (DT no) (JJ pharmacokinetic) (NN drug) (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (JJ following) (NN isoenzyme) (NNS systems))))))) (VP (VBP are) (VP (VBN expected))) (: :) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP3A4/5)) (, ,) (NP (NN CYP2E1)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C8)) (, ,) (CC or) (NP (NN CYP2C19)))) (. .)))
(S1 (S (S (NP (DT No) (JJ pharmacokinetic) (NN interaction)) (VP (VBD was) (VP (VBN observed) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))) (PP (IN in) (NP (NP (NNS studies)) (PP (IN in) (NP (JJ healthy) (NNS volunteers)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN elevation)) (PP (IN of) (NP (NN prothrombin) (NN time))) (VP (VBN induced) (PP (IN by) (NP (NN drug1))))) (VP (VBZ is) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN Effect)) (PP (IN of) (NP (JJ Other) (NNS Drugs))) (PP (IN on) (NP (NP (DT the) (NN Metabolism)) (PP (IN of) (NP (NP (NN drug1)) (: :) (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP induce)) (CC or) (VP (VBP inhibit) (NP (NN CYP450) (NN metabolism)))))))))))) (VP (VBP are) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB alter) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (JJ Single) (NN dose) (JJ pharmacokinetic) (NNS studies)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (RB not) (ADVP (RB significantly)) (VP (VBN affected) (PP (IN by) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Population) (NN PK) (NN analysis)) (PP (IN with) (NP (NP (DT a) (NN database)) (PP (IN of) (NP (CD 625) (NNS patients)))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (RB not) (VP (VBN influenced) (PP (IN by) (NP (NP (ADJP (RB commonly) (VBN prescribed)) (NNS medications)) (PP (JJ such) (IN as) (NP (NP (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN n=77)) (-RRB- -RRB-))) (, ,) (NP (NN drug3))) (PRN (-LRB- -LRB-) (NP (NN n=72)) (-RRB- -RRB-))) (, ,) (NP (NN drug4) (-LRB- -LRB-) (CD n=75) (-RRB- -RRB-)) (, ,) (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN n=21)) (-RRB- -RRB-)) (, ,) (NP (NN drug6) (-LRB- -LRB-) (CD n=79) (-RRB- -RRB-)) (, ,) (NP (NN drug7) (-LRB- -LRB-) (CD n=70) (-RRB- -RRB-)) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (NN n=177)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug9)) (PRN (-LRB- -LRB-) (NP (NN n=35)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug10)) (PRN (-LRB- -LRB-) (NP (NN n=15)) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN with) (NP (NN drug1)))) (: :) (PP (IN Because) (PP (IN of) (NP (NP (PRP$ their) (NN mechanism)) (PP (IN of) (NP (NN action)))))) (, ,) (NP (NNS drug2)) (VP (VBP have) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN drug3))))))))))) (. .)))
(S1 (S (NP (NP (NN Use)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (JJ Other) (NNS drug2))))) (: :) (S (NP (DT A) (JJ synergistic) (NN effect)) (VP (MD may) (VP (VB be) (VP (VBN expected) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBP are) (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug4)) (, ,) (NP (JJ similar) (NN drug5)) (CC or) (NP (NP (NNS drug6)) (PP (JJ such) (IN as) (NP (NN drug7)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS Reports)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ antihypertensive) (NN effect)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN interaction)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (NP (NN consideration)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)))))) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADJP (CD 1000) (NN mg)) (NN TID)) (-RRB- -RRB-)))) (PP (TO to) (NP (JJ healthy) (NNS volunteers)))) (VP (VBD tended) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NP (NP (NN AUC)) (PRN (-LRB- -LRB-) (NP (CD 10) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NN Cmax)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-)))) (PP (IN of) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (PP (IN as) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ is) (RB not) (ADVP (RB generally)) (VP (VBN recommended) (PP (IN because) (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (VBN increased) (JJ adverse) (NNS effects)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (JJ low-dose) (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (VBN increased) (NN rate)) (PP (IN of) (NP (NP (NN GI) (NN ulceration)) (CC or) (NP (JJ other) (NNS complications)))))) (, ,) (S (VP (VBN compared) (PP (TO to) (NP (NP (NN use)) (PP (IN of) (NP (NP (NN drug3)) (ADVP (RB alone))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (DT a) (VP (VB substitute) (PP (IN for) (NP (NN drug2))) (PP (IN for) (NP (JJ cardiovascular) (NN prophylaxis))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Pretreatment)) (PP (IN for) (NP (CD four) (NNS days))) (PP (IN with) (NP (NN drug2)))) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug3))) (PP (IN by) (NP (CD 50) (NN %)))))) (. .))))
(S1 (S (S (NP (DT This)) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN t1/2)) (PRN (, ,) (PP (IN from) (NP (NP (CD 19.2) (NNS hours)) (PP (TO to) (NP (CD 12.5) (NNS hours))))) (, ,))))) (CC and) (NP (NP (DT a) (CD 35) (NN %) (NN reduction)) (PP (IN in) (NP (NN AUC)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ suggests) (NP (NP (DT the) (NN existence)) (PP (IN of) (NP (NP (DT a) (NN recirculation) (NN pathway)) (PP (IN for) (NP (NN drug1))))) (PP (IN in) (NP (DT the) (JJ gastrointestinal) (NN tract)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (CD 200) (NN mg) (JJ drug2) (JJ QID)))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (JJ single-dose) (NNS pharmacokinetics)) (PP (IN of) (NP (ADJP (CD 30) (NN mg)) (NN drug3))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NP (NN drug2) (CD 15) (NN mg)) (ADJP (RB once) (JJ daily) (PP (IN for) (NP (CD 7) (NNS days)))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN plasma) (NN concentration) (NN profile)) (PP (IN of) (NP (NN drug3)))) (PP (IN after) (NP (NP (JJ b-acetyldigoxin) (NN administration)) (PP (IN for) (NP (NP (CD 7) (NNS days)) (PP (IN at) (NP (JJ clinical) (NNS doses)))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NN testing)) (VP (VBD found) (NP (NP (DT no) (NN protein) (NN binding) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Clinical) (NNS studies)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ post-marketing) (NNS observations)) (, ,)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug2)) (VP (MD can) (VP (VB reduce) (NP (NP (DT the) (JJ natriuretic) (NN effect)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (IN in) (NP (DT some) (NNS patients))))))))))) (. .))))
(S1 (S (S (NP (DT This) (NN effect)) (VP (VBZ has) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (PP (IN with) (NP (NP (NN drug1) (NNS agents)) (CC and) (NP (NNS drug2))))) (VP (VBP have) (RB not) (VP (VBN demonstrated) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ natriuretic) (NN effect))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (ADJP (ADJP (JJ single)) (CC and) (ADJP (JJ multiple))) (NP (NP (NN dose) (NNS pharmacodynamics)) (CC and) (NP (NNS pharmacokinetics)))) (VP (VBP are) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NN drug2)))))))) (. .))))
(S1 (S (S (ADVP (RB Nevertheless)) (, ,) (PP (IN during) (NP (NP (JJ concomitant) (NN therapy)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN observed) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (S (VP (VP (VBG declining) (NP (JJ renal) (NN function))) (, ,) (CONJP (RB as) (RB well) (IN as)) (VP (TO to) (VP (VB assure) (NP (JJ diuretic) (NN efficacy))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NNS drug2)) (VP (VBP have) (VP (VBN produced) (NP (NP (NP (DT an) (NN elevation)) (PP (IN of) (NP (NN plasma) (NN drug3) (NNS levels)))) (CC and) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (JJ renal) (NN drug4) (NN clearance)))))))) (. .))))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (VP (VBN conducted) (PP (IN in) (NP (JJ healthy) (NNS subjects)))))) (, ,) (NP (NP (NN mean) (NN pre-dose) (NN drug1) (NN concentration)) (CC and) (NP (NN AUC))) (VP (VBD were) (VP (VBN increased) (PP (IN by) (NP (CD 21) (NN %))) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug2) (NNS doses)) (VP (VBG ranging) (PP (IN from) (NP (CD 804))) (PP (TO to) (NP (ADJP (CD 1072) (NN mg)) (NN BID))))) (PP (IN with) (NP (NP (NN drug3) (ADJP (CD 15) (NN mg)) (NN QD)) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NP (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug4)) (ADVP (RB alone)))))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBP have) (VP (VBN been) (VP (VBN attributed) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ renal) (NN prostaglandin) (NN synthesis))) (PP (IN by) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug1) (NN treatment)))) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VP (VBN introduced)) (CC or) (VP (VBN withdrawn)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT A) (NN study)) (PP (IN in) (NP (NP (NP (CD 13) (JJ rheumatoid) (NN arthritis)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (NNS patients)))) (VP (VBD evaluated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NN drug2))))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))) (VP (VBN taken) (ADVP (RB once) (RB weekly)))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB have) (NP (DT a) (JJ significant) (NN effect)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (JJ single) (NNS doses)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB displace) (NP (NN drug2)) (PP (IN from) (NP (PRP$ its) (JJ human) (NN serum) (NN binding) (NNS sites)))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN Anticoagulant) (NN activity)) (VP (MD should) (VP (VB be) (VP (VBN monitored))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (DT the) (JJ first) (JJ few) (NNS days)) (PP (IN after) (S (VP (VP (VBG initiating)) (CC or) (VP (VBG changing) (NP (NP (NN drug2) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (ADJP (ADJP (JJ drug3)) (CC or) (ADJP (JJ similar))) (NNS agents)))))))))))) (, ,) (SBAR (IN since) (S (NP (DT these) (NNS patients)) (VP (VBP are) (PP (IN at) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding)))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (NN drug2)))))) (VP (VBD was) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (NN group)) (PP (IN of) (NP (NP (JJ healthy) (NNS subjects)) (VP (VBG receiving) (NP (NP (JJ daily) (NNS doses)) (PP (IN of) (NP (NN drug3))) (SBAR (WHNP (WDT that)) (S (VP (VBD produced) (NP (NP (NP (DT an) (NN INR)) (PRN (-LRB- -LRB-) (NP (NP (NNP International)) (VBN Normalized) (NN Ratio)) (-RRB- -RRB-))) (PP (IN between) (NP (NP (CD 1.2)) (CC and) (NP (CD 1.8))))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT these) (NNS subjects))) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (NN drug2) (NNS pharmacokinetics)) (CC and) (NP (NP (DT the) (JJ average) (NN anticoagulant) (NN effect)) (PP (IN of) (NP (NN drug3))))) (SBAR (IN as) (S (VP (VBN determined) (PP (IN by) (NP (NN prothrombin) (NN time))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (CD one) (NN subject)) (VP (VBD showed) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NNS INR)) (PP (IN from) (NP (CD 1.5) (TO to) (CD 2.1)))))))) (. .)))
(S1 (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NN drug2))) (SBAR (IN since) (S (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug3)))) (VP (MD may) (VP (VBP experience) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NN INR)))) (CC and) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (JJ bleeding) (NNS complications))))) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (JJ new) (NN medication)) (VP (VBZ is) (VP (VBN introduced))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VBP inhibit) (NP (NP (DT the) (JJ hepatic) (NN metabolism)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (VP (VBN given) (PP (IN at) (NP (DT a) (JJ common) (JJ clinical) (NN dosage)))) (, ,)) (VP (VP (VBD increased) (NP (DT the) (NN drug2) (NN half-life)) (PP (IN by) (NP (CD 51) (NN %)))) (CC and) (VP (VBD decreased) (NP (DT the) (NN drug3) (JJ metabolic) (NN clearance) (NN rate)) (PP (IN by) (NP (CD 30) (NN %)))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (VP (VBG administering) (NP (DT these) (NNS drugs)) (ADVP (RB concurrently))))) (, ,) (NP (PRP one)) (VP (MD should) (VP (VB be) (ADJP (JJ alert) (PP (IN for) (NP (JJ possible) (JJ excessive) (NN drug1) (NN effect))))))) (. .)))
(S1 (S (S (NP (JJ Excessive) (NN glucocorticoid) (NN therapy)) (VP (MD will) (VP (VB inhibit) (NP (NP (DT the) (JJ growth-promoting) (NN effect)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NN ACTH) (NN deficiency)))) (VP (MD should) (VP (VB have) (NP (NP (PRP$ their) (JJ drug1) (JJ -replacement) (NN dose)) (VP (ADVP (RB carefully)) (VBN adjusted) (S (VP (TO to) (VP (VB avoid) (NP (NP (DT an) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NN growth)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ chronic) (JJ renal) (NN insufficiency))) (VP (VBG receiving) (NP (NN glucocorticoid) (NN therapy)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (JJ Concomitant) (NN glucocorticoid) (NN therapy)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (JJ growth-promoting) (NN effect)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1) (NN replacement)) (VP (VBZ is) (VP (VBN required))))) (, ,) (NP (DT the) (NN drug2) (NN dose)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN adjusted))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (DT no) (NN evidence)) (PP (IN in) (NP (NP (DT the) (JJ controlled) (NNS studies)) (PP (IN of) (NP (NP (NN drug1) (NN s) (NN interaction)) (PP (IN with) (NP (NP (NNS drugs)) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (NP (JJ chronic) (JJ renal) (NN insufficiency)) (NNS patients)))))))))))) (. .)))
(S1 (S (S (NP (JJ Limited) (VBN published) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1) (NN treatment)) (VP (VBZ increases) (NP (NP (NP (NN cytochrome) (NN P450)) (PRN (-LRB- -LRB-) (NP (NN CP450)) (-RRB- -RRB-))) (VP (VBN mediated) (PP (IN drug2) (NP (NP (NN clearance)) (PP (IN in) (NP (NN man)))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN drug1) (NN administration)) (VP (MD may) (VP (VB alter) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NNS compounds)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CP450) (NN liver) (NNS enzymes)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)))) (, ,) (NP (NNS drug5)) (-RRB- -RRB-)))))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Careful) (NN monitoring)) (VP (VBZ is) (ADJP (JJ advisable)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN metabolized) (PP (IN by) (NP (NN CP450) (NN liver) (NNS enzymes)))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (JJ other) (JJ addictive) (NNS medications)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT that))) (S (NP (PRP it)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN likelyhood)) (PP (IN of) (NP (NP (NN addiction)) (CC and) (NP (NN abuse)))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drug2))))) (VP (MD may) (VP (VB increase) (NP (NP (NP (DT the) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (NN drug3)))) (CC or) (NP (DT these) (JJ other) (NNS medications)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (JJ oral) (NN drug2)) (, ,) (NP (JJ certain) (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8)))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NP (NNS compounds)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized/eliminated) (ADVP (RB predominantly)) (PP (IN by) (NP (NP (DT the) (NN UGT1A1) (NN pathway)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NNS drug2)) (-RRB- -RRB-)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN treatment)) (PP (IN with) (NP (NN drug1)))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (ADJP (CD 21) (NN %)) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (NP (NN CYP2B6)) (CC and) (NP (NN CYP2C8))) (ADVP (FW in) (FW vitro)) (PP (IN with) (NP (NP (NN Ki) (NNS values)) (PP (IN of) (NP (NP (NP (CD 6)) (CC and) (NP (CD 1-2))) (. ?) (NP (NN M)))) (, ,) (ADVP (RB respectively)))))) (. .)))
(S1 (S (S (NP (NP (JJ Systemic) (NN exposure)) (PP (TO to) (NP (NP (NNS substrates)) (PP (IN of) (NP (NP (NN CYP2B6)) (CC and) (NP (NN CYP2C8))))))) (VP (VBZ is) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN recommended) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NNS substrates)) (PP (IN of) (NP (NP (NN CYP2B6)) (CC and) (NP (NN CYP2C8))))) (PP (IN with) (NP (NN drug1))))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1)))))) (, ,) (S (NP (NN drug2)) (VP (MD may) (VP (VP (VB enhance)) (CC or) (VP (VB precipitate) (NP (NP (NN bradycardia)) (, ,) (NP (NNP A.V.)))))))))
(S1 (S (NP (NP (NP (NN block)) (CC or) (NP (NN arrhythmia))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP stimulate) (NP (NP (JJ alpha-adrenergic) (NNS receptors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN drug5)))) (-RRB- -RRB-))))))))) (VP (MD may) (VP (VP (VB enhance)) (CC or) (VP (VB potentiate) (NP (NP (DT the) (NN pressor) (NNS effects)) (PP (IN of) (NP (NN drug6))))))) (. .)) (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug7)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP cause) (NP (NN vasoconstriction)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBN treated) (PP (IN with) (NP (NP (JJ salt-retaining) (NN steroid) (NN therapy)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NNS drug2)) (-RRB- -RRB-))))))) (, ,) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (NN salt) (NN supplementation)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN potential)) (PP (IN for) (NP (JJ supine) (NN hypertension)))) (VP (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored) (PP (IN in) (NP (DT these) (NNS patients)))))) (CC and) (VP (MD may) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (CC either) (VP (VBG reducing) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1))))) (CC or) (VP (VBG decreasing) (NP (NP (DT the) (NN salt) (NN intake)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with))))))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (. .) (NP (NN drug2)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))) (, ,)) (VP (MD can) (VP (VB antagonize) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug6)))))) (. .)) (NP (NP (NN Potential)) (PP (IN for) (NP (NN Drug) (NNS Interactions))))) (: :) (S (NP (PRP It)) (VP (VBZ appears) (ADJP (JJ possible)) (, ,) (SBAR (IN although) (S (NP (EX there)) (VP (VBZ is) (NP (DT no) (VBG supporting) (JJ experimental) (NN evidence)) (, ,) (SBAR (IN that) (S (NP (NP (DT the) (JJ high) (JJ renal) (NN clearance)) (PP (IN of) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (DT a) (NN base)) (-RRB- -RRB-))))) (VP (VBZ is) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ active) (JJ tubular) (NN secretion)) (PP (IN by) (NP (NP (DT the) (JJ base-secreting) (NN system)) (ADJP (RB also) (JJ responsible) (PP (IN for) (NP (NP (NP (DT the) (NN secretion)) (PP (IN of) (NP (NP (JJ such) (NNS drugs)) (PP (IN as) (NP (NN drug8)))))) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (NN drug13)) (, ,) (CC and) (NP (NN drug14)))))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (NP (EX there)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN potential)) (PP (IN for) (NP (NP (JJ drug-drug) (NNS interactions)) (PP (IN with) (NP (DT these) (NNS drugs))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB enhance) (NP (NP (DT the) (JJ sedative) (NN activity)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))))))))))) (. .)))
(S1 (S (NP (NP (JJ Peripheral) (NN Neuropathy)) (: :) (S (NP (NP (NNS Medications)) (VP (VBN known) (S (VP (TO to) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (JJ peripheral) (NN neuropathy))))))))) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))))))) (. .))))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (PP (IN In) (NP (CD 10) (JJ healthy) (NNS women))) (, ,) (NP (NP (DT the) (JJ pharmacokinetic) (NNS profiles)) (PP (IN of) (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (VP (VBG containing) (NP (NP (NP (CD 1.0) (NN mg)) (PP (IN of) (NP (NN drug4)))) (CC and) (NP (NP (CD 75) (NN g)) (PP (IN of) (NP (NN drug5))))))))))))) (VP (VBD were) (VP (VBN studied)))) (. .))))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBD were) (ADJP (JJ similar)) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1) (CD 200) (NN mg/day))) (PP (TO to) (NP (JJ steady-state) (NNS levels)))))))) (. .)))
(S1 (S (NP (NP (JJ Important) (NN Non-) (NN drug1) (NN Drug) (NNS Interactions)) (NP (NP (NNS Drugs)) (SBAR (IN That) (S (VP (VBP Interfere) (PP (IN with) (NP (NN drug2))))))) (: :) (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC or) (NP (NP (JJ certain) (JJ herbal) (NNS supplements)) (PP (JJ such) (IN as) (NP (NN St.))))))))))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NP (DT the) (NP (NN contraception)) (CC and) (NP (QP (RB up) (TO to) (CD one)) (NN month))) (PP (IN after) (NP (NP (NN discontinuation)) (PP (IN of) (NP (DT these) (JJ concomitant) (NNS therapies))))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (NP (NNS women)) (VP (VBG requiring) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (NP (CD one)) (CC or) (NP (JJR more))) (PP (IN of) (NP (DT these) (NNS drugs)))))))) (VP (MD must) (VP (VB use) (NP (NP (CD two) (JJ OTHER) (ADJP (ADJP (JJ effective)) (CC or) (ADJP (RB highly) (JJ effective))) (NNS methods)) (PP (IN of) (NP (NP (NN contraception)) (CC or) (NP (NN abstain))))) (PP (IN from) (NP (JJ heterosexual) (JJ sexual) (NN contact)))) (SBAR (IN while) (S (VP (VBG taking) (NP (NN drug1)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (JJ other) (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP increase) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (JJ antihypertensive) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (JJ myeloproliferative) (NNS effects)) (PP (IN of) (NP (NN drug1)))))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (ADJP (FW in) (FW vitro)) (NN binding)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (JJ human) (NN plasma) (NNS proteins)))) (VP (VBZ is) (VP (VBN unaffected) (PP (IN by) (NP (NN drug2)))))) (, ,) (CC and) (S (NP (NN drug3)) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NP (DT the) (NN prothrombin) (NN time)) (PP (IN of) (NP (JJ normal) (NNS volunteers)))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (VBN increased) (NN prothrombin) (NN time)) (CC and) (NP (JJ bleeding))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ concomitant) (NN drug1)) (CC and) (NP (JJ drug2) (NN therapy)))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (JJ adult) (JJ diabetic) (NNS patients)) (PP (IN under) (NP (NP (NN treatment)) (PP (IN with) (NP (CC either) (NP (NN drug1)) (CC or) (NP (NN drug2)))))))) (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NP (DT the) (JJ clinical) (NNS effects)) (PP (IN of) (NP (CC either) (NP (NN drug3)) (CC or) (NP (DT the) (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN drug2))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug3)))) (PP (IN in) (NP (DT an) (JJ animal) (NN model))) (, ,) (S (ADVP (RB possibly)) (VP (VBG enhancing) (NP (NP (DT the) (NN toxicity)) (PP (IN of) (NP (NN drug4))))))))))))) (. .)))
(S1 (S (NP (NN Laboratory) (NNS Tests)) (SBAR (IN Because) (S (NP (NP (JJ serious) (NN GI) (NN tract) (NN ulceration)) (CC and) (NP (JJ bleeding))) (VP (MD can) (VP (VB occur) (PP (IN without) (NP (JJ warning) (NNS symptoms))))))) (, ,) (NP (NNS physicians)) (VP (VP (MD should) (VP (VBP follow) (NP (NP (ADJP (RB chronically) (VBN treated)) (NNS patients)) (PP (IN for) (NP (NP (DT the) (NP (NNS signs)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NP (NN ulceration)) (CC and) (NP (ADJP (JJ bleeding)))))))))) (CC and) (VP (MD should) (VP (VB inform) (NP (PRP them)) (PP (IN of) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT this) (NN follow-up)))))))) (. .)))
(S1 (S (S (S (NP (NP (DT An) (NN inhibitor)) (PP (IN of) (NP (NP (NN CYP2C8)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug1)))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug2))))))) (CC and) (S (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NP (NN CYP2C8)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug3)))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (DT an) (NN inhibitor)) (CC or) (NP (NP (DT an) (NN inducer)) (PP (IN of) (NP (NN CYP2C8))))) (VP (VBZ is) (VP (VP (VBN started)) (CC or) (VP (VBN stopped) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1)))))))))) (, ,) (NP (NP (NNS changes)) (PP (IN in) (NP (NN diabetes) (NN treatment)))) (VP (MD may) (VP (VB be) (VP (VBN needed) (PP (VBN based) (PP (IN upon) (NP (JJ clinical) (NN response)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Pharmacokinetic) (NNS properties)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (RB not) (VP (VBN altered) (PP (IN by) (NP (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (CC either) (NP (NN drug2)) (CC or) (NP (NN drug3))))) (CC or) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (ADJP (RB clinically) (JJ significant)) (NNS changes)) (PP (TO to) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)) (NP (NNS pharmacokinetics))))) (VP (VBD were) (VP (VBN observed) (PP (VBG following) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ pharmacokinetic) (NNS properties)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ decreases) (NP (NP (DT the) (NN elimination)) (PP (IN of) (NP (NP (NNS drug2)) (VP (VBG causing) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ overall) (NN exposure))))))))) (. .)) (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN drug3)))) (VP (VBZ has) (NP (DT no) (ADJP (RB clinically) (JJ significant)) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ pharmacokinetic) (NNS properties)) (PP (IN of) (NP (NN drug4)))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NP (CD 11) (JJ HIV-infected) (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1) (NN -maintenance) (NN therapy)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 40) (NN mg)) (CC and) (NP (CD 90) (NN mg))) (ADVP (RB daily))) (-RRB- -RRB-))) (PP (IN with) (NP (NP (NP (NP (CD 600) (NN mg)) (PP (IN of) (NP (NN drug2)))) (ADVP (RB twice) (RB daily))) (PRN (-LRB- -LRB-) (NP (ADVP (RB twice)) (NP (DT the) (ADJP (RB currently) (VBN recommended)) (NN dose))) (-RRB- -RRB-))))))))) (, ,) (NP (JJ oral) (NN drug3) (NN clearance)) (VP (VBD increased) (NP (NP (CD 22) (NN %)) (PRN (-LRB- -LRB-) (NP (CD 90) (NN %) (NN CI) (CD 6) (NN %) (TO to) (CD 42) (NN %)) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (DT This) (NN alteration)) (VP (MD will) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT a) (JJ drug1) (NN dose) (NN modification)) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NNS patients)))))))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (DT an) (VBN increased) (NN drug1) (NN dose)) (VP (MD may) (VP (VB be) (VP (VBN required) (PP (IN in) (NP (NP (DT a) (JJ small) (NN number)) (PP (IN of) (NP (NNS patients))))))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3) (NN USP)) (-RRB- -RRB-)))) (SBAR (IN because) (S (NP (PRP they)) (VP (MD may) (VP (VB have) (NP (JJ additive) (NNS effects)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug4))) (PP (IN on) (NP (DT the) (JJ vascular) (NN system)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated)))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN study)) (VP (VBN published) (PP (IN in) (NP (NN 2002))))) (VP (VBD found) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ causes) (NP (NP (DT a) (ADJP (RB statistically) (JJ significant)) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NN clearance)) (PP (IN of) (NP (NN drug2))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN 1984))) (, ,) (NP (NP (NNS Drs) (NP (NP (NNP Rimmer)) (CC and) (NP (NNP Richens)))) (PP (IN at) (NP (NP (DT the) (NNP University)) (PP (IN of) (NP (NN Wales)))))) (VP (VBD reported) (SBAR (IN that) (S (S (VP (VBG administering) (NP (NN drug1)) (PP (IN with) (NP (NN drug2))))) (VP (VBD lowered) (NP (DT the) (NN serum) (NN drug3) (NN concentration)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ treatment-resistant) (NN epilepsy))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN concentration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ falls) (PP (TO to) (NP (CD 23) (NN %))) (PP (IN within) (NP (NP (CD five) (NNS weeks)) (, ,) (VP (VBG according) (PP (TO to) (NP (NP (DT an) (NN experiment)) (VP (VBN published) (PP (IN in) (NP (CD 1989))) (PP (IN by) (NP (NP (DT the) (JJ same) (CD two) (NNS scientists)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBD tried)) (CC and) (VP (VBD failed) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (NN mechanism)) (VP (VBP behind) (NP (DT this) (NN interaction))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ sedative) (NNS effects)) (PP (IN of) (NP (NN drug2))) (PP (VBG including) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NN drug8)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (IN by) (NP (NP (DT the) (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB effect) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NNS drugs))) (PP (IN in) (NP (DT the) (NN liver))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NNS drugs))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB fully)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1) (NN therapy)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN mixed) (PP (IN with) (NP (DT any) (JJ other) (NN drug))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (JJ cardioactive) (NNS drugs)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (PP (IN In) (NN addition) (TO to) (NP (NP (JJ bleeding)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (, ,) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (NN platelet) (NN function)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (-RRB- -RRB-)))))) (VP (MD may) (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (JJ bleeding))) (SBAR (IN if) (S (VP (VBN administered) (UCP (ADVP (RB prior) (PP (TO to))) (CC or) (PP (IN after) (NP (NN drug6) (NN therapy)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN occurrence)) (PP (IN of) (NP (NP (NN stupor)) (, ,) (NP (JJ muscular) (NN rigidity)) (, ,) (NP (JJ severe) (NN agitation)) (, ,) (CC and) (NP (JJ elevated) (NN temperature))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBG receiving) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NNS Symptoms)) (ADVP (RB usually)) (VP (VBP resolve) (PP (IN over) (NP (NNS days))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN combination)) (VP (VBZ is) (VP (VBN discontinued))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ is) (ADJP (JJ typical) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (JJ serious) (NNS reactions)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (JJ severe) (NN agitation)) (, ,) (NP (NNS hallucinations)) (, ,) (CC and) (NP (NN death)))) (-RRB- -RRB-))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT this) (NN combination))))))))) (. .)))
(S1 (S (S (NP (JJ Severe) (NN toxicity)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (CC and) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))))))))))) (. .)))
(S1 (S (S (NP (NP (CD One) (NN case)) (PP (IN of) (NP (NN hypertensive) (NN crisis)))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (DT a) (NN patient)) (VP (VBG taking) (NP (NP (NP (DT the) (VBN recommended) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT a) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN used) (ADVP (RB together)))))) (, ,) (NP (NP (DT the) (NNS signs)) (PP (IN of) (NP (NP (NN atropinization)) (PRN (-LRB- -LRB-) (NP (NP (NN flushing)) (, ,) (NP (NN mydriasis)) (, ,) (NP (NN tachycardia)) (, ,) (NP (NP (NN dryness)) (PP (IN of) (NP (DT the) (NN mouth)))) (CC and) (NP (NN nose))) (-RRB- -RRB-))))) (VP (MD may) (VP (VB occur) (ADVP (RBR earlier) (SBAR (IN than) (S (VP (MD might) (VP (VB be) (VP (VBN expected) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN used) (ADVP (RB alone))))))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ is) (ADJP (RB especially) (JJ true)) (SBAR (IN if) (S (S (NP (NP (DT the) (JJ total) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ has) (VP (VBN been) (ADJP (JJ large))))) (CC and) (S (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN delayed))))))))) (. .)))
(S1 (S (S (NP (NP (NP (CD 2)) (CC -) (NP (CD 4))) (DT The) (VBG following) (NNS precautions)) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NN anticholinesterase) (NN poisoning))))) (, ,) (SBAR (IN although) (S (NP (PRP they)) (VP (VBP do) (RB not) (VP (VB bear) (ADVP (RB directly)) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))))))))))))) (: :) (S (SBAR (IN since) (S (NP (NNS drug2)) (VP (VBP are) (VP (VBN potentiated) (PP (IN by) (NP (DT the) (NN drug3))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NNS convulsions))))))))) (: ;)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ organophosphate) (NN poisoning))))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))))) (VP (MD may) (ADVP (RB significantly)) (VP (VBP decrease) (NP (NP (DT the) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN Laboratory) (NNS Tests) (NP (DT The) (NN pathologist))) (VP (MD should) (VP (VB be) (VP (VBN advised) (PP (IN of) (NP (NN progestin) (NN therapy))))) (SBAR (WHADVP (WRB when)) (S (NP (JJ relevant) (NNS specimens)) (VP (VBP are) (VP (VBN submitted))))))) (. .)))
(S1 (S (S (S (NP (DT The) (NN physician)) (VP (MD should) (VP (VB be) (VP (VBN informed) (SBAR (IN that) (S (NP (NP (JJ certain) (NN endocrine) (CC and) (NN liver) (NN function) (NNS tests)) (, ,) (CC and) (NP (NN blood) (NNS components))) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NN progestin) (NN therapy)))))))))))) (: :) (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-)) (S (NP (NN Plasma) (CC and) (JJ urinary) (NN steroid) (NNS levels)) (VP (VBP are) (VP (VBN decreased) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN progesterone)) (, ,) (NP (NN estradiol)) (, ,) (NP (NN pregnanediol)) (, ,) (NP (NN testosterone)) (, ,) (NP (NN cortisol))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-)) (NP (NN Plasma) (CC and) (JJ urinary) (NN gonadotropin) (NNS levels)) (VP (VBP are) (VP (VBN decreased) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN LH))) (, ,) (NP (NN FSH)) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-)) (NN SHBG) (NNS concentrations)) (VP (VBP are) (VP (VBN decreased)))) (. .)))
(S1 (S (S (NP (-LRB- -LRB-) (NN d) (-RRB- -RRB-) (JJ T3-uptake) (NNS values)) (VP (MD may) (VP (VB decrease)))) (. .)))
(S1 (S (S (NP (PRN (-LRB- -LRB-) (NP (NN e)) (-RRB- -RRB-)) (NP (EX There))) (VP (MD may) (VP (VB be) (NP (NP (JJ small) (NNS changes)) (PP (IN in) (NP (NN coagulation) (NNS factors))))))) (. .)))
(S1 (S (S (NP (NP (-LRB- -LRB-) (NN f) (-RRB- -RRB-) (NN Sulfobromophthalein)) (CC and) (NP (JJ other) (NN liver) (NN function) (NN test) (NNS values))) (VP (MD may) (VP (VB be) (VP (VBN increased) (ADVP (RB slightly)))))) (. .)))
(S1 (S (S (NP (PRN (-LRB- -LRB-) (NP (NN g)) (-RRB- -RRB-)) (NP (EX There))) (VP (MD may) (VP (VB be) (NP (NP (JJ small) (NNS changes)) (PP (IN in) (NP (NN lipid) (NNS profiles))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (JJ clinical) (NNS studies)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2)))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (, ,) (NP (NNP Genentech)) (-RRB- -RRB-))) (, ,) (NP (NN drug5)) (, ,) (NP (JJ inhaled) (NN drug6)) (, ,) (NP (JJ other) (NN drug7)) (, ,) (CC or) (NP (JJ parenteral) (NN drug8))))) (VP (VBD demonstrated) (ADJP (JJ adverse) (S (VP (VBP experience) (NP (NP (NNS profiles)) (ADJP (JJ similar) (PP (TO to) (NP (DT the) (NN study) (NN population))))) (PP (IN as) (NP (DT a) (JJ whole))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (ADJP (JJ Concurrent)) (CC and/or) (ADJP (JJ sequential))) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (PP (IN with) (NP (ADJP (ADJP (JJ neurotoxic)) (CC or) (ADJP (JJ ototoxic))) (NN potential)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (DT Some) (NN drug1)) (VP (MD can) (VP (VB enhance) (NP (NN drug2) (NN toxicity)) (PP (IN by) (S (VP (VBG altering) (NP (NP (NN drug3) (NNS concentrations)) (PP (IN in) (NP (NP (NN serum)) (CC and) (NP (NN tissue))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC or) (NP (NN drug5)))))))) (. .)))
(S1 (S (S (S (NP (NP (NN DRUG) (NNS INTERACTIONS)) (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (NN drug/drug) (NNS interactions)) (PP (IN with) (NP (JJ oral) (NN drug1) (NN Vaccinations))) (PP (IN with) (NP (NN drug2))))))) (VP (VBP are) (RB not) (VP (VBN recommended) (PP (IN in) (NP (JJ immunocompromised) (NNS individuals)))))) (S (NP (NP (NN drug3)) (PP (ADVP (RB together)) (IN with) (NP (JJ high-dose) (JJ intravenous) (NN drug4)))) (VP (VBZ has) (VP (VBN caused) (NP (NP (NNS deaths)) (PP (IN in) (NP (NP (NNS children)) (ADJP (JJ due) (PP (TO to) (NP (JJ haemorrhagic) (NN enterocolitis))))))))))) (. .)))
(S1 (S (NP (JJ Impaired) (JJ renal) (NN function)) (VP (VBZ has) (VP (VBN been) (VP (VBN described) (PP (IN in) (NP (NP (NP (NN bone) (NN marrow)) (NN transplant) (NNS patients)) (SBAR (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VBN conditioned) (PP (IN with) (NP (JJ high-dose) (JJ intravenous) (NN drug1))))))) (CC and) (SBAR (WHNP (WP who)) (S (ADVP (RB subsequently)) (VP (VBD received) (NP (NN drug2)) (S (VP (TO to) (VP (VB prevent) (NP (JJ graft-versus-host) (NN disease))))))))))))))))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug2)) (PP (IN because) (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NN conduction) (NNS disturbances)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (PP (IN with) (NP (NP (JJ parasympathomimetic) (NNS effects)) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug1))))))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (JJ additive) (JJ pharmacologic) (NNS effects)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD might) (VP (VB antagonize) (NP (NP (DT the) (JJ anticholinergic) (NNS effects)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN used) (ADVP (RB concomitantly))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN when) (NP (NP (JJ anticholinergic) (NNS properties)) (VP (MD may) (VP (VB be) (VP (VBG contributing) (PP (TO to) (NP (NP (DT the) (JJ therapeutic) (NN effect)) (PP (IN of) (NP (NP (JJ concomitant) (NN medication)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (, ,) (NP (JJ inhaled) (NNS drug2)) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (DT no) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed)))))) (, ,) (NP (DT the) (JJ following) (JJ concomitant) (NNS drugs)) (VP (VBD were) (VP (VBN used) (PP (IN in) (NP (NP (NP (QP (IN at) (JJS least) (CD 10)) (NN %)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (DT either)))))) (CC or) (NP (DT both) (NN Sj) (NNS grens)) (NP (NN efficacy) (NNS studies)) (: :) (NP (NN drug1)) (, ,) (NP (JJ artificial) (NNS tears)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (CD drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (CD drug12)) (, ,) (CC and) (NP (NN drug13))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN induction) (NN dose) (NNS requirements)) (PP (IN of) (NP (NN drug1) (JJ Injectable) (NN Emulsion)))) (VP (MD may) (VP (VB be) (VP (VBN reduced) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (ADJP (JJ intramuscular)) (CC or) (ADJP (JJ intravenous))) (NN premedication))))) (, ,) (ADVP (RB particularly)) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)) (, ,) (NP (NN etc)) (. .)) (-RRB- -RRB-)))))))))
(S1 (S (CC and) (NP (NP (NNS combinations)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN etc)) (. .)) (-RRB- -RRB-)) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (ADJP (ADJP (JJ anesthetic)) (CC or) (ADJP (JJ sedative))) (NNS effects)) (PP (IN of) (NP (JJ drug1) (JJ Injectable) (NN Emulsion)))))) (CC and) (VP (MD may) (ADVP (RB also)) (VP (VB result) (PP (IN in) (NP (NP (ADJP (RBR more) (JJ pronounced)) (NNS decreases)) (PP (IN in) (NP (NP (ADJP (ADJP (JJ systolic)) (, ,) (ADJP (JJ diastolic)) (, ,) (CC and) (ADJP (NN mean) (JJ arterial))) (NNS pressures)) (CC and) (NP (JJ cardiac) (NN output)))))))))) (. .)))
(S1 (S (PP (IN During) (NP (NP (NN maintenance)) (PP (IN of) (NP (NP (NN anesthesia)) (CC or) (NP (NN sedation)))))) (, ,) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (JJ drug1) (JJ Injectable) (NN Emulsion) (NN administration)))) (VP (VP (MD should) (VP (VB be) (VP (VBN adjusted) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (JJ desired) (NN level)) (PP (IN of) (NP (NP (NN anesthesia)) (CC or) (NP (NN sedation)))))))))) (CC and) (VP (MD may) (VP (VB be) (VP (VBN reduced) (PP (IN in) (DT the) (NN presence) (IN of) (NP (NP (JJ supplemental) (NNS drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3)) (CC or) (NP (NN drug4))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (JJ potent) (JJ inhalational) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (-RRB- -RRB-)))) (PP (IN during) (NP (NP (NN maintenance)) (PP (IN with) (NP (NN drug4) (JJ Injectable) (NN Emulsion)))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB extensively)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (DT These) (JJ inhalational) (NNS agents)) (VP (MD can) (ADVP (RB also)) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (JJ anesthetic) (ADJP (CC or) (ADJP (JJ sedative)) (CC and) (ADJP (JJ cardiorespiratory))) (NNS effects)) (PP (IN of) (NP (JJ drug1) (JJ Injectable) (NN Emulsion))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (JJ Injectable) (NN Emulsion)) (VP (VBZ does) (RB not) (VP (VB cause) (NP (NP (DT a) (ADJP (RB clinically) (JJ significant)) (NN change)) (PP (IN in) (NP (NP (NP (NN onset)) (, ,) (NP (NN intensity)) (, ,) (CC or) (NP (NN duration))) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NP (DT the) (ADJP (RB commonly) (VBN used)) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ significant) (JJ adverse) (NNS interactions)) (PP (IN with) (NP (NP (ADJP (RB commonly) (VBN used)) (NNS premedications)) (CC or) (NP (NP (NNS drugs)) (VP (VBN used) (PP (IN during) (NP (NP (NN anesthesia)) (CC or) (NP (NN sedation))))) (-LRB- -LRB-) (PP (VBG including) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (JJ inhalational) (NNS agents)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (JJ local) (NN drug3)))))) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (JJ Oral) (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB potentiate) (NP (NP (DT the) (JJ anticoagulant) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (NN prolongation)) (PP (IN of) (NP (NN prothrombin) (NN time))))))))) (. .)))
(S1 (S (S (NP (NN Drug) (NNS interactions)) (VP (MD should) (VP (VB be) (VP (VBN kept) (PP (IN in) (NP (NN mind))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2) (NN gel)) (-RRB- -RRB-))) (, ,) (NP (CD 1) (NN %))) (VP (VBZ is) (VP (VBN prescribed) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (NN anticoagulant) (NN treatment))) (, ,) (SBAR (IN although) (S (NP (PRP they)) (VP (VBP are) (ADJP (RBR less) (JJ likely)) (S (VP (TO to) (VP (VB occur) (PP (IN with) (NP (JJ topical) (NN drug3) (NN administration))) (PP (IN because) (IN of) (NP (JJ low) (NN absorption)))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (NN caution)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN steroid) (NN therapy))))))) (PP (IN because) (IN of) (NP (NP (DT the) (NN potential)) (PP (IN for) (S (VP (VBG developing) (NP (NN hypokalemia))))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (JJ high-dose) (NN drug1)) (CC and) (NP (NN drug2))) (ADVP (RB concomitantly)))))) (, ,) (SBAR (IN as) (S (NP (NP (NN anorexia)) (, ,) (NP (NN tachypnea)) (, ,) (NP (NN lethargy)) (, ,) (NP (NN coma)) (CC and) (NP (NN death))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ high-dose) (NN drug3)) (CC and) (NP (NN drug4)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB be) (VP (VBN used) (PP (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (JJ other) (NNS drug4)))) (, ,) (CC and) (PP (IN with) (NP (JJ other) (NN drug5)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (NNS signs)) (PP (IN of) (NP (NN folate) (NN deficiency)))) (VP (VBP develop)))) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN discontinued))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (MD should) (VP (VB be) (VP (VBN administered) (SBAR (IN until) (S (NP (JJ normal) (NN hematopoiesis)) (VP (VBZ is) (VP (VBN restored))))))))) (. .)))
(S1 (S (S (NP (JJ Mild) (NN hepatotoxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (DT some) (NNS patients))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBD were) (VP (VBN administered) (ADVP (RB concomitantly)))))))))) (. .)))
(S1 (S (PP (IN Due) (PP (TO to) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (JJ gastric) (NN emptying)))))) (, ,) (NP (NN drug1) (NN therapy)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN considered) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (JJ gastrointestinal) (NN motility)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NNS drug2)) (PP (JJ such) (IN as) (NP (NN drug3)))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (JJ slow) (NP (NP (DT the) (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NNS nutrients)))))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug4)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG using) (NP (DT these) (NNS drugs)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (JJ clinical) (NNS trials))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB delay) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (ADJP (RB concomitantly) (VBN administered)) (JJ oral) (NNS medications)))))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (JJ rapid) (NN onset)) (PP (IN of) (NP (DT a) (JJ concomitant) (ADJP (RB orally) (VBN administered)) (NN agent)))) (VP (VBZ is) (NP (NP (DT a) (JJ critical) (NN determinant)) (PP (IN of) (NP (NN effectiveness)))) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NN drug1)))) (-RRB- -RRB-))))) (, ,) (NP (DT the) (NN agent)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN at) (NP (QP (JJS least) (CD 1)) (NN hour))) (ADVP (ADVP (RB prior)) (PP (TO to) (CC or) (NP (NP (CD 2) (NNS hours)) (PP (IN after) (NP (NN drug2) (NN injection))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (JJ adverse) (NN event) (NN profile)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ formal) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NNS kinetics)) (PP (IN of) (NP (JJ oral) (NN drug2))))))))))))) (. .)))
(S1 (S (PP (VBG Mixing) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (NP (NP (DT The) (JJ pharmacokinetic) (NNS parameters)) (PP (IN of) (NP (NN drug3)))) (VP (VBD were) (VP (VBN altered) (SBAR (WHADVP (WRB when)) (S (VP (VBN mixed) (PP (IN with) (NP (NP (UCP (ADJP (JJ regular)) (, ,) (NP (NN NPH)) (, ,) (CC and) (ADJP (NN 70/30) (VBN premixed))) (NNS formulations)) (PP (IN of) (NP (NP (JJ recombinant) (NNS drug4)) (ADJP (RB immediately) (JJ prior) (PP (TO to) (NP (NN injection))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VP (MD should) (RB not) (VP (VB be) (VP (VBN mixed)))) (CC and) (VP (MD must) (VP (VB be) (VP (VBN administered) (ADVP (RB separately))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (DT the) (JJ metabolic) (NNS pathways)) (VP (VBG involving) (NP (NP (NP (NN CYP2D6)) (CC and) (NP (NN CYP1A2))) (NNS enzymes))))))))) (, ,) (NP (NP (NP (NN inhibition)) (CC or) (NP (NN induction))) (PP (IN of) (NP (NP (DT either)) (PP (IN of) (NP (DT these) (NNS enzymes)))))) (VP (MD would) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB alter) (NP (NN drug2) (NN plasma) (NNS concentrations))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT a) (ADJP (ADJP (JJ formal)) (, ,) (ADJP (JJ single-dose))) (NN interaction) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (NN n)) (ADJP (JJ =) (NP (CD 6) (NNS males)))) (-RRB- -RRB-)))) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP (CD 38) (NN %))) (PP (VBG following) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN CYP1A2))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT another) (JJ formal) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (NN n)) (ADJP (JJ =) (NP (NP (NP (CD 8) (JJ extensive)) (CC and) (NP (ADJP (NN n) (JJ =))) (NP (CD 7) (JJ poor) (NNS metabolizers))) (PP (IN of) (NP (NN CYP2D6)))))) (-RRB- -RRB-)))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS kinetics)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (DT the) (JJ poor) (NN CYP2D6) (NN metabolizer) (NN group)))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (JJ metabolic) (NN clearance)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (DT the) (JJ extensive) (NN metabolizer) (NN phenotype)))) (VP (VBD decreased) (PP (IN by) (NP (QP (RB about) (CD 70)) (NN %))) (S (VP (VBG making) (S (NP (DT the) (ADJP (ADJP (JJ poor)) (CC and) (ADJP (JJ extensive))) (NN metabolizer) (NNS groups)) (ADJP (JJ indistinguishable))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN crossover) (JJ steady) (NN state) (NN study))) (, ,) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (VP (VBN unaffected) (PP (IN in) (NP (DT either) (NN phenotype))) (PP (IN by) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (NP (NN Addition)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NN drug2)))) (VP (VBD did) (RB not) (VP (VB lead) (PP (TO to) (NP (NP (JJ further) (JJ electrocardiographic) (NNS parameters) (NNS changes)) (PP (IN of) (NP (NP (NN QRS) (, ,) (NN QTc) (, ,) (NN RR) (, ,) (CC and) (NN PR) (NNS intervals)) (PP (IN than) (NP (NP (NN drug3)) (ADVP (RB alone))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NP (DT either)) (PP (IN of) (NP (DT these) (CD two) (NNS drugs))))) (PP (IN with) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN initiated))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug2)))) (VP (MD should) (VP (VB be) (ADVP (RB slowly)) (VP (VBN titrated) (PP (TO to) (NP (JJ desired) (NN effect))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ large) (JJ compassionate) (NN use) (NN program))) (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (ADJP (RB commonly) (VBN employed)) (NP (ADJP (JJ antianginal))) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3) (IN without) (VBN observed) (NNS interactions)))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN variety)) (PP (IN of) (NP (NP (NNS drug1)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))) (VP (VBD were) (ADVP (RB also)) (VP (VBN added) (, ,) (ADVP (RB sometimes)) (PP (IN with) (NP (NP (JJ improved) (NN control)) (PP (IN of) (NP (JJ ventricular) (NN ectopy)))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (CC or) (NP (NP (JJ other) (JJ hepatic) (NN enzyme) (NNS inducers)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (VP (VBP have) (VP (VBN been) (VP (VBN taken) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug4)))))))) (, ,) (NP (JJ lowered) (NN drug5) (NN plasma) (NNS levels)) (VP (VBP have) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (NP (NN Monitoring)) (PP (IN of) (NP (NN drug1) (NN plasma) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN during) (NP (NP (JJ such) (JJ concurrent) (NN use)) (S (VP (TO to) (VP (VB avoid) (NP (JJ ineffective) (NN therapy)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT a) (JJ formal) (NN study))) (, ,) (NP (NN drug1)) (VP (VBD were) (VP (VBN shown) (ADVP (RB not)) (S (VP (TO to) (VP (VB affect) (NP (NN drug2) (NN plasma) (NNS concentrations)))))))) (. .)))
(S1 (S (S (NP (NP (NN ECG) (NNS intervals)) (PRN (-LRB- -LRB-) (NP (NP (NN PR)) (, ,) (NP (NN QRS)) (, ,) (CC and) (NP (NN QT))) (-RRB- -RRB-))) (VP (VBD were) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (JJ concurrent) (NN drug1)) (CC and) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VP (VB increase)) (, ,) (VP (VB decrease)) (, ,) (CC or) (VP (VBP leave) (NP (JJ unchanged) (NN drug3) (NN plasma) (NNS levels)))))))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN followed) (ADVP (RB carefully)) (PP (IN during) (NP (JJ concurrent) (NN therapy))))))) (. .)))
(S1 (S (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB alter) (NP (NN serum) (NN drug2) (NNS levels))))) (CC but) (S (NP (NP (NN drug3)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ gastrointestinal) (NNS symptoms)) (PP (JJ due) (TO to) (NP (NN drug4))))))))) (, ,)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (JJR lower) (NP (NN serum) (NN drug5) (NNS levels)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (VBN increased) (NN plasma) (NN drug3) (NNS levels)))))) (. .)))
(S1 (S (S (NP (NP (CD One) (JJ controlled) (NN study)) (PP (IN in) (NP (CD eight) (JJ normal) (NNS subjects)))) (VP (VBD showed) (NP (NP (DT a) (CD 72) (NN %) (NN mean) (NN increase)) (PRN (-LRB- -LRB-) (NP (NN range) (CD 35-136) (NN %)) (-RRB- -RRB-))) (PP (IN in) (NP (NN plasma) (NN drug1) (NNS levels))))) (. .)))
(S1 (S (S (NP (DT This) (NN increase)) (VP (VBD was) (VP (VBN observed) (PP (IN at) (NP (NP (DT the) (JJ first) (NN test) (NN point)) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (NP (DT the) (JJ second) (NN day)) (PP (IN after) (S (VP (VBG starting) (NP (NN drug1)))))))))))) (. .)) (S (NP (NN drug2) (NN plasma) (NNS levels)) (VP (VBD returned) (PP (TO to) (NP (ADJP (JJ pre-)) (NN drug3) (NNS values))) (PP (IN within) (NP (NP (NP (CD 48) (NNS hours)) (PP (IN after) (NP (NN discontinuing) (NN drug4))) (. .)) (SBAR (IN If) (S (NP (NP (NN drug5)) (CC and) (NP (NN drug6))) (VP (VBP are) (S (VP (TO to) (VP (VB be) (VP (VBN used) (S (ADVP (RB concurrently)) (, ,) (NP (NN drug7) (NN blood) (NNS levels)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (, ,) (SBAR (WHADVP (RB particularly) (WRB when)) (S (NP (DT the) (NN drug8) (NN dose)) (VP (VBZ is) (VP (VBN changed)))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ appropriate) (NN adjustment)) (PP (IN in) (NP (NN drug1) (NN dose)))) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (. .)))
(S1 (S (S (ADVP (RB Additionally)) (, ,) (PP (IN in) (NP (NP (CD one) (JJ controlled) (NN study)) (PP (IN in) (NP (NP (CD five) (JJ normal) (NNS subjects)) (CC and) (NP (CD seven) (NNS patients)))))) (, ,) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN decreased) (NP (CD 50) (NN %)) (PP (VBG following) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (JJ oral)) (-RRB- -RRB-))) (: :) (S (NP (NP (DT The) (NN activity)) (PP (IN of) (NP (JJ oral) (NN drug2)))) (VP (MD may) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (NN anti-vitamin-K) (NN activity)) (VP (VBN attributed) (PP (TO to) (NP (NN drug3)))))))))) (. .))))
(S1 (S (S (NP (CC -) (NN drug1) (: :) (NN Hyperthyroidism)) (VP (MD may) (VP (VB cause) (NP (NP (DT an) (VBN increased) (NN clearance)) (PP (IN of) (NP (NN beta) (NN ratio))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN dose) (NN reduction)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN needed))) (SBAR (WHADVP (WRB when)) (S (NP (DT a) (JJ hyperthyroid) (NN patient)) (VP (VBZ becomes) (ADJP (JJ euthyroid))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN Serum) (NN digitalis) (NNS levels)) (VP (MD may) (VP (VB be) (VP (VBN increased) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ hyperthyroid) (NNS patients)) (PP (IN on) (NP (DT a) (JJ stable) (NN drug2) (NN regimen)))) (VP (VBP become) (ADJP (JJ euthyroid))))))))) (: ;))))
(S1 (S (S (NP (NP (VBN reduced) (NN dosage)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2) (NN clearance)) (VP (MD may) (VP (VB decrease) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ hyperthyroid) (NNS patients)) (PP (IN on) (NP (DT a) (JJ stable) (NN drug3) (NN regimen)))) (VP (VBP become) (ADJP (JJ euthyroid)))))))) (: ;))))
(S1 (S (S (NP (NP (DT a) (VBN reduced) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN needed))))) (. .)))
(S1 (S (S (NP (JJ Other) (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug2))) (SBAR (IN because) (S (NP (PRP they)) (VP (MD may) (VP (VB have) (NP (JJ additive) (NNS effects)))))))))) (. .)))
(S1 (S (S (NP (DT Some) (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (PRP They)) (VP (MD can) (ADVP (RB either)) (VP (VP (VB increase)) (CC or) (VP (VB decrease) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (DT Those) (NNS drug1)) (VP (VBP include) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB also)) (VP (VB affect) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP include) (S (NP (DT some) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (JJ certain) (NN heart) (NNS medicines)) (, ,) (NP (NN birth) (NN control) (NNS pills)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))) (NN Please)) (VP (VB note) (SBAR (IN that) (S (NP (NN drug7)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (VP (VBN listed) (ADVP (RB here))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN with) (NP (JJ Other) (NN drug1)))) (: :) (NP (NP (DT The) (NN depressant) (NNS effects)) (PP (IN of) (NP (NN drug2)))) (VP (VBP are) (VP (VBN potentiated) (PP (IN by) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ other) (NNS drug3)) (PP (JJ such) (IN as) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC or) (NP (NN drug7))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (JJ oral) (NN drug2)))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ respiratory) (NN depression)) (, ,) (NP (NP (NN hypotension)) (CC and) (NP (JJ profound) (NN sedation))) (CC or) (NP (NN coma)))))))) (. .)))
(S1 (S (NP (NP (NP (NN Interaction)) (PP (IN with) (NP (NN drug1)))) (: :) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6))) (-RRB- -RRB-)))) (VP (MD should) (RB NOT) (VP (VB be) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VP (VBP have) (VP (VBN received))) (CC or) (VP (VBP are) (VP (VBG receiving) (NP (NP (DT a) (NN course)) (PP (IN of) (NP (NN therapy)))) (PP (IN with) (NP (DT a) (NN proof) (NN drug7))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT these) (NNS patients))) (, ,) (NP (DT the) (JJ mixed) (NN agonist/antagonist)) (VP (VP (MD may) (VP (VB alter) (NP (DT the) (JJ analgesic) (NN effect)))) (CC or) (VP (MD may) (VP (VB precipitate) (NP (NN withdrawal) (NNS symptoms)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (JJ hypotensive) (NN effect)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN Use)) (VP (ADVP (RB cautiously)) (PP (IN with) (NP (JJ pressor) (NNS agents))))) (. .)))
(S1 (S (S (NP (JJ Human) (JJ pharmacologic) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))) (-RRB- -RRB-))) (, ,) (NP (NN drug7)) (, ,) (CC and) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11))) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Downward) (NN dosage) (NNS adjustments)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD may) (VP (VB be) (VP (VBN required) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (JJ Serious) (JJ adverse) (NNS events)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (JJ concomitant) (NN use)) (PP (IN with) (NP (NN drug1)))))) (, ,) (SBAR (IN although) (S (NP (NP (DT no) (NN causality)) (PP (IN for) (NP (DT the) (NN combination)))) (VP (VBZ has) (VP (VBN been) (VP (VBN established))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN safety)) (PP (IN of) (S (VP (VBG using) (NP (NN drug1)) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (JJ other) (ADJP (RB centrally) (VBG acting)) (NNS drug3)))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB systemically)) (VP (VBN evaluated))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ strong) (NNS inhibitors)) (PP (IN of) (NP (NP (DT the) (NN CYP3A4) (NN family)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12))) (-RRB- -RRB-))))))) (MD may) (VP (VBZ increases) (NP (NN drug13) (NNS concentrations)))) (. .)))
(S1 (S (S (NP (NN Grapefruit)) (VP (MD may) (ADVP (RB also)) (VP (VBP increase) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS inducers)) (PP (IN of) (NP (NP (DT the) (NN CYP3A4) (NN family)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN St.) (NP (NNP Johns) (NNP Wort)))) (-RRB- -RRB-))))))) (VP (MD may) (VP (VB decrease) (NP (NN drug9) (NNS concentrations))))) (. .)))
(S1 (S (NP (NN St.))))
(S1 (S (S (NP (NNP Johns) (NNP Wort)) (VP (MD may) (VP (VB decrease) (NP (NN drug1) (NN plasma) (NNS concentrations)) (ADVP (RB unpredictably))))) (. .)))
(S1 (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (MD should) (RB not) (VP (VB take) (NP (NN St.))))))
(S1 (S (NP (NP (NP (NNP Johns) (NNP Wort)) (ADVP (RB concomitantly))) (. .))))
(S1 (S (S (NP (JJ drug1) (NN dose) (NN modification)) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG using) (NP (NP (JJ concomitant) (JJ CYP3A4) (NNS inhibitors)) (CC or) (NP (NNS inducers))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Excessive) (NNS reductions)) (PP (IN in) (NP (NN blood) (NN pressure)))) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (JJ diuretic) (NN therapy))))) (SBAR (WHADVP (WRB when)) (S (NP (NNS drug2)) (VP (VBP are) (VP (VBN started)))))))) (. .))))
(S1 (S (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (NP (JJ hypotensive) (NNS effects)) (PP (IN with) (NP (NN drug1)))))) (VP (MD can) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (VP (VBG discontinuing) (NP (NP (JJ diuretic) (NN therapy)) (PP (IN for) (NP (JJ several) (NNS days))))) (CC or) (VP (ADVP (RB cautiously)) (VBG increasing) (NP (NN salt) (NN intake)) (PP (IN before) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2)))))))))))))) (. .)) (S (SBAR (IN If) (S (NP (DT this)) (VP (VBZ is) (RB not) (ADJP (JJ possible))))) (, ,) (NP (NP (DT the) (VBG starting) (NN dose)) (PP (IN of) (NP (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN reduced)))) (. .))) (. .)))
(S1 (S (NP (NP (NP (NN drug1) (NNS Supplements)) (CC and) (NP (NNS drug2))) (: :) (S (NP (NN drug3)) (VP (MD can) (VP (VB increase) (NP (NN serum) (NN potassium)) (SBAR (IN because) (S (NP (PRP it)) (VP (VBZ decreases) (NP (NN aldosterone) (NN secretion)))))))) (. .))))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (CC or) (NP (NN drug5) (NNS supplements)))) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug6)))) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hyperkalemia))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ such) (NNS agents)))) (VP (VBZ is) (VP (VBN indicated))))) (, ,) (S (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN caution))))))) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NN serum) (NN potassium)) (VP (MD should) (VP (VB be) (VP (VBN monitored)))))) (. .)))
(S1 (S (S (NP (NP (JJ Oral) (NN drug1) (: :) (NN Interaction) (NNS studies)) (PP (IN with) (NP (NN drug2)))) (VP (VBD failed) (S (VP (TO to) (VP (VB identify) (NP (NP (DT any) (ADJP (RB clinically) (JJ important)) (NN effect)) (PP (PP (IN on) (NP (NP (DT the) (NN serum) (NNS concentrations)) (PP (IN of) (NP (DT the) (NN drug3))))) (CC or) (PP (IN on) (NP (PRP$ its) (JJ anticoagulant) (NN effect)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (VBN Increased) (NN serum) (NN drug2) (NNS levels)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (NN drug3) (NN toxicity)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug4)) (PP (IN during) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug5)))))))))))) (. .))))
(S1 (S (S (S (NP (DT These) (NNS drugs)) (VP (MD should) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NN caution))))))) (, ,) (CC and) (S (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug1) (NNS levels)))) (VP (VBZ is) (VP (VBN recommended))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (DT a) (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN used))))) (, ,) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN toxicity)))) (VP (MD may) (VP (VB be) (VP (VBN increased))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS Agents)) (: :) (S (NP (DT No) (ADJP (RB clinically) (JJ important)) (JJ pharmacokinetic) (NNS interactions)) (VP (VBD occurred) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (JJ oral) (NN drug6)) (, ,) (CC and) (NP (JJ cholesterol-lowering) (NNS agents)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN evidence)) (PP (IN of) (NP (ADJP (RB clinically) (JJ important)) (JJ adverse) (NNS interactions)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB primarily)) (VP (VBN eliminated) (ADJP (JJ unchanged)) (ADVP (RB renally)) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (JJ glomerular) (NN filtration)) (CC and) (NP (JJ tubular) (NN secretion))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (JJ nephrotoxic) (NNS drugs)))) (VP (MD could) (VP (VB result) (PP (IN in) (NP (NP (VBN delayed) (NN clearance)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NP (NNS substances)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADVP (RB also)) (ADVP (RB tubularly)) (VP (VBN secreted)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-))))) (VP (MD could) (ADVP (RB potentially)) (VP (VB result) (PP (IN in) (NP (NP (VBN delayed) (NN clearance)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (CD 400) (NN mg) (JJ qid)) (-RRB- -RRB-))) (VP (MD can) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN drug2))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ normal) (JJ renal) (NN function)) (PRN (-LRB- -LRB-) (NP (NN creatinine) (NN clearance) (CD 80) (NN mL/min)) (-RRB- -RRB-))))))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NP (NN drug3)) (PP (ADVP (RB concurrently)) (IN with) (NP (NN drug4)))) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (ADJP (ADJP (JJ mild)) (TO to) (ADJP (JJ moderate))) (NP (NP (JJ renal) (NN insufficiency)) (PRN (-LRB- -LRB-) (NP (NP (NN creatinine) (NN clearance)) (PP (IN from) (NP (QP (CD 45) (TO to) (CD 79)) (NN mL/min)))) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (NP (NP (NNS Patients)) (PP (IN with) (NP (ADJP (ADJP (JJ mild)) (TO to) (ADJP (JJ moderate))) (JJ renal) (NN insufficiency)))) (VP (MD should) (VP (VB avoid) (S (VP (VBG taking) (NP (NP (NN drug1)) (PP (IN with) (NP (NP (JJ short) (NN elimination) (NNS half-lives)) (PP (IN for) (NP (NP (DT a) (NN period)) (PP (IN of) (NP (NP (NP (CD 2) (NNS days)) (PP (IN before))) (, ,) (NP (NP (DT the) (NN day)) (PP (IN of))) (, ,) (CC and) (NP (NP (CD 2) (NNS days)) (VP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug2))))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (NNS data)) (VP (VBG regarding) (NP (NP (JJ potential) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (PP (IN with) (NP (JJR longer) (NNS half-lives))))))))) (, ,) (NP (NP (DT all) (NNS patients)) (VP (VBG taking) (NP (DT these) (NNS drug3)))) (VP (MD should) (VP (VB interrupt) (NP (NN dosing)) (PP (IN for) (NP (NP (NP (NP (QP (IN at) (JJS least) (CD 5)) (NNS days)) (PP (IN before))) (, ,) (NP (NP (DT the) (NN day)) (PP (IN of))) (, ,)) (CC and) (NP (NP (CD 2) (NNS days)) (VP (VBG following) (NP (NN drug4) (NN administration)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (DT an) (NN drug1)))) (VP (VBZ is) (ADJP (JJ necessary))))) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN for) (NP (NP (NN toxicity)) (, ,) (ADVP (RB especially)) (NP (NN myelosuppression)) (, ,) (NP (ADJP (JJ renal))) (, ,) (CC and) (NP (JJ gastrointestinal) (NN toxicity)))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (VP (NN None) (VBN known))) (. .)))
(S1 (S (S (NP (NP (NN Prothrombin) (NN time)) (CC or) (NP (JJ other) (JJ suitable) (NN anticoagulation) (NN test))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ oral) (NN drug2)))) (VP (MD may) (VP (VB render) (NP (NP (JJ oral) (NN drug3)) (ADJP (RBR less) (JJ effective)))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB There)) (VP (VBP are) (NP (DT no) (VBN reported) (JJ drug-laboratory) (NN test) (NNS interactions)))) (. .)))
(S1 (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NP (NP (NP (DT the) (JJ following) (NNS drugs)) (: :) (NP (NP (NN drug2)) (CC and) (NP (NP (JJ other) (NNS drug3)) (-LRB- -LRB-) (VP (MD may) (VP (JJR lower) (NP (NN drug4) (NNS levels)))) (-RRB- -RRB-) (, ,)))) (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN bioavailability)) (PP (IN of) (NP (NP (JJ oral) (NN drug6)) (VP (VBZ is) (VP (VBN increased) (PP (IN with) (NP (NN coadministration))))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (VP (MD may) (VP (VB decrease) (NP (NN drug8) (NNS levels)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug9)) (PRN (-LRB- -LRB-) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (JJ psychotic) (NNS episodes)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered))))))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug10)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug11))) (PP (IN with) (NP (NN drug12)))) (VP (MD can) (VP (VB inhibit) (NP (NP (JJ ovarian) (NN function)) (PP (IN in) (NP (NNS women))))))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN drug13)) (CC and) (NP (JJ other) (JJ sedating) (NNS drugs))) (PRN (-LRB- -LRB-) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ additive) (NN sedation)) (CC and) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (JJ adverse) (NNS effects)))))))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN drug14)) (PRN (-LRB- -LRB-) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NP (NN drug15)) (CC and) (NP (NN drug16))) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT the) (NN drug17)))))))))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN with) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (ADVP (RB also)) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (JJ CYP2D6-mediated) (NN metabolism)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB be) (PP (IN of) (NP (JJ clinical) (NN relevance))) (PP (IN for) (NP (NP (NNS compounds)) (VP (ADVP (RB predominantly)) (VBN metabolized) (PP (IN by) (NP (DT this) (NN enzyme)))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN -blockers)) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN drug4)))))) (, ,) (SBAR (IN if) (S (NP (PRP they)) (VP (VBP have) (NP (DT a) (JJ narrow) (JJ therapeutic) (NN window)))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vivo)) (JJ drug-drug) (NN interaction) (NNS studies)) (VP (VBN conducted) (PP (IN in) (NP (JJ normal) (NN volunteer) (NNS subjects))))) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB affect) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ decreases) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (CD 19) (NN %))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ increases) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug2))) (PP (IN by) (NP (CD 15) (NN %)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ spontaneous) (NNS reports)) (PP (IN of) (NP (NP (NN increase)) (CC or) (NP (NN decrease)))) (PP (IN in) (NP (NP (NN prothrombin) (NNS times)) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG taking) (NP (NP (JJ oral) (NN drug1)) (CC and) (NP (NN drug2)))))))))))) (, ,) (S (ADVP (RB however)) (, ,) (NP (NP (DT a) (JJ causal) (NN relationship)) (PP (IN between) (NP (NP (NN drug3) (NNS Tablets)) (CC and) (NP (DT these) (NNS changes))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN clearance)) (VP (VBZ is) (VP (VP (VBN increased) (NP (CD 100) (NN %)) (PP (IN by) (NP (NP (NN drug2)) (, ,) (NP (DT a) (NN CyP450) (NN enzyme) (NN inducer)) (, ,)))) (CC and) (VP (VBN decreased) (NP (CD 33) (NN %)) (PP (IN by) (NP (NP (NN drug3)) (, ,) (NP (DT a) (NN CyP450) (NN enzyme) (NN inhibitor)))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN clearance)) (VP (VBZ is) (VP (VBN unaffected) (PP (IN by) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (DT no) (NN information)) (ADJP (JJ available) (PP (IN from) (NP (NP (JJ adequate) (JJ drug-drug) (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NP (DT the) (JJ following) (NNS classes)) (PP (IN of) (NP (NNS drugs)))) (: :) (NP (NP (JJ oral) (NN drug1)) (, ,) (NP (NN hormone) (NN replacement) (NNS therapies)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VBP demonstrate) (NP (JJ additive) (NN toxicity)) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (JJ cytotoxic) (NNS drugs))))))))))) (. .)))
(S1 (S (NP (NN drug1)) (VP (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB prolong) (NP (NP (DT the) (NN elimination) (NN half-life)) (PP (IN of) (NP (NN drug2)))))))))) (CC and) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (JJ severe) (NN bone) (NN marrow) (NN suppression)))))) (: ;)))
(S1 (S (S (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (DT the) (NN drug1) (NN dosage)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2))))) (ADVP (RB concurrently)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (CD one) (NN case))) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (VBN reduced) (NN drug3) (NN cytotoxicity)))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (VP (VBZ causes) (NP (NP (DT a) (CD 60) (NN %) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NP (NN absorption)) (CC and) (NP (JJ enterohepatic) (NN cycling))) (PP (IN of) (NP (NN drug3))))))) (CC and) (VP (MD should) (RB not) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NN drug4)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN assessed) (PP (IN under) (NP (JJ chronic) (NNS conditions))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (ADJP (CD 10) (NN %)) (NNS decreases)) (PP (IN in) (NP (NN prothrombin) (NN time)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (JJ single-dose) (NNS studies))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2))))))) (, ,) (NP (NN prothrombin) (NN time)) (VP (MD should) (VP (VB be) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (JJ Other) (ADJP (RB Highly) (JJ Protein-Bound)) (NNS Drugs)) (: :) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (QP (JJR more) (IN than) (CD 95)) (NN %)) (VP (VBD bound) (PP (TO to) (NP (NN plasma) (NNS proteins))))))) (. .))))
(S1 (S (S (ADVP (FW In) (FW vitro)) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (JJ other) (ADJP (RB highly) (JJ protein-bound)) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7)))))))))))))) (. .)))
(S1 (S (S (VP (VB See) (ADVP (RB also)) (NP (JJ CLINICAL) (NN PHARMACOLOGY)))) (, ,) (NP (JJ Drug-Drug) (NNS Interactions))))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (MD may) (ADVP (RB also)) (VP (VB interact) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN thrombocytopenia)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN nephrotoxicity)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (VBN increased) (JJ hypoglycemic) (NN response)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN anticoagulant) (NN effect)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (VBN decreased) (JJ renal) (NN excretion)) (PP (IN of) (NP (NN drug6)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NP (VBN decreased) (JJ hepatic) (NN clearance)) (PP (IN of) (NP (NN drug8)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (DT the) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5))) (-RRB- -RRB-))) (CC or) (NP (NN drug6)))) (, ,)) (ADVP (RB ordinarily)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN administered) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (DT a) (NN drug8)) (-RRB- -RRB-))))))) (: ;)))
(S1 (S (S (NP (DT these) (NNS agents)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (QP (RB approximately) (CD 90)) (NN %)) (VP (VBD bound) (PP (TO to) (NP (NN plasma) (NNS proteins)))))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (IN if) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN coadministered) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (VBN known) (S (VP (TO to) (VP (VB affect) (NP (NN protein) (NN binding)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Drug) (NNS Interactions)) (: :) (NP (NP (NNS Women)) (PP (IN on) (NP (JJ oral) (NN drug1))))) (VP (VBP have) (VP (VBN shown) (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN plasma) (NN drug2) (NNS levels))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ gastrointestinal) (NN motility)))) (VP (VBP are) (VP (VBN antagonized) (PP (IN by) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (JJ Additive) (JJ sedative) (NNS effects)) (VP (MD can) (VP (VB occur) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC or) (NP (NN drug6))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN finding) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ releases) (NP (NNS catecholamines)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ essential) (NN hypertension))))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (PRP it)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (, ,) (ADVP (IN if) (PP (IN at) (NP (NN all)))) (, ,) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Absorption)) (PP (IN of) (NP (NNS drugs))) (PP (IN from) (NP (DT the) (NN stomach)))) (VP (MD may) (VP (VB be) (VP (VBN diminished) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NN drug1)) (-RRB- -RRB-)) (PP (IN by) (NP (NN drug2))))))) (, ,) (IN whereas) (S (NP (NP (DT the) (NP (NN rate)) (CC and/or) (NP (NN extent))) (PP (IN of) (NP (NP (NN absorption)) (PP (IN of) (NP (NP (NNS drugs)) (PP (IN from) (NP (DT the) (JJ small) (NN bowel)))))))) (VP (MD may) (VP (VB be) (VP (VBN increased) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (NN Gastroparesis)) (PRN (-LRB- -LRB-) (NP (JJ gastric) (NN stasis)) (-RRB- -RRB-))) (VP (MD may) (VP (VB be) (ADJP (JJ responsible) (PP (IN for) (NP (NP (JJ poor) (JJ diabetic) (NN control)) (PP (IN in) (NP (DT some) (NNS patients))))))))) (. .)))
(S1 (S (S (NP (ADJP (RB Exogenously) (VBN administered)) (NN drug1)) (VP (VP (MD may) (VP (VB begin) (S (VP (TO to) (VP (VB act) (SBAR (IN before) (S (NP (NN food)) (VP (VBZ has) (NP (JJ left) (DT the) (NN stomach)))))))))) (CC and) (VP (VB lead) (PP (TO to) (NP (NN hypoglycemia)))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug1)))) (VP (MD will) (VP (VP (VB influence) (NP (NP (DT the) (NN delivery)) (PP (IN of) (NP (NN food))) (PP (TO to) (NP (DT the) (NNS intestines))))) (CC and) (RB thus) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (NN absorption)))))))) (, ,) (NP (NP (NP (NN drug2) (NN dosage)) (CC or) (NP (NN timing))) (PP (IN of) (NP (NN dosage)))) (VP (MD may) (VP (VB require) (NP (NN adjustment))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pharmacokinetic) (NNS interactions)) (VP (VBN listed) (PP (IN below)))) (VP (VBP are) (ADJP (RB potentially) (RB clinically) (JJ important)))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP induce) (NP (NP (JJ hepatic) (NNS enzymes)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (VP (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug4)))))) (CC and) (VP (MD may) (VP (VB require) (NP (NP (NNS increases)) (PP (IN in) (NP (NN drug5) (NN dose)))) (S (VP (TO to) (VP (VB achieve) (NP (DT the) (JJ desired) (NN response))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (MD may) (VP (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3))))) (CC and) (ADVP (RB thus)) (VP (VB decrease) (NP (PRP$ their) (NN clearance)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN titrated) (S (VP (TO to) (VP (VB avoid) (NP (NN steroid) (NN toxicity))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (JJ chronic) (JJ high) (NN dose) (NN drug2))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VP (MD could) (VP (VB lead) (PP (TO to) (NP (VBN decreased) (NN drug1) (NN serum) (NNS levels))))) (CC or) (VP (VBP increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN toxicity)))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN withdrawn)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (ADVP (RB cautiously)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG suffering) (PP (IN from) (NP (NN hypoprothrombinemia)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (JJ oral) (NNS drug2)))) (VP (VBZ is) (NP (NN variable)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (VBN enhanced)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (VBN diminished) (NNS effects)) (PP (IN of) (NP (NN drug1))))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (ADVP (RB concurrently)) (PP (IN with) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN coagulation) (NNS indices)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (S (VP (TO to) (VP (VB maintain) (NP (DT the) (JJ desired) (JJ anticoagulant) (NN effect))))))))) (. .)))
(S1 (S (NP (NP (NN Co-administration)) (PP (IN of) (NP (NP (JJ oral) (NN drug1) (CD 200) (NN mg)) (ADVP (RB twice) (RB daily))))) (VP (VBD increased) (NP (NP (NP (NN drug2) (JJ geometric) (JJ mean) (NN AUC)) (PRN (-LRB- -LRB-) (NP (NN 0-24)) (-RRB- -RRB-))) (CC and) (NP (NN Cmax))) (PP (IN by) (NP (CD 81) (NN %))) (PP (IN after) (NP (NP (JJ topical) (NN application)) (PP (IN of) (NP (NP (NN drug3) (NN ointment)) (, ,) (NP (CD 1) (NN %)))) (PP (IN on) (NP (NP (DT the) (JJ abraded) (NN skin)) (PP (IN of) (NP (JJ healthy) (JJ adult) (NNS males)))))))) (. .)))
(S1 (S (S (PP (JJ Due) (TO to) (NP (NP (JJ low) (JJ systemic) (NN exposure)) (PP (TO to) (NP (NN drug1))) (PP (VBG following) (NP (NP (JJ topical) (NN application)) (PP (IN in) (NP (NNS patients))))))) (, ,) (NP (NP (NN dosage) (NNS adjustments)) (PP (IN for) (NP (NN drug2)))) (VP (VBP are) (ADJP (JJ unnecessary)) (SBAR (WHADVP (WRB when)) (S (VP (VBN co-administered) (PP (IN with) (NP (NP (JJ CYP3A4) (NNS inhibitors)) (, ,) (PP (JJ such) (IN as) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (NP (ADJP (FW in) (FW vitro)) (NN P450) (NN inhibition) (NNS studies)) (CC and) (NP (NP (DT the) (JJ low) (JJ systemic) (NN exposure)) (VP (VBN observed) (PP (VBG following) (NP (NP (JJ topical) (NN application)) (PP (IN of) (NP (NN drug1)))))))))) (, ,) (NP (NN drug2)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB affect) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (JJ other) (NN P450) (NNS substrates)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NP (JJ concurrent) (NN application)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (JJ topical) (NNS products)))) (PP (TO to) (NP (NP (DT the) (JJ same) (NN area)) (PP (IN of) (NP (NN skin)))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3) (NN type)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10))) (-RRB- -RRB-))) (, ,) (NP (NP (CD drug11)) (, ,) (NP (CD drug12)) (, ,) (NP (NP (CD drug13)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (CD drug14)) (-RRB- -RRB-))) (, ,) (NP (JJ other) (NN drug15)) (, ,) (NP (CD drug16) (NNS supplements)) (, ,) (NP (CD drug17)) (, ,) (NP (NP (CD drug18)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (QP (CD drug19) (CC -) (CD drug20)) (-RRB- -RRB-))) (, ,) (NP (NP (CD drug21)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug22))) (, ,) (NP (CD drug23)) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (ADVP (RB highly)) (VP (NN protein) (VBN bound))) (, ,) (CC and) (ADVP (RB therefore)) (, ,) (VP (MD might) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB displace) (NP (JJ other) (JJ protein-bound) (NNS drugs)))))))))) (. .)))
(S1 (S (SBAR (IN Although) (S (NP (DT this)) (VP (VBZ has) (RB not) (VP (VBN occurred) (PP (IN in) (NP (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (PP (IN with) (NP (NN drug1))))))))) (, ,) (S (NP (NP (NNS interactions)) (PP (IN with) (NP (NN drug2)))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NN drug3))) (SBAR (IN since) (S (NP (JJ marketing)) (, ,) (ADVP (RB therefore)) (, ,) (NP (NNS physicians)) (VP (MD should) (ADVP (RB closely)) (VP (VB monitor) (NP (NP (NNS patients)) (PP (IN for) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NN dosage) (NNS requirements)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug4)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (NN drug5)) (CC and) (NP (JJ other) (ADJP (RB highly) (JJ protein-bound)) (NNS drugs)))))))))))))))) (. .))))
(S1 (S (S (S (S (NP (NP (NN Plasma) (NNS levels)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (VP (VBN depressed) (PP (TO to) (NP (NP (QP (RB approximately) (CD 80)) (NN %)) (PP (IN of) (NP (PRP$ their) (JJ normal) (NNS values))))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBZ is) (VP (VBN administered) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN 3900) (NN mg/day)) (-RRB- -RRB-))))))))))))) (, ,) (CC but) (S (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug4)))) (VP (VBZ has) (NP (DT no) (NN effect)) (PP (IN on) (NP (NN drug5) (NN plasma) (NNS levels))))) (. .)) (S (NP (NP (NN drug6)) (, ,) (VP (VBG including) (NP (NN drug7))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB increase) (NP (JJ steady) (NN state) (NN plasma) (NN drug8) (NNS levels)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN plasma) (NN drug1) (NNS levels)) (VP (VB be) (VP (VBN monitored) (SBAR (WHADVP (WRB when)) (S (VP (VP (VBG initiating)) (, ,) (VP (VBG adjusting)) (CC and) (VP (VBG discontinuing) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (VP (VBN administered) (ADVP (RB concurrently))))) (, ,) (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ oral) (NNS drug2))))))) (: ;)))
(S1 (S (S (VP (VP (VB monitor)) (CC and) (VP (VB adjust) (NP (NN drug1) (NN dosage)) (ADVP (RB accordingly))))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NP (JJ Physiologic) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN decreased) (NN estradiol) (NNS concentrations)) (PP (IN with) (NP (NP (NNS radioimmunoassays)) (PP (IN for) (NP (NP (NN estradiol)) (, ,) (NP (VBN increased) (NN plasma) (NN calcium) (NNS concentrations)) (, ,) (CC and) (NP (NP (VBN increased) (JJ 24-hour) (JJ urinary) (NN excretion)) (PP (IN of) (NP (NP (NN creatine)) (CC and) (NP (NN 17-ketosteroids)))))))))))))) (. .))))
(S1 (S (SBAR (IN Although) (S (NP (DT a) (JJ causal) (NN relationship)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established)))))) (, ,) (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (ADJP (ADJP (JJ bleeding)) (CC and/or) (ADJP (JJ prolonged))) (NN prothrombin) (NN time))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug1)))) (VP (MD should) (VP (VB have) (NP (NP (ADJP (RBR more) (JJ frequent)) (NN monitoring)) (PP (IN of) (NP (NN prothrombin) (NNS times)))) (, ,) (SBAR (IN while) (S (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ other) (NN risk) (NNS factors)) (VP (VBN complicated) (PP (IN by) (NP (NP (NN hemorrhage)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (JJ recent) (NN surgery))) (, ,) (NP (JJ peptic) (NN ulceration)) (-RRB- -RRB-)))))))) (VP (MD should) (VP (VB have) (NP (JJ periodic) (NNS examinations)) (PP (IN for) (NP (NP (JJ bleeding)) (PP (VBG including) (NP (NP (NN hematocrit)) (CC and/or) (NP (NN hemoglobin))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (JJ -containing) (NNS drugs))))) (VP (VBZ leads) (PP (TO to) (NP (NP (NP (VBN increased) (NN drug3) (NNS levels)) (CC and) (NP (NN drug4) (NN toxicity))) (PP (IN in) (NP (DT some) (NNS individuals))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS patients)) (VP (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (PP (IN for) (NP (NP (NNS signs)) (PP (IN of) (NP (NN toxicity)))))))) (CC and) (VP (VB have) (NP (NP (PRP$ their) (JJ drug1) (NN dosage)) (VP (VBN adjusted) (PP (IN as) (ADJP (JJ necessary)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7)) (, ,)) (PP (IN without) (NP (VBN observed) (NNS problems))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Small) (NNS decreases)) (PP (IN in) (NP (NN blood) (NN pressure)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (DT some) (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1)))))))))) (: ;)))
(S1 (S (S (NP (JJ periodic) (JJ systemic) (NN blood) (NN pressure) (NN monitoring)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (JJ antihypertensive) (NN therapy)))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (VP (VBN indicated)))) (, ,) (NP (NP (NN dosage)) (PP (IN of) (NP (DT the) (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (NP (NP (NN Drug) (NNS Interactions)) (: :) (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NN drug1) (-LRB- -LRB-) (NN drug2) (-RRB- -RRB-) (NN Injection)) (PP (IN before) (NP (NN drug3)))))) (, ,) (PP (IN for) (NP (NP (DT the) (NN purpose)) (PP (IN of) (S (VP (VBG attenuating) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NN drug4))))))))))) (, ,) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .))))
(S1 (S (S (SBAR (IN If) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (NN drug2))))))))) (, ,) (NP (PRP it)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN given) (PP (IN until) (NP (NN recovery))) (SBAR (IN from) (S (NP (NN drug3)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ median) (NN duration)) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN drug1) (CD 0.6) (NN mg/kg)))))) (VP (VBN administered) (PP (IN after) (NP (NP (DT a) (ADJP (CD 1) (NN mg/kg)) (NN dose)) (PP (IN of) (NP (NN drug2))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN T) (CD 1)) (VP (VBD returned) (PP (TO to) (NP (NP (CD 75) (NN %)) (PP (IN of) (NP (NN control))))))) (VP (VBD was) (NP (NP (CD 36) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (NP (NN range) (CD 14-57)) (, ,) (NP (NN n=12))) (-RRB- -RRB-))) (ADVP (CC vs))))))) (. .)))
(S1 (S (S (NP (NP (CD 28) (NNS minutes)) (PRN (-LRB- -LRB-) (NP (NP (NN 17-51)) (, ,) (NP (NN n=12))) (-RRB- -RRB-))) (PP (IN without) (NP (NN drug1)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ controlled) (NNS studies)) (VP (VBG documenting) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (PP (IN before)) (CC or) (PP (IN after) (NP (JJ other) (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NNS Interactions)) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (JJ other) (NNS drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN administered) (PP (IN in) (NP (NN succession)))))))))))) (. .)))
(S1 (S (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NN None)) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug2))) (, ,) (NP (NN drug3)) (-RRB- -RRB-))))) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (JJ bactericidal) (NNS effects)) (PP (IN of) (NP (NN drug4)))) (PP (IN by) (S (VP (VBG slowing) (NP (NP (DT the) (NN rate)) (PP (IN of) (NP (JJ bacterial) (NN growth)))))))))) (. .)))
(S1 (S (S (NP (JJ Bactericidal) (NNS agents)) (VP (VBP work) (ADVP (RBS most) (RB effectively)) (PP (IN against) (NP (NP (DT the) (JJ immature) (NN cell) (NN wall)) (PP (IN of) (NP (ADJP (RB rapidly) (VBG proliferating)) (NNS microorganisms))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (ADVP (FW in) (FW vitro)))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (NP (DT the) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBZ is) (RB not) (ADVP (RB well)) (VP (VBN documented)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (JJ few) (JJ clinical) (NNS situations)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (JJ '') (JJ static) (NNS '')) (CC and) (NP (NP (NN '')) (NP (JJ cidal) (`` ') ('' ') (NN drug1)))))) (VP (VBP are) (VP (VBN indicated)))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (NP (VBN selected) (NNS circumstances)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ such) (NN therapy)) (VP (VBZ is) (ADJP (JJ appropriate)) (, ,) (S (VP (VP (VBG using) (NP (NP (JJ adequate) (NNS doses)) (PP (IN of) (NP (JJ drug1) (NNS agents))))) (CC and) (VP (VBG beginning) (NP (NN penicillin) (NN therapy)) (ADVP (RB first)))))))))) (, ,) (VP (MD should) (VP (VB minimize) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN interaction))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN blood) (NNS levels)) (VP (MD may) (VP (VB be) (VP (VBD prolonged) (PP (IN by) (NP (NP (JJ concurrent) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (SBAR (WHNP (WDT which)) (S (VP (VBZ blocks) (NP (NP (DT the) (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (NN drug3))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Displacement)) (PP (IN of) (NP (NN drug1))) (PP (IN from) (NP (NN plasma) (NN protein) (NN binding) (NNS sites)))) (VP (MD will) (VP (VBP elevate) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ free) (NN drug2))) (PP (IN in) (NP (DT the) (NN serum))))))) (. .)))
(S1 (S (S (NP (NP (JJ Catecholamine-depleting) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC plus) (NP (DT a) (JJ catecholamine-depleting) (NN agent))))) (VP (MD should) (, ,) (ADVP (RB therefore)) (, ,) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (NN hypotension)) (CC and/or) (NP (JJ marked) (NN bradycardia))) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB produce) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (, ,) (CC or) (NP (JJ postural) (NN hypotension))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (PP (IN with) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN drug2))) (, ,) (PP (VBG including) (NP (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))) (PP (IN without) (NP (JJ unexpected) (JJ adverse) (NNS interactions))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB increase) (NP (NN serum) (NN drug2) (NNS levels)) (SBAR (WHADVP (WRB when)) (S (NP (DT both) (NNS drugs)) (VP (VBP are) (NP (NN co-administered)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NNS levels)) (VP (MD may) (ADVP (RB also)) (VP (VB be) (VP (VBN increased) (PP (IN with) (NP (DT this) (NN combination))))))) (. .)))
(S1 (S (NP (NP (NP (NN Risk)) (PP (IN of) (NP (JJ anaphylactic) (NN reaction)))) (: :) (S (SBAR (IN While) (S (VP (VBG taking) (NP (NN drug1))))) (, ,) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (NN history)) (PP (IN of) (NP (NP (JJ severe) (JJ anaphylactic) (NN reaction)) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS allergens)))))))))) (VP (MD may) (VP (VB be) (ADJP (ADJP (RBR more) (JJ reactive) (PP (TO to) (NP (JJ repeated) (NN challenge)))) (, ,) (CC either) (ADJP (JJ accidental)) (, ,) (ADJP (JJ diagnostic)) (, ,) (CC or) (ADJP (JJ therapeutic)))))) (. .))))
(S1 (S (S (NP (JJ Such) (NNS patients)) (VP (MD may) (VP (VB be) (ADJP (JJ unresponsive) (PP (TO to) (NP (NP (DT the) (JJ usual) (NNS doses)) (PP (IN of) (NP (NN drug1))) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (JJ allergic) (NNS reactions)))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (JJ specific) (NN drug) (CC or) (NN food) (NNS interactions)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied)))))) (, ,) (PP (IN on) (DT the) (NN basis) (IN of) (NP (NP (DT this) (NN drug) (NN s) (NN metabolism)) (PP (IN by) (NP (NN CYP) (NN 3A4))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN grapefruit) (NN juice))) (VP (MD may) (VP (VB inhibit) (NP (NP (PRP$ its) (NN metabolism)) (PRN (-LRB- -LRB-) (VP (VBG increasing) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug5))))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (ADVP (RB Furthermore)) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN St.)))))
(S1 (S (S (NP (NNP John) (NNP s) (NNP Wort) (, ,) (CC and) (NP (NP (JJ certain) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-)))) (VP (MD may) (VP (VB induce) (NP (NN drug5) (NN metabolism)) (PRN (-LRB- -LRB-) (S (VP (VBG lowering) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug6)))))) (-RRB- -RRB-))))) (. .)))
(S1 (S (PP (VBN Based) (PP (IN on) (NP (ADJP (FW in) (FW vitro)) (NN inhibition) (NN information)))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NN CYP) (NN 3A4) (NNS substrates))))))))))))) (. .)))
(S1 (S (S (PP (IN Due) (PP (TO to) (NP (NP (DT the) (JJ slow) (NN elimination)) (PP (IN of) (NP (NN drug1))) (PP (IN from) (NP (DT the) (NN body)))))) (, ,) (NP (JJ such) (NN interaction)) (VP (MD may) (VP (VB be) (VP (VBN observed) (PP (IN for) (NP (NP (DT a) (JJ prolonged) (NN period)) (PP (IN after) (NP (PRP$ its) (NN administration))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP are) (NP (NN CYP) (NN 3A4) (NNS substrates))) (CC and) (VP (VBP have) (NP (JJ narrow) (JJ therapeutic) (NN range)))))) (, ,) (PP (VBG including) (NP (NP (DT some) (NNS agents)) (VP (VBN used) (PP (IN during) (NP (JJ general) (NN anesthesia)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NN erythema)) (CC and) (NP (NP (JJ histamine-like) (NN flushing)) (CC and) (NP (JJ anaphylactoid) (NNS reactions))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (ADJP (JJ Concurrent)) (CC and/or) (ADJP (JJ sequential))) (ADJP (ADJP (JJ systemic)) (CC or) (ADJP (JJ topical))) (NN use)) (PP (IN of) (NP (NP (JJ other) (ADJP (ADJP (RB potentially) (JJ neurotoxic)) (CC and/or) (ADJP (JJ nephrotoxic))) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC or) (NP (NN drug7)))))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN indicated)))) (, ,)) (VP (VBZ requires) (NP (JJ careful) (NN monitoring)))) (. .)))
(S1 (S (S (NP (NP (NN Potential)) (PP (IN for) (NP (NN drug1))) (VP (TO to) (VP (VB Affect) (NP (NP (JJ Other) (NNS Drugs)) (VP (VBN drug2)))))) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB cause) (NP (NP (ADJP (RB clinically) (JJ important)) (JJ pharmacokinetic) (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN cytochrome) (NN P450)) (NNS isozymes)))))))))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (PP (IN in) (NP (JJ human) (NN liver) (NNS microsomes)))) (VP (VBD showed) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (ADVP (RB substantially)) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN cytochrome) (NN P450) (NNS isozymes)) (, ,) (PP (VBG including) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2C8/9/10)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP2E1)) (, ,) (NP (NN CYP3A4)) (, ,) (CC and) (NP (NN CYP3A5)))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB inhibit) (NP (NP (NN clearance)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT these) (JJ metabolic) (NNS pathways))) (PP (IN in) (NP (DT a) (ADJP (RB clinically) (JJ relevant)) (NN manner)))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB also)) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB have) (NP (NN enzyme) (NN inducing) (NNS properties)))))))) (. .)))
(S1 (S (S (PP (IN At) (NP (JJ therapeutic) (NNS concentrations))) (, ,) (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB inhibit) (NP (NN P-glycoprotein))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (ADVP (RB therefore)) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VB inhibit) (NP (NP (JJ P-glycoprotein-mediated) (NN transport)) (PP (IN of) (NP (JJ other) (NNS drugs)))) (PP (IN in) (NP (DT a) (ADJP (RB clinically) (JJ relevant)) (NN manner))))))))) (. .)))
(S1 (S (S (PP (IN Given) (NP (NP (DT the) (JJ primary) (NN CNS) (NNS effects)) (PP (IN of) (NP (NN drug1))))) (, ,) (NP (NN drug2)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (JJ other) (NN drug3)) (CC and) (NP (NN drug4)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (JJ other) (NN drug3)))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (PRP$ its) (NN potential)) (PP (IN for) (S (VP (VBG inducing) (NP (JJ orthostatic) (NN hypotension)))))))) (, ,) (NP (DT an) (JJ additive) (NN effect)) (VP (MD may) (VP (VB be) (VP (VBN observed) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NP (JJ other) (JJ therapeutic) (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (DT this) (NN potential))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Potential)) (PP (IN for) (NP (JJ Other) (NNS Drugs))) (PP (TO to) (NP (NN Affect) (NN drug1) (NN drug2)))) (VP (VBZ is) (RB not) (NP (NP (DT a) (NN substrate)) (PP (IN of) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2C9)) (, ,) (CC and) (NP (NN CYP2C19))))) (, ,) (SBAR (RB so) (IN that) (S (NP (NP (DT an) (NN interaction)) (PP (IN with) (NP (NP (NNS inhibitors)) (CC or) (NP (NNS inducers)))) (PP (IN of) (NP (DT these) (NNS isozymes)))) (VP (VBZ is) (ADJP (JJ unlikely))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN CYP2D6)) (CC and) (NP (NN CYP3A4))) (VP (MD may) (VP (VB be) (ADVP (RB minimally)) (VP (VBN involved) (PP (IN in) (NP (NN drug1) (NN metabolism))))))))))) (, ,) (S (NP (ADJP (FW in) (FW vivo)) (NNS studies)) (VP (VBP do) (RB not) (VP (VB show) (NP (NP (VBN decreased) (NN elimination)) (PP (IN by) (NP (DT these) (NNS isozymes))))))) (CC and) (S (NP (PRP they)) (VP (VBP contribute) (PP (TO to) (NP (NP (RB only) (DT a) (JJ small) (NN fraction)) (PP (IN of) (NP (JJ total) (NN body) (NN clearance)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))) (PP (IN with) (NP (JJ other) (NNS drugs)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NNS humans))))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG receiving) (NP (NN drug1)) (PP (ADVP (RB concurrently)) (IN with) (NP (JJ other) (NNS drugs)))))))) (, ,) (ADVP (RB especially)) (NP (NP (NNS drugs)) (PP (IN with) (NP (NN CNS) (NN activity)))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB carefully)))))) (. .)))
(S1 (S (S (NP (VBN Decreased) (NN seizure) (NN threshold)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (S (VP (VBG CYP) (NP (NP (NN 3A4) (NNS Inhibitors)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (-RRB- -RRB-))))) (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ rare) (NNS reports)) (PP (IN of) (NP (NP (JJ serious) (JJ adverse) (NNS events)) (PP (IN in) (NP (NP (NN connection)) (PP (IN with) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NP (NP (JJ certain) (NNS drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))) (-RRB- -RRB-))) (CC and) (NP (JJ potent) (NN CYP) (NN 3A4) (NNS inhibitors)))))))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN vasospasm)) (VP (VBG leading) (PP (TO to) (NP (NP (NP (JJ cerebral) (NN ischemia)) (CC and/or) (NP (NN ischemia))) (PP (IN of) (NP (DT the) (NNS extremities)))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (EX there)) (VP (VBP have) (VP (VBN been) (NP (NP (DT no) (NNS reports)) (PP (IN of) (NP (NP (JJ such) (NNS interactions)) (PP (IN with) (NP (NP (NN drug1)) (ADVP (RB alone))))))))))) (, ,) (NP (JJ potent) (NN CYP) (NN 3A4) (NNS inhibitors)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NN methylergonovine))))))) (. .)))
(S1 (S (S (NP (NP (NNS Examples)) (PP (IN of) (NP (NP (DT some)) (PP (IN of) (NP (DT the) (ADJP (RBR more) (JJ potent)) (NN CYP) (NN 3A4) (NNS inhibitors)))))) (VP (VBP include) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN drug5)) (CC or) (NP (NN drug6))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug11)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (QP (CD drug12) (, ,) (CD drug13) (, ,) (CD drug14)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (ADJP (RBR Less) (JJ potent)) (NN CYP) (NN 3A4) (NNS inhibitors)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (NP (ADJP (RBR Less) (JJ potent)) (NNS inhibitors)) (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN grapefruit) (NN juice)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7))))) (. .)))
(S1 (S (S (S (NP (DT These) (NNS lists)) (VP (VBP are) (RB not) (ADJP (JJ exhaustive)))) (, ,) (CC and) (S (NP (DT the) (NN prescriber)) (VP (MD should) (VP (VB consider) (S (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (NP (NN CYP) (NN 3A4)) (PP (IN of) (NP (JJ other) (NNS agents)))))) (VP (VBG being) (VP (VBN considered) (PP (IN for) (NP (NP (JJ concomitant) (NN use)) (PP (IN with) (NP (NN drug1)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ pharmacokinetic) (NNS interactions)) (VP (VBG involving) (NP (JJ other) (NN cytochrome) (NN P450) (NNS isoenzymes)))) (VP (VBP are) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN used) (ADVP (RB concurrently)) (PP (IN with) (NP (JJ other) (NP (NN drug3)) (CC or) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB minimize) (NP (NP (NN CNS) (NN depression)) (CC and) (NP (JJ possible) (NP (NP (NN potentiation)) (, ,) (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC or) (NP (NN drug5)))))))) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (RB not) (VP (VB be) (VP (VBN used) (SBAR (IN since) (S (NP (EX there)) (VP (MD may) (VP (VB be) (NP (DT an) (ADJP (NN Antabuse) (-LRB- -LRB-) (NN disulfiram) (-RRB- -RRB-) (JJ -like)) (NN reaction)))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ exhibits) (NP (NP (DT some) (NN monoamine) (NN oxidase) (JJ inhibitory) (NN activity)) (, ,) (NP (NN drug2)))))) (, ,) (NP (NP (NP (NP (JJ drug3) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug4))) (, ,) (NP (NN drug5)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (JJ other) (NNS drugs)) (CC and) (NP (NNS foods))) (PP (IN with) (NP (JJ known) (JJ high) (NN drug6) (NN content))))) (, ,) (PP (JJ such) (IN as) (NP (NP (NN wine)) (, ,) (NP (NN yogurt)) (, ,) (NP (JJ ripe) (NN cheese)) (CC and) (NP (NN bananas)))) (, ,)) (VP (MD should) (VP (VB be) (VP (VBN avoided)))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ further) (NN phenomenon)) (PP (IN of) (NP (NP (NN toxicity)) (ADJP (JJ common) (PP (TO to) (NP (JJ many) (NNS drug1))))))) (VP (VBZ is) (NP (NP (NN hemolysis)) (CC and) (NP (NP (DT the) (NN appearance)) (PP (IN of) (NP (JJ Heinz-Ehrlich) (NN inclusion) (NNS bodies))) (PP (IN in) (NP (NNS erythrocytes))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (NN cross-resistance)) (PP (IN with) (NP (NP (JJ other) (NN drug1)) (, ,) (NP (NN radiotherapy)) (CC or) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP are) (ADJP (JJ capable) (PP (IN of) (NP (NN potentiating) (NN drug2)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN etc)) (. .)) (-RRB- -RRB-))))
(S1 (S (S (VP (ADVP (RB as) (RB well)) (PP (IN as) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (VP (VBG affecting) (NP (NP (NN pituitary)) (CC or) (NP (JJ adrenocortical) (NN function)))) (, ,) (PP (VBG including) (NP (NN all) (NN corticosteroid) (NN therapy))) (, ,)) (VP (MD must) (VP (VB be) (VP (VBN discontinued) (UCP (ADVP (RB prior) (PP (TO to))) (CC and) (PP (IN during) (NP (NP (NN testing)) (PP (IN with) (NP (NN drug1)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN metabolism)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN accelerated) (PP (IN by) (NP (NN drug2)))))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (DT the) (NN test)))) (VP (MD may) (VP (VB be) (ADJP (JJ inaccurate) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NN drug1)) (PP (IN within) (NP (NP (CD two) (NNS weeks)) (PP (IN before))))))))))) (. .)))
(S1 (S (S (NP (JJ Asubnormal) (NN response)) (VP (MD may) (VP (VB occur) (PP (IN in) (NP (NP (NNS patients)) (PP (IN on) (NP (NN estrogen) (NN therapy)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ inhibits) (NP (NP (DT the) (NN glucuronidation)) (PP (IN of) (NP (NN drug2))))) (CC and) (VP (MD could) (ADVP (RB possibly)) (VP (VB potentiate) (NP (NN drug3) (NN toxicity)))))) (. .)))
(S1 (S (S (NP (JJ Preliminary) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN drug1)) (VP (VP (VBZ inhibits) (NP (NN drug2) (NN metabolism))) (CC and) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug3)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (VP (VBN metabolized) (PP (IN through) (NP (NP (DT the) (NP (NN cytochrome) (NN P450)) (NN system)) (, ,) (NP (ADVP (RB primarily)) (NP (DT the) (NP (NP (NN CYP2C19)) (CC and) (NP (NN CYP3A4))) (NNS isozymes))))))) (, ,) (CC and) (ADVP (RB subsequently)) (VP (VBZ undergoes) (NP (NN Phase) (CD II) (NN conjugation))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (NP (NNS studies)) (VP (VBG evaluating) (NP (NP (JJ possible) (NNS interactions)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drugs)))))))) (, ,) (NP (DT no) (JJ dosage) (NN adjustment)) (VP (VBZ is) (VP (VBN needed) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (DT the) (NN following)) (: :) (NP (NP (NP (NP (CD drug2)) (, ,) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)))) (-LRB- -LRB-) (CC and) (NP (NP (PRP$ its) (JJ active) (NN metabolite)) (, ,) (NP (NN drug8))) (-RRB- -RRB-)) (, ,) (NP (NN drug9)) (, ,) (NP (CD drug10)) (, ,) (NP (CD drug11)) (, ,) (NP (CD drug12)) (, ,) (NP (CD drug13)) (, ,) (NP (CD drug14)) (, ,) (NP (NP (DT an) (JJ oral) (NN drug15)) (PRN (-LRB- -LRB-) (NP (CD drug16) (: /) (CD drug17)) (-RRB- -RRB-))) (, ,) (NP (CD drug18)) (, ,) (NP (CD drug19)) (, ,) (NP (CD drug20)) (, ,) (NP (CD drug21)) (, ,) (NP (CD drug22)) (, ,) (NP (CD drug23)) (, ,) (NP (CD drug24)) (, ,) (CC or) (NP (CD drug25)))))))))) (. .)))
(S1 (S (S (NP (NP (ADJP (RB Clinically) (JJ relevant)) (NNS interactions)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (PP (IN with) (NP (DT the) (JJ same) (JJ metabolic) (NNS pathways)))))) (VP (VBP are) (RB not) (VP (VBN expected)))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug1)))))) (, ,) (NP (NP (NN adjustment)) (PP (IN of) (NP (NP (DT the) (NN dosage)) (PP (PP (IN of) (NP (NN drug2))) (CC or) (PP (IN of) (NP (JJ such) (NNS drugs))))))) (VP (MD may) (RB not) (VP (VB be) (ADJP (JJ necessary))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (ADVP (RB also)) (NP (NP (DT no) (NN interaction)) (PP (IN with) (NP (ADJP (RB concomitantly) (VBN administered)) (NN drug1)))))) (. .)))
(S1 (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (JJ postmarketing) (NNS reports)) (PP (IN of) (NP (NP (VBN increased) (NN INR)) (CC and) (NP (NN prothrombin) (NN time)))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug1))))))) (, ,) (S (VP (VBG including) (NP (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (ADVP (RB concomitantly))))) (. .)))
(S1 (S (S (NP (NP (NNS Increases)) (PP (IN in) (NP (NP (NN INR)) (CC and) (NP (NN prothrombin) (NN time))))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJ abnormal) (JJ bleeding)) (CC and) (NP (JJ even) (NN death))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (ADVP (RB concomitantly)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN INR)) (CC and) (NP (NN prothrombin) (NN time)))))))))) (. .)))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (ADJP (ADJP (JJ profound)) (CC and) (ADJP (JJ long) (JJ lasting))) (NN inhibition)) (PP (IN of) (NP (JJ gastric) (NN acid) (NN secretion)))))) (, ,) (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NN absorption)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHADVP (WRB where)) (S (NP (JJ gastric) (NN pH)) (VP (VBZ is) (NP (NP (DT an) (JJ important) (NN determinant)) (PP (IN of) (NP (NP (PRP$ their) (NN bioavailability)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3) (NNS esters)) (, ,) (CC and) (NP (NN drug4) (NNS salts))) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (NP (NP (NN Laboratory) (NNS Tests)) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (JJ false-positive) (NN urine) (NN screening) (NNS tests)) (PP (IN for) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ most) (NN drug3))))))) (, ,) (PP (VBG including) (NP (NN drug4))))))))) (. .))))
(S1 (S (S (NP (DT An) (JJ alternative) (NN confirmatory) (NN method)) (VP (MD should) (VP (VB be) (VP (VBN considered) (S (VP (TO to) (VP (VB verify) (NP (JJ positive) (NNS results))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (MD may) (ADVP (RB also)) (VP (VB interact) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN thrombocytopenia)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN nephrotoxicity)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (VBN increased) (JJ hypoglycemic) (NN response)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (VBN increased) (NN anticoagulant) (NN effect)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (VBN decreased) (JJ renal) (NN excretion)) (PP (IN of) (NP (NN drug6)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (NP (NP (VBN decreased) (JJ hepatic) (NN clearance)) (PP (IN of) (NP (NN drug8)))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB compete) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,))) (PP (IN for) (NP (NP (NNS sites)) (PP (IN of) (NP (NN metabolism))) (PP (IN in) (NP (DT the) (NN liver))))) (, ,) (S (ADVP (RB thus)) (VP (VBG elevating) (NP (NP (DT the) (NN serum) (NNS levels)) (PP (IN of) (NP (JJ such) (NNS compounds)))) (PP (TO to) (NP (ADJP (RB potentially) (JJ toxic)) (NNS levels)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (ADJP (JJ anticipated))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (S (VP (TO to) (VP (VP (VB monitor) (NP (NN blood) (NNS levels))) (CC and/or) (VP (VB reduce) (NP (NP (DT the) (NN dosage)) (PP (IN of) (NP (JJ such) (NNS compounds)))))))))))) (. .)))
(S1 (S (S (NP (JJ Such) (JJ concomitant) (NN use)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN under) (NP (JJ careful) (JJ medical) (NN supervision))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ decreases) (NP (NP (JJ oral) (NN clearance)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (QP (RB about) (CD 5)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN implication)) (PP (IN of) (NP (DT this) (NN effect)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (JJ Severe) (ADJP (ADJP (JJ Hepatic)) (CC or) (ADJP (JJ Renal))) (NN Impairment)) (NN Caution)))) (VP (MD should) (VP (VB be) (VP (VBN exercised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1) (NNS Capsules)) (VP (VBP are) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ severe) (ADJP (ADJP (JJ hepatic)) (CC or) (ADJP (JJ renal))) (NN impairment))))))))))))) (. .)))
(S1 (S (S (NP (JJ Pharmacokinetic) (NNS studies)) (VP (VBP show) (SBAR (IN that) (S (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (JJ significant) (NNS alterations)) (PP (IN in) (NP (NP (JJ pharmacokinetic) (NNS parameters)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))) (S (VP (TO to) (VP (VBP warrant) (NP (NN dosage) (NN adjustment)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug3)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (DT these) (NNS drugs))))))))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ pharmacokinetic) (NN study)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ results) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN decrease)) (PP (IN in) (NP (NP (NP (DT the) (JJ pharmacokinetic) (NNS parameters)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD ~36) (NN %)) (PP (IN for) (NP (NN Cmax)))) (CC and) (NP (NP (CD ~28) (NN %)) (PP (IN for) (NP (NN AUC))))) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug3)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Administration)) (PP (IN of) (NP (NP (DT a) (JJR higher) (NN dose)) (PP (IN of) (NP (NN drug1)))))) (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG coadministering) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC or) (NP (NN drug3)))) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NNS drug4)))))) (VP (VBD were) (RB not) (VP (VBN studied)))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (ADVP (RB particularly)) (NP (NN drug2)) (, ,)) (VP (VP (MD may) (VP (VB cause) (NP (JJ serious) (JJ cardiac) (NNS arrhythmias)) (PP (IN during) (NP (NN drug3) (NN anesthesia))))) (CC and) (ADVP (RB therefore)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (PP (RB only) (IN with) (NP (JJ great) (NN caution))) (CC or) (PP (RB not) (IN at) (NP (NN all))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (NP (DT The) (JJ pressor) (NN effect)) (PP (IN of) (NP (NN drug2))))) (VP (VBZ is) (ADVP (RB markedly)) (VP (VBN potentiated) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG initiating) (NP (NP (NN pressor) (NN therapy)) (PP (IN in) (NP (DT these) (NNS patients))))))) (, ,) (NP (DT the) (JJ initial) (NN dose)) (VP (VP (MD should) (VP (VB be) (ADJP (JJ small)))) (CC and) (VP (VBD used) (PP (IN with) (NP (JJ due) (NN caution))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pressor) (NN response)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (ADVP (RB also)) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ CNS-depressant) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NP (JJ other) (NNS drug2)) (, ,) (PP (VBG including) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (VP (VBZ is) (NP (NP (DT the) (NN case)) (PP (IN with) (NP (JJ many) (JJ medicinal) (NNS agents))))))) (, ,) (NP (NN drug1)) (VP (MD may) (VP (JJ slow) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (DT a) (ADJP (RB concomitantly) (VBN administered)) (NN drug))))))) (. .)))
(S1 (S (SINV (MD Should) (NP (DT this)) (VP (VB occur))) (, ,) (NP (NP (DT the) (JJR higher) (NN serum) (NNS concentrations)) (PP (IN of) (NP (DT that) (NN drug)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (ADJP (ADJP (JJ pharmacologic)) (CC or) (ADJP (JJ adverse))) (NNS effects)) (PP (IN of) (NP (DT that) (NN drug))))))) (. .)))
(S1 (S (S (NP (JJ Such) (NNS occurrences)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN administered) (PP (TO to) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (JJ drug4) (JJ -like) (NNS drugs)))))))))))))) (. .)))
(S1 (S (S (NP (NP (VB Sever) (NP (JJ neurologic) (NNS signs))) (, ,) (PP (VBG including) (NP (NN coma))) (, ,)) (VP (VBP have) (VP (VBN occurred) (PP (IN with) (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug1)))))))) (. .)))
(S1 (S (S (NP (NP (VBN Reduced) (NN absorption)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (SBAR (WHADVP (WRB when)) (S (NP (DT those) (NNS agents)) (VP (VBD were) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NP (JJ daily) (NNS doses)) (PP (IN of) (NP (NN drug1) (CD 2) (NN g)))) (CC and) (NP (NP (JJ weekly) (NNS doses)) (PP (IN of) (NP (NN drug2) (CD 7.5) (NN mg))))) (VP (VBD were) (VP (VBN coadministered) (PP (TO to) (NP (NP (CD 15) (NP (JJ rheumatoid) (NN arthritis)) (NNS patients)) (PP (IN in) (NP (DT a) (JJ drug-drug) (NN interaction) (NN study))))))))) (, ,) (NP (NP (DT the) (JJ pharmacokinetic) (NN disposition)) (PP (IN of) (NP (DT the) (NNS drugs)))) (VP (VBD was) (RB not) (VP (VBN altered)))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Daily) (NNS doses)) (PP (IN of) (NP (NP (NN drug1) (CD 2) (NN g)) (PRN (-LRB- -LRB-) (NP (NN maximum) (CD 3) (NN g)) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ weekly) (NNS doses)) (PP (IN of) (NP (NP (NN drug2) (CD 7.5) (NN mg)) (PRN (-LRB- -LRB-) (NP (NN maximum) (CD 15) (NN mg)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN administered) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (TO to) (NP (NP (CD 310) (JJ rheumatoid) (NN arthritis) (NNS patients)) (PP (IN in) (NP (CD two) (JJ controlled) (JJ 52-week) (JJ clinical) (NNS studies))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ overall) (NN toxicity) (NN profile)) (PP (IN of) (NP (DT the) (NN combination)))) (VP (VBD revealed) (NP (NP (DT an) (VBN increased) (NN incidence)) (PP (IN of) (NP (NP (JJ gastrointestinal) (JJ adverse) (NNS events)) (, ,) (NP (ADVP (RB especially)) (NP (NN nausea))) (, ,)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT the) (NN incidence)) (VP (VBN associated) (PP (IN with) (NP (NP (DT either) (NN drug)) (VP (VBN administered) (ADVP (RB alone))))))))))))) (. .)))
(S1 (S (NP (NP (NN Drug/Laboratory) (NN Test) (NNS Interactions)) (: :) (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (PRP$ its) (NNS metabolites)))) (PP (IN in) (NP (NN body) (NNS fluids)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB interfere) (PP (IN with) (NP (JJ laboratory) (NN test) (NNS procedures)))))))))) (. .))))
(S1 (S (S (NP (NNS REFERENCES)) (VP (VBD 7.Farr) (NP (NP (NN M)) (, ,) (NP (FW et) (FW al))))) (. .)))
(S1 (S (S (NP (NNS Immunodeficiencies)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug1) (NN therapy)) (PP (IN in) (NP (JJ inflammatory) (NN arthritis))))))) (. .)))
(S1 (S (S (NP (NNP British) (NNP Jnl) (FW Rheum) (CD 1991)) (: ;) (NP (NN 30:413-417))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (EX There)) (VP (VBD was) (NP (NP (DT a) (JJ slight) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN area)) (PP (IN under) (NP (NP (NP (DT the) (NN curve)) (PRN (-LRB- -LRB-) (NP (NP (NN AUC)) (, ,) (NP (CD 11) (NN %))) (-RRB- -RRB-))) (CC and) (NP (NP (JJ mean) (JJ peak) (NN drug) (NN concentration)) (PRN (-LRB- -LRB-) (NP (NP (NN Cmax)) (, ,) (NP (CD 18) (NN %))) (-RRB- -RRB-))))) (PP (IN of) (NP (NN drug2)))))) (PP (IN with) (NP (NP (DT the) (NN co-administration)) (PP (IN of) (NP (ADJP (CD 100) (NN mg)) (NN drug3))) (PP (IN for) (NP (CD 10) (NNS days))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB appropriately)))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ dosage) (NN adjustment)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (NP (NN co-administration)) (PP (IN of) (NP (NN drug1)))) (VP (VBD appeared) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug2))) (PP (IN by) (NP (CD 70) (NN %)))))))))) (, ,) (NP (DT these) (NNS results)) (VP (VBP are) (RB not) (ADJP (JJ conclusive)) (PP (IN because) (IN of) (NP (NP (DT the) (JJ small) (NN number)) (PP (IN of) (NP (NP (NNS subjects)) (VP (VBN studied)))))) (SBAR (CC and) (SBAR (IN because) (S (NP (NNS patients)) (VP (VBD took) (NP (NP (JJ variable) (NNS doses)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Combination) (NN therapy)) (PP (IN with) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NN drug3))))) (VP (VBZ is) (RB not) (VP (VBN indicated)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB reverse) (NP (NP (DT the) (JJ analgesic) (NN activity)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN with) (NP (NN drug1))) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (NP (NN smoking))) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (VBN enhanced) (NN vasoconstriction)))))) (. .)))
(S1 (S (NP (NP (NP (NNS Interactions)) (PP (IN for) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (: :) (NP (NP (NN drug3)) (, ,) (NP (JJ Oral) (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6))))))
(S1 (S (NP (NP (NNS Interactions)) (SBAR (IN for) (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (NP (NN drug3)) (: -)) (VP (VBZ impairs) (NP (NP (DT the) (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug4))))))))))
(S1 (S (S (NP (NP (NN drug1)) (CC -) (NP (JJ concurrent) (NN use))) (VP (VBZ decreases) (NP (NP (JJ gastrointestinal) (NN absorption)) (PP (IN of) (NP (NN drug2)))))) (: ;)))
(S1 (S (S (NP (NP (NNS requirements)) (PP (IN for) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD can) (VP (VB interact) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (NP (NN Absorption)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug2)))))) (VP (VBD was) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (TO to) (NP (NP (CD 12) (JJ stable) (JJ renal) (NN transplant) (NNS patients)) (VP (ADVP (RB also)) (VBG taking) (NP (NP (NP (NN drug3)) (CC -) (NP (NN drug4))) (VP (VBG containing) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN mL)) (-RRB- -RRB-)))))))))))))) (: :) (S (NP (NP (DT the) (NN mean) (NN Cmax) (CC and) (NN AUC) (PRN (-LRB- -LRB-) (NP (NN 0-t)) (-RRB- -RRB-)) (NNS values)) (PP (IN for) (NP (NN MPA)))) (VP (VBD were) (ADJP (NP (NP (CD 25) (NN %)) (CC and) (NP (CD 37) (NN %))) (JJR lower)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN than) (SBAR (WHADVP (WRB when)) (S (NP (NN drug6)) (VP (VBD was) (VP (VBN administered) (ADVP (RB alone)) (PP (IN under) (NP (JJ fasting) (NNS conditions))))))))))) (. .))))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (ADVP (RB not)) (VP (VB be) (VP (VBN administered) (ADVP (RB simultaneously))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (WHADVP (WRB When)) (S (VP (VBN studied) (PP (IN in) (NP (JJ stable) (JJ renal) (NN transplant) (NNS patients)))))) (, ,) (NP (NN drug2) (, ,) (NN USP) (-LRB- -LRB-) (JJ MODIFIED) (-RRB- -RRB-) (NNS pharmacokinetics)) (VP (VBD were) (VP (VBN unaffected) (PP (IN by) (NP (NP (JJ steady) (NN state) (NN dosing)) (PP (IN of) (NP (NN drug3)))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :)) (VP (MD may) (VP (VB be) (VP (VBN taken) (PP (IN with) (NP (NN drug3))))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (PP (IN during) (NP (NP (DT the) (NN period)) (PP (IN of) (NP (NN treatment))))) (, ,) (NP (NNS physicians)) (VP (MD should) (VP (VB monitor) (NP (NN blood) (NN cell) (NNS counts))))) (. .)))
(S1 (S (NP (NP (DT Both) (NN drug1)) (: /) (S (S (NP (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (NNS concentrations)) (VP (VBP are) (VP (VBN increased) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ renal) (NN impairment)))))))) (, ,) (S (NP (PRP$ their) (NN coexistence)) (VP (MD may) (VP (VB compete) (PP (IN for) (NP (NP (JJ tubular) (NN secretion)) (CC and) (NP (JJ further) (NN increase)))) (PP (IN in) (NP (NP (DT the) (NNS concentrations)) (PP (IN of) (NP (DT the) (CD two))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (S (PP (IN Given) (SBAR (IN that) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBP inhibit) (NP (NN purine) (NN metabolism)))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (NP (NN drug5)) (ADVP (RB not)) (VP (VB be) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NN drug6)) (CC or) (NP (NN drug7))))))))))) (. .))))
(S1 (S (NP (NP (NP (NP (NNS drug1)) (CC and) (NP (NNS Drugs))) (SBAR (WHNP (WDT that)) (S (VP (VBP Bind) (NP (JJ Bile) (NNS Acids)))))) (: :) (S (NP (DT These) (NNS drugs)) (VP (VP (VBP interrupt) (NP (JJ enterohepatic) (NN recirculation))) (CC and) (VP (VBP reduce) (NP (NN drug2) (NN exposure)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (VP (VBP do) (RB not) (VP (VB administer) (NP (NP (NN drug1)) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NP (NP (NP (JJ other) (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (JJ enterohepatic) (NN recirculation)))))))) (CC or) (NP (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB bind) (NP (JJ bile) (NNS acids)))))))))) (, ,) (PP (IN for) (NP (NN example) (NP (JJ bile) (NN acid) (NNS sequestrates)) (CC or) (NP (JJ oral) (NN drug3)))) (, ,) (PP (IN because) (IN of) (NP (DT the) (NN potential) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (NN drug4)))))))))))) (. .)))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (PP (IN Given) (NP (NP (DT the) (JJ different) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (JJ oral) (NN drug3)))))) (, ,) (NP (NP (DT no) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (DT these) (CD two) (NNS classes)) (PP (IN of) (NP (NN drug)))))) (VP (VBZ is) (VP (VBN expected)))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN in) (NP (DT a) (JJ drug-drug) (NN interaction) (NN study))) (, ,) (NP (JJ mean) (NN drug1) (NN AUC)) (VP (VBD was) (VP (VBN decreased) (PP (IN by) (NP (CD 15) (NN %))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN recommended) (SBAR (IN that) (S (S (NP (JJ oral) (NN drug1)) (VP (VBP are) (NP (NP (NN co-)) (VP (VBN administered) (PP (IN with) (NP (NN drug2))) (PP (IN with) (NP (NN caution))))))) (CC and) (S (NP (JJ additional) (NN birth) (NN control) (NNS methods)) (VP (VB be) (VP (VBN considered)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN During) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2))))) (, ,) (S (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (CC and) (S (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN advised) (SBAR (IN that) (S (NP (NN vaccinations)) (VP (MD may) (VP (VB be) (ADJP (RBR less) (JJ effective))))))))))) (. .))))
(S1 (S (S (NP (NN Influenza) (NN vaccination)) (VP (MD may) (VP (VB be) (PP (IN of) (NP (NN value)))))) (. .)))
(S1 (S (S (NP (NN Prescribers)) (VP (MD should) (VP (VBP refer) (PP (TO to) (NP (NP (JJ national) (NNS guidelines)) (PP (IN for) (NP (NN influenza) (NN vaccination)))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (DT the) (JJ gastrointestinal) (NN flora)))))) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NN drug1))) (PP (IN by) (S (VP (VBG disrupting) (NP (JJ enterohepatic) (NN recirculation)))))))) (. .)))
(S1 (S (S (NP (NP (NN Interference)) (PP (IN of) (NP (NN drug1) (NN hydrolysis)))) (VP (MD may) (VP (VB lead) (PP (TO to) (NP (NP (JJR less) (NNS drug2)) (ADJP (JJ available) (PP (IN for) (NP (NN absorption))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (VP (ADVP (RB commonly)) (VBN used) (PP (IN in) (NP (NN COPD))) (PP (IN without) (NP (NP (NNS increases)) (PP (IN in) (NP (JJ adverse) (NN drug) (NNS reactions)))))))))))) (. .)))
(S1 (S (S (NP (DT These)) (VP (VBP include) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (ADJP (ADJP (JJ oral)) (CC and) (ADJP (JJ inhaled))) (NN drug3))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN co) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NN drug2) (NN containing) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug3)) (-RRB- -RRB-))))) (VP (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied)))) (CC and) (VP (VBZ is) (ADVP (RB therefore)) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN Interaction)) (PP (IN with) (NP (JJ Other) (NN drug1) (: :) (NN drug2)))) (VP (MD SHOULD) (VP (VB BE) (VP (VBN USED) (PP (PP (IN WITH) (NP (JJ GREAT) (NN CAUTION))) (CC AND) (PP (IN IN) (NP (NP (VBN REDUCED) (NN DOSAGE)) (PP (IN IN) (NP (NP (NNS PATIENTS)) (SBAR (WHNP (WP WHO)) (S (VP (VBP ARE) (ADVP (RB CONCURRENTLY)) (VP (VBG RECEIVING) (NP (NP (NP (JJ OTHER) (NN drug3)) (, ,) (NP (JJ GENERAL) (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (JJ OTHER) (NN drug6)) (, ,) (NP (NP (NN drug7)) (PRN (-LRB- -LRB-) (PP (VBG INCLUDING) (NP (NN drug8))) (-RRB- -RRB-))) (, ,) (NP (NN drug9)) (CC AND) (NP (JJ OTHER) (NN drug10))) (PRN (-LRB- -LRB-) (PP (VBG INCLUDING) (NP (NN drug11))) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ RESPIRATORY) (NN DEPRESSION)) (, ,) (NP (NN HYPOTENSION)) (, ,) (CC AND) (NP (JJ PROFOUND) (NP (NP (NN SEDATION)) (CC OR) (NP (NN COMA))))) (VP (MD MAY) (VP (VB RESULT)))) (. .)))
(S1 (S (NP (NP (JJ Drug-Drug) (NNS Interactions)) (: :) (S (NP (NP (DT The) (ADJP (ADJP (JJ pharmacokinetic)) (CC and) (ADJP (JJ pharmacodynamic))) (NNS interactions)) (PP (IN between) (NP (NP (JJ drug1) (NNS capsules)) (CC and) (NP (JJ other) (NNS drug2))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN determined))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (S (NP (NNS interactions)) (VP (MD may) (VP (VB be) (VP (VBN expected))))) (CC and) (S (NP (NN drug1) (NNS capsules)) (VP (MD should) (RB NOT) (VP (VB be) (VP (VBN used) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (JJ other) (NNS drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NNS capsules))))) (VP (VBD was) (VP (VBN investigated)))) (. .)))
(S1 (S (S (NP (DT The) (NNS results)) (VP (VBP indicate) (NP (NP (JJ significant) (NNS changes)) (PP (IN in) (NP (NP (NP (JJ drug1) (NN clearance)) (PRN (-LRB- -LRB-) (NP (CD 26) (NN %) (NN decrease)) (-RRB- -RRB-))) (CC and) (NP (NP (NN AUC)) (PRN (-LRB- -LRB-) (NP (CD 44) (NN %) (NN increase)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN drug1) (NNS capsules)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))) (, ,) (ADVP (RB particularly)) (PP (IN at) (NP (NP (NNS doses)) (ADJP (JJR higher) (PP (IN than) (NP (CD 0.4) (NN mg))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Results)) (PP (IN from) (NP (NP (JJ limited) (ADJP (ADJP (FW in) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (JJ drug-drug) (NN interaction) (NNS studies)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBP are) (ADJP (JJ inconclusive)))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN exercised) (PP (IN with) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ drug2))) (NNS capsules))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Catecholamine-depleting) (NNS drugs)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NN drug1))) (-RRB- -RRB-))) (VP (MD may) (VP (VB have) (NP (DT an) (JJ additive) (NN effect)) (SBAR (WHADVP (WRB when)) (S (VP (VBN given) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN treated) (PP (IN with) (NP (NP (VBN extended) (NN release) (NN drug1)) (CC plus) (NP (DT a) (NN catecholamine) (NN depletor)))))) (VP (MD should) (ADVP (RB therefore)) (VP (VB be) (ADVP (RB closely)) (VP (VBN observed) (PP (IN for) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (NP (NN hypotension)) (CC or) (NP (JJ marked) (NN bradycardia))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB produce) (NP (NP (NN vertigo)) (, ,) (NP (NN syncope)) (, ,) (CC or) (NP (JJ postural) (NN hypotension))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration) (JJ contra-indicated)) (: :) (CC -) (NP (JJ Vasoconstrictive) (NN drug1)))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Concomitant) (NNS administrations)) (VP (RB not) (VBN recommended))) (: :) (NP (CC -) (NP (NN drug1)) (CC and) (NP (NN drug2))) (: :) (NP (JJ Certain) (NN drug3))) (VP (VBP interact) (PP (IN with) (NP (NP (NP (NN drug4)) (CC and) (NP (NN drug5))) (VP (VBG leading) (PP (TO to) (NP (NP (VBN increased) (NN serum) (NNS concentrations)) (PP (IN of) (NP (DT the) (JJ latter)))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (JJ severe) (NN ventricular) (NN arrhythmia)) (, ,) (ADVP (RB typically)) (NP (NNS torsades) (NN de) (NN pointe))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (PDT such) (DT a) (NN reaction)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN demonstrated) (PP (IN with) (NP (NN drug1)))))))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (NP (NN drug3)) (CC or) (NP (NN drug4))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (CC -) (NP (NN drug1)) (, ,) (NP (NN drug2))) (: :) (S (NP (NP (JJ Other) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug3)) (CC or) (NP (NN drug4))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN metabolised) (PP (IN by) (NP (JJ hepatic) (NN CYP3A) (NNS isozymes)))))))))) (VP (VBP have) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (NN QT) (NN interval) (NN prolongation)) (CC and/or) (NP (NP (JJ cardiac) (NNS arrythmias)) (PRN (-LRB- -LRB-) (FRAG (ADVP (RB typically)) (NP (NNS torsades) (NN de) (NN pointe))) (-RRB- -RRB-))))) (PP (IN as) (NP (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN increase)) (PP (IN in) (NP (NP (PRP$ their) (NN serum) (NN level)) (ADJP (JJ subsequent) (PP (TO to) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (JJ significant) (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN isozyme))) (, ,) (PP (VBG including) (NP (DT some) (NN drug5)))))))))))))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (PDT such) (DT a) (NN risk)) (VP (VBZ is) (RB not) (VP (VBN verified) (PP (IN for) (NP (NN drug1))))))) (, ,) (NP (NP (NN combination)) (PP (IN of) (NP (NN drug2))) (PP (IN with) (NP (JJ such) (NNS drugs)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ chronic) (NN drug2) (NN use))) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug3)))))) (VP (VBP are) (RB not) (VP (VBN known)))) (. .))))
(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT a) (JJ single) (ADJP (CD 100) (NN mg)) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN administered) (PP (NP (CD one) (NN hour)) (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN drug2))))) (PRN (-LRB- -LRB-) (NP (NP (CD 300) (NN mg) (CD four) (NNS times)) (NP (DT a) (NN day))) (-RRB- -RRB-)))))) (, ,) (NP (NP (DT the) (JJ apparent) (JJ total) (NN drug3) (NN clearance)) (PP (IN of) (NP (DT this) (JJ single) (NN dose))) (PP (IN in) (NP (JJ normal) (JJ healthy) (NNS adults)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (CD 18) (NN %))) (PRN (-LRB- -LRB-) (PP (VBN compared) (PP (TO to) (NP (NP (DT the) (JJ apparent) (JJ total) (NN drug4) (NN clearance)) (PP (IN in) (NP (DT the) (JJ same) (NNS subjects))) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN drug5)))))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (, ,) (NP (CD 100) (NN mg)) (, ,)) (VP (VBD was) (VP (VBN given) (ADVP (RB twice) (RB daily)) (PP (IN for) (NP (CD 13) (NNS days))) (PP (TO to) (NP (CD 12) (JJ healthy) (NNS volunteers)))))) (. .)))
(S1 (S (S (PP (IN On) (NP (NN day) (CD 11))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 650) (NN mg)) (ADVP (NP (CD four) (NNS times)) (RB daily))) (-RRB- -RRB-))) (VP (VBD was) (VP (VP (VBN started)) (CC and) (VP (VBN continued) (PP (IN for) (NP (CD 8) (NNS days))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (VP (VBN assessed) (PP (IN on) (NP (NNS days) (CD 11) (CC and) (CD 13)))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN with) (NP (NN drug1)))) (VP (VBD reduced) (NP (NP (DT the) (NN peak) (NN concentration) (CC and) (NN AUC) (NNS values)) (PP (IN for) (NP (NN drug2)))) (PP (IN by) (NP (QP (RB approximately) (CD 11)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (: :) (NN drug2)) (, ,) (NP (CD 100) (NN mg)) (, ,)) (VP (VBD was) (VP (VBN given) (NP (ADJP (RB twice) (JJ daily)) (NN fro) (CD 13) (NNS days)) (PP (TO to) (NP (CD 12) (JJ healthy) (NNS volunteers)))))) (. .)))
(S1 (S (S (PP (IN On) (NP (NN day) (CD 11))) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 650) (NN mg)) (, ,) (ADVP (NP (CD four) (NNS times)) (RB daily))) (-RRB- -RRB-))) (VP (VBD was) (VP (VP (VBN started)) (CC and) (VP (VBN continued) (PP (IN for) (NP (CD 8) (NNS days))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (VP (VBN assessed) (PP (IN on) (NP (NNS days) (CD 11) (CC and) (CD 13)))))) (. .)))
(S1 (S (S (NP (NP (NN Peak) (NN plasma) (NNS concentrations)) (CC and) (NP (NP (NN AUC)) (PP (IN of) (NP (NN drug1))))) (VP (VBD were) (VP (VBN reduced) (NP (QP (RB approximately) (CD 10)) (NN %)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB depress) (NP (NN plasma) (NN prothrombin) (NN activity)))))))))) (, ,) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (PP (IN on) (NP (NN drug2) (NN therapy))))))) (VP (MD may) (VP (VB require) (NP (NP (JJ downward) (NN adjustment)) (PP (IN of) (NP (PRP$ their) (NN drug3) (NN dosage))))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (JJ bacteriostatic) (NNS drugs)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (JJ bactericidal) (NN action)) (PP (IN of) (NP (NN drug1))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ advisable) (S (VP (TO to) (VP (VB avoid) (NP (NN giving) (NN drug2)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Absorption)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN impaired) (PP (IN by) (NP (NP (NN drug2)) (VP (VBG containing) (NP (NP (NN drug3)) (, ,) (NP (NP (NN drug4)) (CC or) (NP (NN drug5))) (, ,) (CC and) (NP (NN drug6) (JJ -containing) (NNS preparations))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB result) (PP (IN in) (NP (JJ fatal) (JJ renal) (NN toxicity)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ oral) (NN drug2)))) (VP (MD may) (VP (VB render) (NP (NP (JJ oral) (NN drug3)) (ADJP (RBR less) (JJ effective)))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (DT no) (JJ formal) (NN drug) (NN interaction) (NNS studies)) (VP (VBN performed) (PP (IN with) (NP (NN drug1))) (PP (IN in) (NP (NNS humans)))))))) (. .)))
(S1 (S (NP (NP (NN Administration)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))) (VP (VBD resulted) (PP (PP (IN in) (NP (NP (DT a) (JJ two-fold) (NN decrease)) (PP (IN in) (NP (NP (NN drug3) (NN clearance)) (PP (IN in) (NP (DT a) (JJ non-human) (JJ primate) (NN study))))))) (CC and) (PP (IN in) (NP (NP (DT a) (JJ 1.5-fold) (NN increase)) (PP (IN in) (NP (NP (NN drug4) (NN serum) (NNS levels)) (PP (IN in) (NP (JJ clinical) (NNS studies))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (JJ other) (NNS drug2)) (SBAR (WHNP (WDT that)) (S (VP (VBP produce) (NP (JJ dry) (NP (NN mouth)) (, ,) (NP (NN constipation)) (, ,) (CC and) (NP (JJ other) (JJ anticholinergic) (JJ pharmacological) (NNS effects))))))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NP (NN frequency)) (CC and/or) (NP (NN severity))) (PP (IN of) (NP (JJ such) (NNS effects))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB potentially)) (VP (VB alter) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (DT some) (ADJP (RB concomitantly) (VBN administered)) (NNS drugs)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ anticholinergic) (NNS effects)) (PP (IN on) (NP (JJ gastrointestinal) (NN motility)))))))))))) (. .)))
(S1 (S (S (NP (NNS Drugs)) (VP (VBN Eliminated) (PP (IN by) (NP (JJ Active) (JJ Tubular) (NN Secretion))))) (: :) (S (SBAR (IN Although) (S (NP (NP (NNS studies)) (VP (TO to) (VP (VB assess) (NP (NP (JJ drug-drug) (NNS interactions)) (PP (IN with) (NP (NN drug1))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted)))))) (, ,) (NP (NN drug2)) (VP (VBZ has) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (JJ pharmacokinetic) (NNS interactions)) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN eliminated) (PP (IN by) (NP (NP (JJ active) (JJ tubular) (NN secretion)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (CC and) (NP (NN drug9))) (-RRB- -RRB-))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN eliminated) (PP (IN by) (NP (JJ active) (JJ renal) (JJ tubular) (NN secretion)))))))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN serum) (NN concentration)) (PP (IN of) (NP (NP (NN drug2)) (CC and/or) (NP (DT the) (JJ coadministered) (NN drug))))) (PP (IN due) (TO to) (NP (NP (NN competition)) (PP (IN for) (NP (DT this) (NN elimination) (NN pathway)))))))) (. .)))
(S1 (S (S (NP (JJ Careful) (NN patient) (NN monitoring)) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ such) (NNS drugs)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Drug-Laboratory-Test) (NNS Interactions) (NNS Interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN laboratory) (NNS tests))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN in) (S (VP (VBG administering) (NP (NN drug1)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (SBAR (IN because) (S (NP (NP (DT the) (JJ extrapyramidal) (NNS effects)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD can) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN catecholamine) (NN synthesis))))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (JJ other) (NN drug3))))) (VP (MD can) (VP (VB increase) (NP (PRP$ their) (JJ sedative) (NNS effects))))) (. .)))
(S1 (S (S (NP (NN You)) (VP (MD cannot) (VP (VB take) (NP (NN drug1)) (SBAR (IN if) (S (ADVP (RB you)) (VP (VBP have) (VP (VBN taken) (NP (NP (NP (DT a) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (PP (JJ such) (IN as) (NP (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (NN drug9)) (-RRB- -RRB-)))))) (PP (IN in) (NP (DT the) (JJ last) (CD 14) (NNS days)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (NN diabetes) (NN drug) (NNS therapies))))) (VP (MD may) (VP (VB be) (ADJP (JJ necessary) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB reduce) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD could) (VP (VB lead) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN blood) (NN pressure)))))))) (. .)))
(S1 (S (S (NP (NP (NN Tell) (NN your) (NN doctor)) (PP (IN if) (NP (NN you)))) (VP (VBP are) (VP (VBG taking) (NP (NN drug1))))) (. .)))
(S1 (S (PP (IN Before) (S (VP (VBG taking) (NP (NP (DT this) (NN medication)) (, ,) (S (NP (NP (NN tell) (NN your) (NN doctor)) (PP (IN if) (NP (NN you)))) (VP (VBP are) (VP (VBG taking) (NP (NP (DT a) (NN drug1)) (ADJP (JJ such) (PP (IN as) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug6)) (PRN (-LRB- -LRB-) (NP (NN drug7)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug8)) (PRN (-LRB- -LRB-) (NP (NN drug9)) (-RRB- -RRB-))) (, ,) (NP (NN drug10) (-LRB- -LRB-) (CD drug11) (-RRB- -RRB-)) (, ,) (NP (NN drug12) (-LRB- -LRB-) (CD drug13) (-RRB- -RRB-)) (, ,) (NP (NN drug14) (-LRB- -LRB-) (CD drug15) (-RRB- -RRB-)) (, ,) (CC or) (NP (NN drug16) (-LRB- -LRB-) (CD drug17) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS drugs)) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB accelerate) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))) (PP (IN by) (NP (NP (DT the) (NN mechanism)) (PP (IN of) (NP (JJ hepatic) (JJ microsomal) (NN enzyme) (NN induction))))) (, ,) (S (VP (VBG leading) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN dosage) (NNS requirements)) (PP (IN for) (NP (NN drug3)))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NNS physicians)) (VP (MD should) (ADVP (RB closely)) (VP (VB monitor) (NP (NP (NNS patients)) (PP (IN for) (NP (NP (DT a) (NN change)) (PP (IN in) (NP (NN drug1) (NN dosage) (NNS requirements)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug2)) (PP (TO to) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN caution))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ other) (NNS drugs)) (ADJP (JJ susceptible) (PP (TO to) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (JJ hepatic) (NN enzyme) (NN induction)))))))))))))) (. .)))
(S1 (S (S (NP (JJ drug1) (JJ -containing) (NNS drugs)) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB cause) (NP (JJ prolonged) (JJ vasospastic) (NNS reactions))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (JJ theoretical) (NN basis)) (SBAR (IN that) (S (NP (DT these) (NNS effects)) (VP (MD may) (VP (VB be) (ADJP (JJ additive)))))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NP (NP (ADJP (JJ drug1) (JJ -containing) (CC or)) (NN drug2)) (PRN (-LRB- -LRB-) (PP (IN like) (NP (NP (NN drug3)) (CC or) (NP (NN drug4)))) (-RRB- -RRB-))) (CC and) (NP (NN drug5)))) (PP (IN within) (NP (NP (CD 24) (NNS hours)) (PP (IN of) (NP (DT each) (JJ other)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBP reduce) (NP (NN drug2) (NN clearance)) (, ,) (S (ADVP (RB significantly)) (VP (VBG increasing) (NP (JJ systemic) (NN exposure)))))) (. .)))
(S1 (S (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN drug1) (NNS tablets)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)))))))) (VP (VBZ is) (VP (VBN contraindicated))) (. .)) (S (NP (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8))) (-RRB- -RRB-))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (, ,) (ADVP (RB rarely)) (, ,) (S (VP (TO to) (VP (VB cause) (NP (NP (NN weakness)) (, ,) (NP (NN hyperreflexia)) (, ,) (CC and) (NP (NN incoordination))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug9)))))))))))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (DT an) (NN drug2))))) (VP (VBZ is) (ADVP (RB clinically)) (VP (VBN warranted))))) (, ,) (NP (NP (JJ appropriate) (NN observation)) (PP (IN of) (NP (DT the) (NN patient)))) (VP (VBZ is) (VP (VBN advised)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN bioavailability)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN decreased) (NP (NP (NP (CD 80) (NN %)) (PP (IN by) (NP (NP (NN drug2)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (VP (VBP are) (VP (VBN administered) (PP (IN at) (NP (DT the) (JJ same) (NN time))))))) (, ,)))) (CC and) (NP (CD 60) (NN %))) (PP (IN by) (NP (NP (NP (DT some) (NN drug5)) (: -)) (CC or) (NP (NN drug6) (JJ -containing) (NN drug7)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (NP (CD 1) (NN hour)) (IN before) (NP (NN drug8))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (NN bioavailability)) (PP (IN of) (NP (NN drug2))) (PP (IN by) (NP (QP (RB up) (TO to) (CD 50)) (NN %)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (NP (CD 2) (NNS hours)) (IN after) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN bioavailability)) (PP (IN of) (NP (NN drug1)))) (VP (VP (VBZ is) (VP (VBN increased) (NP (CD 2-4) (NN fold)) (PP (IN by) (NP (NN drug2))))) (CC but) (VP (VBZ is) (RB not) (ADVP (RB significantly)) (VP (VBN altered) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pharmacokinetic) (NNS parameters)) (PP (IN of) (NP (NN drug1)))) (VP (VBP are) (RB not) (ADVP (RB significantly)) (VP (VBN modified) (PP (IN by) (NP (NN drug2) (NN coadministration)))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP show) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB displace) (NP (NN drug2)) (PP (IN from) (NP (NP (PRP$ its) (VBG binding) (NN site)) (PP (IN on) (NP (NN protein))))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (ADVP (RB usually)) (NP (NP (JJ complete) (NN cross-resistance)) (PP (IN between) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NN drug3) (NN brand) (NNS drug4))))))) (. .)))
(S1 (S (S (SBAR (IN As) (S (NP (EX there)) (VP (VBZ is) (NP (ADJP (FW in) (FW vitro)) (NN evidence) (SBAR (IN that) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))) (-RRB- -RRB-))) (VP (VBP inhibit) (NP (DT the) (NN TPMT) (NN enzyme))))))))) (, ,) (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NN caution))) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concurrent) (NN drug5) (NN therapy))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NN eye) (NN drops) (CC or) (NNS medications)) (PP (JJ such) (IN as) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NP (NN drug4)) (, ,) (NP (NN drug5))) (-RRB- -RRB-)))))) (VP (MD may) (VP (VB decrease) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN drug6) (JJ ophthalmic))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (ADVP (RB particularly)) (NP (NN drug2)) (, ,)) (VP (VP (MD may) (VP (VB cause) (NP (JJ serious) (JJ cardiac) (NNS arrhythmias)) (PP (IN during) (NP (NN drug3) (NN anesthesia))))) (CC and) (ADVP (RB therefore)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (PP (RB only) (IN with) (NP (JJ great) (NN caution))) (CC or) (PP (RB not) (IN at) (NP (NN all))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (JJ pressor) (NN effect)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ is) (ADVP (RB markedly)) (VP (VBN potentiated) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG initiating) (NP (NP (NN pressor) (NN therapy)) (PP (IN in) (NP (DT these) (NNS patients))))))) (, ,) (NP (DT the) (JJ initial) (NN dose)) (VP (VP (MD should) (VP (VB be) (ADJP (JJ small)))) (CC and) (VP (VBD used) (PP (IN with) (NP (JJ due) (NN caution))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ pressor) (NN response)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (ADVP (RB also)) (VP (VB be) (VP (VBN potentiated) (PP (IN by) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN expected) (S (VP (TO to) (VP (VP (VB inhibit) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN cytochrome) (NN P450) (NNS enzymes)) (NP (NP (NN CYP1A2)) (, ,) (NP (NN CYP2A6)) (, ,) (NP (NN CYP2B6)) (, ,) (NP (NN CYP2C8)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2C19)) (, ,) (NP (NN CYP2D6) (NN CYP2E1)) (CC or) (NP (NN CYP3A)))))))))) (CC nor) (VP (VB induce) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NP (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (NP (NN CYP2B6)) (, ,) (NP (NN CYP2C9)) (CC or) (NP (NN CYP3A))))))))))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ multiple) (NN dose) (JJ drug-drug) (NN interaction) (NN study)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN drug1)) (ADVP (RB approximately)) (VP (VBD doubled) (NP (NN drug2) (CD AUC0-))) (. .)))) (SBAR (IN Since) (S (S (NP (NN drug3)) (VP (VBZ is) (ADVP (RB partially)) (VP (VBN metabolized) (PP (IN by) (NP (NN CYP3A)))))) (CC and) (S (NP (NN drug4) (NN le)) (VP (VBZ is) (VP (VBN known) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (JJ strong) (NN inhibitor)) (PP (IN of) (NP (NP (NN cytochrome) (NN P450) (NN 3A) (NN enzyme)) (, ,) (S (NP (NN care)) (VP (MD should) (VP (VB be) (VP (VBN taken) (PP (IN while) (NP (NP (NN dosing) (NN drug5)) (PP (IN with) (NP (NP (NN drug6)) (CC and) (NP (NP (JJ other) (JJ strong) (NN P450) (NN 3A) (NNS inhibitors)) (PP (VBG including) (NP (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (QP (CD drug10) (, ,) (CD drug11) (, ,) (CD drug12) (, ,) (CD drug13) (, ,) (CD drug14) (, ,) (CD drug15) (CC or) (CD drug16))))))))))))))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NN Dose) (NN adjustment)) (PP (IN of) (NP (NN drug1) (NNS Capsules)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (, ,) (CC and) (S (NP (NN iPTH) (CC and) (NN serum) (NN calcium) (NNS concentrations)) (VP (MD should) (VP (VB be) (ADVP (RB closely)) (VP (VBN monitored) (SBAR (IN if) (S (NP (DT a) (NN patient)) (VP (VP (VBZ initiates)) (CC or) (VP (VBZ discontinues) (NP (NP (NN therapy)) (PP (IN with) (NP (NP (DT a) (JJ strong) (NN CYP3A4) (NN inhibitor)) (PP (JJ such) (IN as) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP impair) (NP (NP (JJ intestinal) (NN absorption)) (PP (IN of) (NP (NN drug1))))))) (, ,) (PP (JJ such) (IN as) (NP (NN drug2))) (, ,)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug3) (NNS Capsules)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (ADVP (RB competitively)) (VP (VBZ inhibits) (NP (NP (DT the) (JJ intracellular) (NN phosphorylation)) (PP (IN of) (NP (NN drug2)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2)))))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (FW In) (FW vitro) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NN phosphorylation)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN inhibited) (PP (IN at) (NP (JJ relevant) (NNS concentrations))) (PP (IN by) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (ADJP (FW in) (FW vitro)) (NNS interactions)))) (VP (VBZ is) (ADJP (JJ unknown)))) (: ;)))
(S1 (S (S (ADVP (RB therefore)) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (DT either)) (PP (IN of) (NP (DT these) (NNS drugs)))))) (VP (MD should) (VP (VB be) (VP (VBN undertaken) (PP (IN with) (NP (NN caution))))))) (. .)))
(S1 (S (S (NP (DT No) (JJ specific) (NN cytochrome) (JJ P450-based) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN conducted))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ pharmacokinetic) (NN interaction)) (PP (IN between) (NP (NP (ADJP (CD 85) (NN mg/m2)) (NN drug1)) (CC and) (NP (JJ infusional) (NN drug2))))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (NP (DT every) (CD 2) (NNS weeks))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Increases)) (PP (IN of) (NP (NN drug1) (NN plasma) (NNS concentrations))) (PP (IN by) (NP (QP (RB approximately) (CD 20)) (NN %)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed) (SBAR (IN with) (S (NP (NP (NNS doses)) (PP (IN of) (NP (CD 130) (NN mg/m2)))) (VP (VBP drug2) (VP (VBN dosed) (NP (DT every) (CD 3) (NNS weeks)))))))))) (. .)))
(S1 (S (SBAR (IN Since) (S (NP (NN platinum) (NN containing) (NNS species)) (VP (VBP are) (VP (VBN eliminated) (ADVP (RB primarily)) (PP (IN through) (NP (DT the) (NN kidney))))))) (, ,) (S (NP (NP (NN clearance)) (PP (IN of) (NP (DT these) (NNS products)))) (VP (MD may) (VP (VB be) (VP (VBN decreased) (PP (IN by) (NP (NP (NN coadministration)) (PP (IN of) (NP (ADJP (RB potentially) (JJ nephrotoxic)) (NNS compounds))))))))) (: ;)))
(S1 (S (S (ADVP (IN although)) (, ,) (NP (DT this)) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB specifically)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN known) (S (VP (TO to) (VP (VB interact) (PP (IN with) (NP (NP (JJ other) (NNS drugs)) (PP (VBG including) (NP (NN drug2) (NNS supplements))))))))))) (: ;)))
(S1 (S (S (NP (NNS interactions)) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NN chelation) (NN therapy))) (, ,) (PP (JJ such) (IN as) (NP (NN drug2)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (S (NP (NN Drug/Laboratory) (NNS Tests)) (NP (NN Interaction))) (: :) (S (NP (NN drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NN serum)) (CC and) (NP (JJ urinary) (NN laboratory) (NNS tests)))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (NP (NN drug1)) (S (VP (TO to) (VP (VB cause) (NP (NP (ADJP (ADJP (JJ false)) (ADJP (JJ positive))) (NNS results)) (PP (IN for) (NP (NNS ketones)))) (PP (IN in) (NP (NP (NN urine)) (VP (VBG using) (NP (NP (NN nitroprusside) (NNS reagents)) (PP (JJ such) (IN as) (NP (NP (NN Ketostix)) (CC and) (NP (NP (ADJP (RB falsely) (VBN decreased)) (NNS measurements)) (PP (IN of) (NP (NP (NN serum) (JJ uric) (NN acid)) (CC and) (NP (NN CPK))))))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB accentuate) (NP (NP (DT the) (JJ orthostatic) (NN hypotension)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB occur) (PP (IN with) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Antihypertensive) (NNS effects)) (PP (IN of) (NP (ADJP (ADJP (JJ drug1)) (CC and) (ADJP (JJ related))) (NNS compounds)))) (VP (MD may) (VP (VB be) (VP (VBN counteracted) (SBAR (WHADVP (WRB when)) (S (NP (NNS drug2)) (VP (VBP are) (VP (VBN used) (ADVP (RB concomitantly)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ results) (PP (IN in) (NP (NP (VBN increased) (NN plasma) (NNS levels)) (PP (IN of) (NP (DT both) (NNS drugs))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (CD 11) (JJ clinical) (JJ drug-drug) (NN interaction) (NNS studies)))) (VP (VBD were) (VP (VBN conducted) (PP (IN in) (NP (JJ healthy) (NNS volunteers))) (S (VP (TO to) (VP (VB evaluate) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (NN drug10))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT these) (NNS studies))) (, ,) (NP (NP (DT no) (NN interaction)) (SBAR (WHNP (WDT that)) (S (VP (VBD altered) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug1)))))))) (VP (VBD was) (VP (VBN observed)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (CC or) (NP (NP (JJ multiple) (NNS doses)) (PP (IN of) (NP (NN drug1)))))) (PP (IN on) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6) (NNS pharmacokinetics))))))) (. .)))
(S1 (S (S (NP (NN drug1) (NN AUC)) (VP (VBD was) (VP (VBN increased) (PP (IN by) (NP (NP (CD 21) (NN %)) (PP (IN with) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NN Cmax))))))) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ steady-state) (NN drug2))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN drug3)) (ADVP (RB alone)))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NN AUC)) (CC and) (NP (NN Cmax))) (VP (VBD were) (VP (VBN increased) (PP (IN by) (NP (NP (CD 18) (NN %)) (CC and) (NP (CD 42) (NN %)) (, ,) (ADVP (RB respectively)))) (, ,) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (JJ steady-state) (NNS drug2)) (PP (VBN compared) (PP (IN with) (NP (NP (NN drug3)) (ADVP (RB alone)))))))))))) (. .)))
(S1 (S (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug3))))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (NP (NN drug4)) (CC or) (NP (NN drug5)) (NP (NN toxicity))) (CC and) (NP (NN drug6)))))))) (CC or) (S (NP (NN drug7) (NN dosage)) (VP (MD should) (VP (VB be) (VP (VBN reduced) (SBAR (IN if) (ADJP (JJ necessary)))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ is) (RB not) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NN P-glycoprotein))))) (CC and) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB alter) (NP (JJ P-glycoprotein-mediated) (NN drug) (NN transport) (NN activity)))))))))) (. .)))
(S1 (S (S (NP (NN Hypokalemia)) (VP (MD can) (VP (VP (VB sensitize)) (CC or) (VP (VB exaggerate) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (DT the) (NN heart))) (PP (TO to) (NP (NP (DT the) (JJ toxic) (NNS effects)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (VBN increased) (NN ventricular) (NN irritability))) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (NN Hypokalemia)) (VP (MD may) (VP (VB develop) (PP (IN during) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS requirements)) (PP (IN in) (NP (JJ diabetic) (NNS patients)))) (VP (MD may) (VP (VB be) (ADJP (ADJP (VBN increased)) (, ,) (ADJP (VBN decreased)) (, ,) (CC or) (ADJP (JJ unchanged)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB decrease) (NP (NP (JJ arterial) (NN responsiveness)) (PP (TO to) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (DT This) (NN diminution)) (VP (VBZ is) (RB not) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB preclude) (NP (NP (NN effectiveness)) (PP (IN of) (NP (NP (DT the) (JJ pressor) (NN agent)) (PP (IN for) (NP (JJ therapeutic) (NN use)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN responsiveness)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NN drug1) (JJ renal) (NN clearance)) (VP (VBZ is) (VP (VBN reduced) (PP (IN by) (NP (NN drug2))) (, ,) (S (VP (VBG increasing) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VP (VBP add) (PP (TO to))) (CC or) (VP (VB potentiate) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (JJ other) (NNS drug2)))))))) (. .)))
(S1 (S (S (NP (NN Potentiation)) (VP (VBZ occurs) (PP (IN with) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: /) (NP (NN drug2)) (: :) (NP (NN drug3)) (: /) (NP (NN drug4))) (VP (VBZ does) (RB not) (VP (VB influence) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug5))) (PP (IN in) (NP (NP (JJ healthy) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN N=) (CD 10)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (CD 5) (NNS hours)) (. .))))
(S1 (S (S (NP (NN drug1)) (: :) (PP (IN In) (NP (NP (JJ healthy) (NNS volunteers)) (PRN (-LRB- -LRB-) (NP (NN N=) (CD 11)) (-RRB- -RRB-)))) (, ,) (NP (NN drug2)) (VP (VBD did) (RB not) (VP (VB influence) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NN drug1) (: :) (NN Population) (JJ pharmacokinetic) (NN analysis)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN drug2)) (VP (VBZ is) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB alter) (NP (NP (DT the) (JJ oral) (NN clearance)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN N=) (CD 54)) (-RRB- -RRB-)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (, ,) (NP (NP (DT a) (JJ known) (NN inhibitor)) (PP (IN of) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (JJ organic) (NNS bases))) (PP (IN via) (NP (DT the) (JJ cationic) (NN transport) (NN system)))))) (, ,)) (VP (VBD caused) (NP (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN increase)) (PP (IN in) (NP (NN drug3) (NN AUC)))) (CC and) (NP (NP (DT a) (ADJP (CD 40) (NN %)) (NN increase)) (PP (IN in) (NP (NP (NN half-life)) (PRN (-LRB- -LRB-) (NP (NN N=) (CD 12)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (, ,) (NP (NP (DT a) (JJ known) (NN inhibitor)) (PP (IN of) (NP (NP (JJ renal) (JJ tubular) (NN secretion)) (PP (IN of) (NP (JJ organic) (NNS acids))) (PP (IN via) (NP (DT the) (JJ aruonic) (NN transporter)))))) (, ,)) (VP (VBD did) (RB not) (ADVP (RB noticeably)) (VP (VB influence) (NP (NP (NN drug3) (NNS pharmacokinetics)) (PRN (-LRB- -LRB-) (NP (NN N=) (CD 12)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (NP (NP (NP (JJ Other) (NNS drugs)) (VP (VBN eliminated) (PP (IN via) (NP (JJ renal) (NN secretion))))) (: :) (S (NP (NN Population) (JJ pharmacokinetic) (NN analysis)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN secreted) (PP (IN by) (NP (NP (DT the) (JJ cationic) (NN transport) (NN system)) (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (CC and) (NP (NN drug7)))) (-RRB- -RRB-)))))))))) (VP (VBZ decreases) (NP (NP (DT the) (JJ oral) (NN clearance)) (PP (IN of) (NP (NN drug8)))) (PP (IN by) (NP (QP (RB about) (CD 20)) (NN %))) (, ,) (SBAR (IN while) (S (NP (DT those) (VP (VBN secreted) (PP (IN by) (NP (NP (DT the) (JJ anionic) (NN transport) (NN system)) (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (CC and) (NP (NN drug13)))) (-RRB- -RRB-))))) (VP (VBP are) (ADJP (JJ likely) (S (VP (TO to) (VP (VB have) (NP (JJ little) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ oral) (NN clearance)) (PP (IN of) (NP (NN drug14))))))))))))))))) (. .))))
(S1 (S (NP (NP (JJ CYP) (NNS interactions)) (: :) (S (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NNS enzymes)))) (VP (MD would) (RB not) (VP (VB be) (VP (VBN expected) (S (VP (TO to) (VP (VB affect) (NP (NN drug1) (NN elimination)) (SBAR (IN because) (S (NP (NN drug2)) (VP (VBZ is) (RB not) (ADVP (RB appreciably)) (VP (VBN metabolized) (PP (IN by) (NP (DT these) (NNS enzymes))) (ADVP (ADVP (FW in) (FW vivo)) (CC or) (ADVP (FW in) (FW vitro)))))))))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB inhibit) (NP (JJ CYP) (NNS enzymes) (NP (NP (NN CYPIA2)) (, ,) (NP (NN CYP2C9)) (, ,) (NP (NN CYP2CI9)) (, ,) (NP (NN CYP2EI)) (, ,) (CC and) (NP (NN CYP3A4))))))) (. .)))
(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN CYP2D6)))) (VP (VBD was) (VP (VBN observed) (PP (IN with) (NP (NP (DT an) (JJ apparent) (NN Ki)) (PP (IN of) (NP (CD 30) (NN uM))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD will) (RB not) (VP (VBP inhibit) (NP (JJ CYP) (NNS enzymes)) (PP (IN at) (NP (NP (NN plasma) (NNS concentrations)) (VP (VBN observed) (PP (VBG following) (NP (NP (DT the) (JJS highest) (VBN recommended) (JJ clinical) (NN dose)) (PRN (-LRB- -LRB-) (NP (CD 1.5) (NN mg) (JJ tid)) (-RRB- -RRB-)))))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (SBAR (IN Since) (S (NP (NN drug2)) (VP (VBZ is) (NP (DT a) (NN drug3))))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (NNS drug4)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (DT the) (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8))) (-RRB- -RRB-))) (CC or) (NP (NN drug9)))) (, ,)) (VP (MD may) (VP (VB diminish) (NP (NP (DT the) (NN effectiveness)) (PP (IN of) (NP (NN drug10)))))))))) (. .))))
(S1 (S (S (S (VP (VBG Drug/) (NP (NN Laboratory) (NN Test) (NNS Interactions)))) (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ known) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN laboratory) (NNS tests))))))) (. .)))
(S1 (S (S (VP (VBP Do) (RB not) (VP (VB exceed) (NP (NP (DT a) (ADJP (CD 5) (NN mg)) (JJ daily) (NN dose)) (PP (IN of) (NP (NN drug1)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN administered) (PP (IN with) (NP (NP (JJ therapeutic) (NNS doses)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (JJ other) (JJ potent) (JJ CYP3A4) (NNS inhibitors)))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (PP (IN with) (NP (NP (ADJP (ADJP (JJ Congenital)) (CC or) (ADJP (JJ Acquired))) (NN QT) (NN Prolongation)) (PP (IN In) (NP (NP (DT a) (NN study)) (PP (IN of) (NP (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (JJ QT) (NN interval)) (PP (IN in) (NP (CD 76) (JJ healthy) (NNS women)))))) (, ,) (NP (NP (DT the) (JJ QT) (VBG prolonging) (NN effect)) (VP (VBD appeared) (ADJP (ADJP (JJR less)) (PP (IN with) (NP (NN drug2) (CD 10) (NN mg))) (PP (IN than) (PP (IN with) (NP (NP (CD 30) (NN mg)) (PRN (-LRB- -LRB-) (NP (NP (CD three) (NNS times)) (NP (DT the) (JJ maximum) (VBN recommended) (NN dose))) (-RRB- -RRB-)))))))) (, ,) (CC and) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN drug3) (CD 30) (NN mg))))))))))) (VP (VBD did) (RB not) (VP (VB appear) (PP (IN as) (ADJP (JJ large) (PP (IN as) (NP (NP (DT that)) (PP (IN of) (NP (NP (DT the) (JJ positive) (NN control) (NN drug4)) (PP (IN at) (NP (PRP$ its) (JJ therapeutic) (NN dose)))))))))))) (. .)))
(S1 (S (NP (DT This) (NN observation)) (VP (MD should) (VP (VB be) (VP (VBN considered) (PP (IN in) (NP (JJ clinical) (NNS decisions))) (S (VP (TO to) (VP (VB prescribe) (NP (NP (NN drug1)) (PP (IN for) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (DT a) (JJ known) (NN history)) (PP (IN of) (NP (NN QT) (NN prolongation)))))) (CC or) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBG taking) (NP (NP (NNS medications)) (VP (VBN known) (S (VP (TO to) (VP (VB prolong) (NP (DT the) (JJ QT) (NN interval))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN at) (NP (NP (DT a) (NN Dose)) (PP (IN of) (NP (NP (CD 10) (NN mg)) (ADJP (RB Once) (JJ Daily) (PP (JJ Dosed) (TO to) (NP (JJ Pharmacokinetic) (JJ Steady) (NN State)))))))) (: -)) (VP (VBD did) (RB not) (VP (VB cause) (NP (NP (ADJP (RB clinically) (JJ significant)) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NNS kinetics)) (PP (IN of) (NP (NP (DT a) (JJ single) (JJ intravenous) (NN dose)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (ADVP (RB predominantly)) (DT a) (NN cytochrome) (NN P450) (NN 1A2) (NN substrate)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (CC -) (VP (VBD did) (RB not) (VP (VP (VP (VB change) (NP (NP (DT the) (JJ pharmacokinetic) (NN profile)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN substrate)) (PP (IN of) (NP (NP (NN cytochromes) (NN P450) (NN 2A6)) (CC and) (NP (NN 2C9))))) (-RRB- -RRB-)))))) (CC or) (VP (VB influence) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN 30-mg) (JJ oral) (NN dose)) (PP (IN of) (NP (NN drug2))))) (PP (IN on) (NP (NP (NN prothrombin) (NN time)) (CC or) (NP (DT the) (NN INR))))))) (PRN (-LRB- -LRB-) (NP (NP (NNP International)) (VP (VBN Normalized) (NP (NN Ratio)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (CC -) (VP (VBD did) (RB not) (VP (VB change) (NP (NP (DT the) (NP (JJ pharmacokinetic) (NN profile)) (CC or) (NP (JJ urinary) (NN excretion))) (PP (IN of) (NP (JJ immunoreactive) (NN drug1))))))) (. .)))
(S1 (S (S (TO -) (VP (VP (VBD did) (RB not) (VP (VB change) (NP (NP (DT the) (NN plasma) (NN concentration) (NN profile)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN substrate)) (PP (IN of) (NP (NN cytochrome) (NN P450) (NN 3A4)))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug2)) (, ,) (NP (PRP$ its) (JJ carboxylated) (NN metabolite)) (, ,))))))) (CC and) (VP (VBD did) (RB not) (VP (VB prolong) (NP (NP (DT the) (NN QTc) (NN interval)) (PP (VBG following) (NP (NP (NN co-administration)) (PP (IN with) (NP (NP (NN drug3) (CD 60) (NN mg)) (ADVP (RB twice) (RB daily))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (PP (IN at) (NP (NP (NNS Doses)) (PP (IN of) (NP (CD 100) (NN mg)))))) (VP (VP (ADVP (RB Daily)) (VBN Dosed) (PP (TO to) (NP (JJ Pharmacokinetic) (JJ Steady) (NN State)))) (: :) (CC -) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB alter) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (DT either) (NN component)) (PP (IN of) (NP (NP (DT an) (JJ oral) (NN drug2)) (VP (VBG containing) (NP (NN drug3) (CD 1) (NN mg/ethinyl) (NN drug4) (CD 35) (NN mcg)))))))))))) (. .)))
(S1 (S (S (CC -) (VP (VBD did) (RB not) (VP (VB cause) (NP (NP (DT any) (ADJP (RB clinically) (JJ significant)) (NN change)) (PP (IN in) (NP (NP (NN plasma) (NNS profiles)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (PP (VBG following) (NP (NP (NN administration)) (PP (IN of) (NP (CC either) (NP (JJ oral) (NN drug3)) (CC or) (NP (JJ intravenous) (NN drug4)))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ induces) (NP (JJ hepatic) (NN metabolism))))) (, ,)) (VP (VBD decreased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug2)))) (PP (NP (QP (RB approximately) (CD 40)) (NN %)) (VBG following) (NP (NP (DT a) (JJ single) (JJ 10-mg) (NN dose)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ dosage) (NN adjustment)) (PP (IN for) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ reasonable) (S (VP (TO to) (VP (VB employ) (NP (JJ appropriate) (JJ clinical) (NN monitoring)))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ potent) (NN cytochrome) (NN P450) (NN enzyme) (NNS inducers)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (, ,)) (VP (VBP are) (VP (VBN co-administered) (PP (IN with) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (PP (IN with) (NP (NP (JJ other) (NNS therapies)) (VP (ADVP (RB routinely)) (VBN used) (PP (IN in) (NP (NP (DT the) (NP (NN prophylaxis)) (CC and) (NP (JJ chronic) (NN treatment))) (PP (IN of) (NP (NN asthma))))) (PP (IN with) (NP (NP (DT no) (JJ apparent) (NN increase)) (PP (IN in) (NP (JJ adverse) (NNS reactions)))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN drug-interaction) (NNS studies))) (, ,) (NP (NP (DT the) (VBN recommended) (JJ clinical) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (VBD did) (RB not) (VP (VB have) (NP (ADJP (RB clinically) (JJ important)) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT the) (JJ following) (NNS drugs)) (: :) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NP (JJ oral) (NN drug5)) (PRN (-LRB- -LRB-) (NP (NN drug6) (CD 1) (NN mg/) (NN drug7) (CD 35) (NN mcg)) (-RRB- -RRB-))) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (NN drug10)))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (JJ additional) (JJ specific) (NN interaction) (NNS studies)) (VP (VBD were) (RB not) (VP (VBN performed))))) (, ,) (NP (NN drug1)) (VP (VBD was) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT a) (JJ wide) (NN range)) (PP (IN of) (NP (ADJP (RB commonly) (VBN prescribed)) (NNS drugs))))) (PP (IN in) (NP (NP (JJ clinical) (NNS studies)) (PP (IN without) (NP (NP (NN evidence)) (PP (IN of) (NP (JJ clinical) (JJ adverse) (NNS interactions)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS medications)) (VP (VBD included) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ induces) (NP (JJ hepatic) (NN metabolism))))) (, ,)) (VP (VBD decreased) (NP (NP (DT the) (NN AUC)) (PP (IN of) (NP (NN drug2)))) (PP (NP (QP (RB approximately) (CD 40)) (NN %)) (VBG following) (NP (NP (DT a) (JJ single) (JJ 10-mg) (NN dose)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ dosage) (NN adjustment)) (PP (IN for) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ reasonable) (S (VP (TO to) (VP (VB employ) (NP (JJ appropriate) (JJ clinical) (NN monitoring)))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (JJ potent) (NN cytochrome) (NN P450) (NN enzyme) (NNS inducers)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))) (, ,)) (VP (VBP are) (VP (VBN co-administered) (PP (IN with) (NP (NN drug3))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ pharmacokinetic) (NN study)) (PP (IN of) (NP (NP (CD 18) (JJ chronic) (NN hepatitis) (NN C) (NNS patients)) (VP (ADVP (RB concomitantly)) (VBG receiving) (NP (NN drug1))))))) (, ,) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2))) (PP (ADVP (RB once) (RB weekly)) (IN for) (NP (CD 4) (NNS weeks)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (JJ mean) (NN increase)) (PP (IN of) (NP (CD 16) (NN %))) (PP (IN in) (NP (NN drug3) (NN AUC))))))) (: ;)))
(S1 (S (S (PP (IN in) (NP (QP (CD 2) (IN out) (IN of) (CD 18)) (NNS patients))) (, ,) (NP (NN drug1) (NN AUC)) (VP (VBD doubled))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT this) (NN finding)))) (VP (VBZ is) (ADJP (JJ unknown)))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (NP (DT the) (NP (NNS signs)) (CC and) (NP (NNS symptoms))) (PP (IN of) (NP (VBN increased) (JJ narcotic) (NN effect))))))))) (. .)))
(S1 (S (PP (IN As) (PP (IN with) (NP (JJ other) (NNS drugs)))) (, ,) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN interaction))) (PP (IN by) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS mechanisms)))))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (ADJP (ADJP (JJ pharmacodynamic)) (, ,) (ADJP (JJ pharmacokinetic))) (NN inhibition)) (CC or) (NP (NN enhancement)) (, ,) (NP (NN etc)) (. .)) (-RRB- -RRB-))))
(S1 (S (S (VP (VBZ is) (NP (DT a) (NN possibility)))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (VP (VBG Affecting) (NP (JJ Hepatic) (NN Metabolism) (NP (DT The) (NN metabolism)) (CC and) (NP (NP (NNS pharmacokinetics)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (NP (ADJP (RB Orally) (JJ Disintegrating)) (NNS Tablets))))) (VP (MD may) (VP (VB be) (VP (VBN affected) (PP (IN by) (NP (NP (DT the) (NN induction)) (CC or) (NP (NP (NN inhibition)) (PP (IN of) (NP (JJ drug-metab-olizing) (NNS enzymes)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN Metabolized) (PP (IN by) (NP (CC and/or)))))))) (VP (VP (VBP Inhibit) (NP (NP (NN Cytochrome) (NN P450) (NNS Enzymes)) (S (NP (JJ Many) (NNS drugs)) (VP (VBP are) (VP (VBN metabolized) (PP (IN by))))))) (CC and/or) (VP (VBP inhibit) (NP (NP (JJ various) (NN cytochrome) (NN P450) (NNS enzymes)) (, ,) (PP (FW e.g.) (, ,) (NP (NP (NN 2D6)) (, ,) (NP (NN 1A2)) (, ,) (NP (NN 3A4)) (, ,) (NP (NN etc)))))))) (. .)))
(S1 (S (S (NP (ADJP (FW In) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT a) (NN substrate)) (PP (IN for) (NP (NP (JJ several)) (PP (IN of) (NP (NP (DT these) (NNS enzymes)) (, ,) (PP (VBG including) (NP (NP (NN 2D6)) (, ,) (NP (NN 1A2)) (, ,) (CC and) (NP (NN 3A4))))))))))))))) (. .)))
(S1 (S (SBAR (IN While) (S (NP (ADJP (FW in) (FW vitro)) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (NP (NP (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (NNS enzymes)))))) (, ,) (NP (NP (DT an) (NN indication)) (SBAR (IN that) (S (NP (NN drug2)) (VP (VBZ is) (RB not) (ADVP (RB likely)) (VP (TO to) (VP (VB have) (NP (NP (DT a) (ADJP (RB clinically) (JJ significant)) (JJ inhibitory) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (NP (NP (NNS substrates)) (PP (IN for) (NP (DT these) (NN cytochrome) (NN P450) (NNS enzymes)))))))))))))))))))))))))) (, ,) (NP (NP (DT the) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug3))) (PP (IN with) (NP (NP (JJ most) (JJ other) (NNS drugs)) (VP (VBN metabolized) (PP (IN by) (NP (DT these) (NNS enzymes))))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB formally)) (VP (VBN studied)))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ possible)) (S (VP (TO to) (VP (VB make) (NP (NP (DT any) (JJ definitive) (NNS statements)) (PP (IN about) (NP (NP (DT the) (NNS risks)) (PP (IN of) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ such) (NNS drugs))))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (QP (JJ equivalent) (TO to) (CD 60)) (NN g)) (-RRB- -RRB-))))) (VP (VBD had) (NP (DT a) (JJ minimal) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg)) (-RRB- -RRB-)))) (PP (IN in) (NP (CD 6) (JJ healthy) (JJ male) (NNS subjects))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN impairment)) (PP (IN of) (NP (NP (JJ cognitive) (CC and) (NN motor) (NNS skills)) (VP (VBN produced) (PP (IN by) (NP (NN drug1))))))) (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT those)) (VP (VBN produced) (PP (IN by) (NP (NN drug2))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Accordingly)) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN advised) (S (VP (TO to) (VP (VB avoid) (NP (NN drug1)) (SBAR (IN while) (S (VP (VBG taking) (NP (NP (NN drug2) (. .)) (NN drug3)))))))))))) (: :) (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg)) (-RRB- -RRB-))))) (VP (VBD had) (NP (DT a) (JJ minimal) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (CD 15) (NN mg)) (-RRB- -RRB-))) (PP (IN in) (NP (CD 12) (JJ healthy) (NNS subjects))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN impairment)) (PP (IN of) (NP (NN motor) (NNS skills))) (VP (VBN produced) (PP (IN by) (NP (NN drug1))))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT those)) (VP (VBN caused) (PP (IN by) (NP (NN drug2)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Accordingly)) (, ,) (NP (NNS patients)) (VP (MD should) (VP (VB be) (VP (VBN advised) (S (VP (TO to) (VP (VB avoid) (NP (NP (NN drug1)) (CC and) (NP (JJ other) (JJ similar) (NNS drugs))) (SBAR (IN while) (S (VP (VBG taking) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Spontaneous) (JJ adverse) (NN reaction) (NNS reports)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG taking) (NP (JJ concomitant) (NN drug2)) (PP (IN with) (NP (NP (VBN recommended) (NNS doses)) (PP (IN of) (NP (NN drug3))))))))) (VP (VBP demonstrate) (NP (NP (NN QT) (JJ interval) (NN prolongation)) (CC and) (NP (JJ rare) (JJ serious) (JJ cardiac) (NNS events))) (, ,) (PP (FW e.g.)))))))
(S1 (S (S (NP (NP (NN death)) (, ,) (NP (JJ cardiac) (NN arrest)) (, ,) (CC and) (NP (JJ ventricular) (NN arrhythmia))) (VP (VBG including) (NP (NP (NNS torsades)) (ADJP (FW de) (FW pointes))))) (. .)))
(S1 (S (S (NP (JJ Pharmacokinetic) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug1)) (ADVP (RB markedly)) (VP (VBZ inhibits) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NN drug2)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (JJ elevated) (NN plasma) (NN drug3) (NNS levels)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Presence)) (PP (IN of) (NP (JJ unchanged) (NN drug1)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (ADJP (RB statistically) (JJ significant)) (NN prolongation)) (PP (IN of) (NP (DT the) (NP (NN QT)) (CC and) (NP (NN QTc) (NNS intervals))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (NNS Torsades)) (ADJP (FW de) (FW pointes))) (CC and) (NP (JJ elevated) (NN parent) (NN drug2) (NNS levels))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN during) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))) (PP (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN of) (NP (NN drug5))))) (CC and) (PP (IN from) (NP (JJ foreign) (JJ post-marketing) (NNS sources)))))))))) (. .))))
(S1 (S (S (NP (CD One) (NN death)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN been) (VP (VBN reported) (PP (IN from) (NP (JJ foreign) (JJ post-) (JJ marketing) (NNS sources))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (PP (JJ Due) (TO to) (NP (NP (DT the) (JJ chemical) (NN similarity)) (PP (IN of) (NP (NP (JJ other) (NN drug1)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))) (-RRB- -RRB-)))) (PP (TO to) (NP (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))))) (, ,) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (DT these) (NNS products))) (PP (IN with) (NP (NN drug7)))) (VP (VBZ is) (RB not) (VP (VBN recommended) (S (VP (VBG pending) (NP (NP (JJ full) (NN examination)) (PP (IN of) (NP (JJ potential) (NNS interactions)))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (JJ Clinical) (NN drug) (NN interaction) (NNS studies)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (MD can) (VP (VB exert) (NP (DT an) (NN effect)) (PP (IN on) (NP (NN drug4) (NN metabolism))) (PP (IN by) (NP (NP (DT a) (NN mechanism)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (ADJP (JJ similar) (PP (PP (TO to) (NP (NP (DT that)) (PP (IN of) (NP (NN drug5))))) (, ,) (CC but) (PP (TO to) (NP (DT a) (JJR lesser) (NN extent))))))))))))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (NN erythromycin)) (ADVP (RB measurably)) (VP (VBZ decreases) (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (DT the) (NN drug1) (NN acid) (NN metabolite))))))) (, ,) (NP (NP (PRP$ its) (NN influence)) (PP (IN on) (NP (NN terfenadine) (NN plasma) (NNS levels)))) (VP (VBZ is) (ADVP (RB still)) (PP (IN under) (NP (NN investigation))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ few) (JJ spontaneous) (VBZ accounts)) (PP (IN of) (NP (NP (NN QT) (JJ interval) (NN prolongation)) (PP (IN with) (NP (NP (JJ ventricular) (NN arrhythmia)) (PP (VBG including) (NP (NNS torsades) (ADJP (FW de) (FW pointes)) (, ,)))))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC or) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN administration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4))))) (VP (VBZ is) (VP (VBN contraindicated)))) (: :) (S (S (VP (VBG Pending) (NP (NP (JJ full) (NN characterization)) (PP (IN of) (NP (JJ potential) (NNS interactions)))))) (, ,) (NP (NP (JJ concomitant) (NN administration)) (PP (IN of) (NP (NN drug5))) (PP (IN with) (NP (NP (JJ other) (NNS drug6)) (, ,) (PP (VBG including) (NP (NN drug7))) (, ,)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (NP (NNS Studies)) (VP (TO to) (VP (VB evaluate) (NP (NP (JJ potential) (NNS interactions)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NNS drug2))))))) (VP (VBP are) (PP (IN in) (NP (NN progress))))) (. .)))
(S1 (S (S (NP (NP (JJ Acromegalic) (NNS patients)) (PP (IN with) (NP (NP (NN diabetes) (NN mellitus)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug1)) (CC and/or) (NP (JJ oral) (JJ drug2) (NNS agents))))))))) (VP (MD may) (VP (VB require) (NP (NP (NN dose) (NNS reductions)) (PP (IN of) (NP (DT these) (JJ therapeutic) (NNS agents)))) (PP (IN after) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NP (NN therapy)) (PP (IN with) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS studies))) (, ,) (NP (NP (NNS patients)) (PP (IN on) (NP (NN drug1)))) (ADVP (RB often)) (VP (VBD needed) (NP (JJR higher) (NN serum) (NN drug2) (NNS concentrations)) (S (VP (TO to) (VP (VB achieve) (NP (JJ appropriate) (NN IGF-I) (NN suppression)) (PP (VBN compared) (PP (IN with) (NP (NP (NNS patients)) (VP (RB not) (VBG receiving) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN mechanism)) (PP (IN of) (NP (DT this) (NN interaction)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN caution))) (PP (IN in) (NP (JJ digitalized) (NNS patients))) (, ,) (SBAR (IN since) (S (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB cause) (NP (JJ ectopic) (NN arrhythmias)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC or) (NP (NN drug2))) (VP (MD may) (VP (VB potentiate) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG initiating) (NP (NP (NN pressor) (NN therapy)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT these) (NNS drugs))))))))) (, ,) (NP (DT the) (JJ initial) (NN dose)) (VP (VP (MD should) (VP (VB be) (ADJP (JJ small)))) (CC and) (VP (VBN given) (PP (IN with) (NP (NN caution)))))) (. .)))
(S1 (S (S (S (NP (NP (NN drug1)) (, ,) (NP (DT a) (JJ bacteriostatic) (NN drug2)) (, ,)) (VP (MD may) (VP (VB antagonize) (NP (NP (DT the) (JJ bactericidal) (NN effect)) (PP (IN of) (NP (NN drug3))))))) (CC and) (S (NP (NP (JJ concurrent) (NN use)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD should) (VP (VB be) (VP (VBN avoided)))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (DT an) (JJ adverse) (NN drug) (NN interaction)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ has) (VP (VBN been) (VP (VBN studied) (PP (IN on) (NP (NP (DT a) (NN background)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug1)))) (, ,) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))) (, ,) (VP (VBZ has) (VP (VBN been) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ bleeding))) (VP (VBN compared) (PP (TO to) (NP (NP (NN drug4)) (CC and) (NP (NN drug5)))) (ADVP (RB alone))))) (PRN (-LRB- -LRB-) (NP (VB see))))))))
(S1 (S (NP (NP (NN Drug) (NNS Interactions)) (: :) (NP (NP (NNS Inhibitors)) (PP (IN of) (NP (NN CYP3A4) (NNS Isozymes)))) (: :) (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN administered) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN known) (S (VP (TO to) (VP (VB inhibit) (NP (DT the) (NP (NN cytochrome) (NN P450) (NN 3A4)) (NN enzyme) (NN system))))) (PRN (-LRB- -LRB-) (PP (FW ie)) (, ,) (NP (NP (DT some) (NNS drugs)) (PP (IN in) (NP (NP (DT the) (NN drug) (NNS classes)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))))) (-RRB- -RRB-))))))))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Drugs)) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (CC and) (NP (NN drug6))))) (VP (VBD were) (VP (VBN shown) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB increase) (NP (NP (DT the) (NP (NN C) (NN max)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (ADJP (RB orally) (VBN administered)) (NN drug7)))))))))) (. .)))
(S1 (S (S (NP (DT These) (NN drug) (NNS interactions)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (ADJP (ADJP (VBN increased)) (CC and) (ADJP (JJ prolonged))) (NN sedation)) (ADJP (JJ due) (PP (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN plasma) (NN clearance)) (PP (IN of) (NP (NN drug1))))))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (VP (RB not) (VBN studied)))) (, ,) (NP (NP (DT the) (JJ potent) (NP (NN cytochrome) (NN P450) (NN 3A4)) (NNS inhibitors)) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)))) (VP (MD may) (VP (VB cause) (NP (NP (ADJP (ADJP (JJ intense)) (CC and) (ADJP (JJ prolonged))) (NN sedation)) (CC and) (NP (JJ respiratory) (NN depression))) (PP (JJ due) (TO to) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN plasma) (NN clearance)) (PP (IN of) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (DT these) (NNS drugs)))))))))) (. .)))
(S1 (S (S (S (NP (NN Dose) (NNS adjustments)) (VP (MD should) (VP (VB be) (VP (VBN considered))))) (CC and) (S (NP (NP (NP (JJ possible) (NN prolongation)) (CC and) (NP (NN intensity))) (PP (IN of) (NP (NN effect)))) (VP (MD should) (VP (VB be) (VP (VBN anticipated)))))) (. .)))
(S1 (S (NP (NP (NP (NNS Inducers)) (PP (IN of) (NP (NN CYP3A4) (NNS Isozymes)))) (: :) (S (NP (NP (NP (NN Cytochrome) (NN P450)) (NNS inducers)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3)))) (, ,)) (VP (VP (VBP induce) (NP (NN metabolism))) (CC and) (VP (VBD caused) (NP (NP (NP (DT a) (ADJP (RB markedly) (VBN decreased)) (NN C) (NN max)) (CC and) (NP (NN AUC))) (PP (IN of) (NP (JJ oral) (NNS drug4))) (PP (IN in) (NP (JJ adult) (NNS studies))))))) (. .))))
(S1 (S (S (SBAR (IN Although) (S (NP (JJ clinical) (NNS studies)) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed)))))) (, ,) (NP (NN drug1)) (VP (VBZ is) (VP (VBN expected) (S (VP (TO to) (VP (VB have) (NP (DT the) (JJ same) (NN effect)))))))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (VBZ is) (VP (VBN advised) (SBAR (SBAR (WHADVP (WRB when)) (S (VP (VBG administering) (NP (NN drug1)) (PP (TO to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (DT these) (NNS medications)))))))) (CC and) (SBAR (IN if) (S (NP (JJ necessary) (NN dose) (NNS adjustments)) (VP (MD should) (VP (VB be) (VP (VBN considered)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN difficulty)) (PP (IN in) (S (VP (VBG achieving) (NP (JJ adequate) (NN sedation)))))) (VP (MD may) (VP (VBP have) (VP (VBN been) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (NP (VBN decreased) (NN absorption)) (PP (IN of) (NP (NP (DT the) (NN drug1)) (ADJP (JJ due) (PP (TO to) (NP (NP (CC both) (DT the) (NP (JJ gastrointestinal) (NNS effects)) (CC and) (NP (JJ stimulant) (NNS effects))) (PP (IN of) (NP (NN drug2))))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ sedative) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN accentuated) (PP (IN by) (NP (NP (NP (DT any) (ADJP (RB concomitantly) (VBN administered)) (NN medication)) (SBAR (WHNP (WDT which)) (S (VP (VBZ depresses) (NP (DT the) (JJ central) (JJ nervous) (NN system)))))) (, ,) (ADVP (RB particularly)) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NN drug5))) (-RRB- -RRB-))) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (CC and) (NP (NN drug10)))))))) (. .)))
(S1 (S (S (ADVP (RB Consequently)) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN adjusted) (PP (VBG according) (PP (TO to) (NP (NP (DT the) (NP (NN type)) (CC and) (NP (NN amount))) (PP (IN of) (NP (NP (NP (JJ concomitant) (NNS medications)) (VP (VBN administered))) (CC and) (NP (DT the) (JJ desired) (JJ clinical) (NN response))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ significant) (JJ adverse) (NNS interactions)) (PP (IN with) (NP (NP (NP (JJ common) (NNS premedications)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (JJ other) (NN drug6))))) (-RRB- -RRB-))) (CC or) (NP (JJ local) (NN drug7))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (JJ other) (NN drug1)) (PP (VBG including) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (JJ general) (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (JJ other) (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (CC and) (NP (NN drug10))))))) (VP (MD may) (VP (VB produce) (NP (JJ additive) (NN CNS) (NN depressant) (NNS effects))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (JJ such) (JJ combined) (NN therapy)) (VP (VBZ is) (VP (VBN contemplated))))) (, ,) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (CD one)) (CC or) (NP (DT both)) (NP (NNS agents))))) (VP (MD should) (VP (VB be) (VP (VBN reduced))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (CC or) (NP (JJ other) (NNS medications))) (VP (PP (IN with) (NP (JJ anticholinergic) (NN activity))) (SBAR (WHADVP (WRB when)) (S (VP (VBN used) (ADVP (RB concurrently)) (SBAR (IN with) (S (NP (NN drug2)) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NP (JJ urinary) (NN retention)) (CC and/or) (NP (JJ severe) (NN constipation)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB lead) (PP (TO to) (NP (JJ paralytic) (NNS ileus)))))))))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (SBAR (IN that) (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN bradycardia)))) (VP (VBD was) (VP (VBN increased)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug1)) (VP (VBD was) (VP (VBN combined) (PP (IN with) (NP (NN drug2))) (PP (IN for) (NP (NP (NN induction)) (PP (IN of) (NP (NN anesthesia)))))))))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN CNS) (NN toxicity)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PRN (-LRB- -LRB-) (NP (NP (NN confusion)) (, ,) (NP (NN disorientation)) (, ,) (NP (JJ respiratory) (NN depression)) (, ,) (NP (NN apnea)) (, ,) (NP (NN seizures))) (-RRB- -RRB-)) (PP (VBG following) (NP (NP (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))))))) (: ;)))
(S1 (S (S (NP (DT no) (JJ clear-cut) (NP (NP (NN cause)) (CC and) (NP (NN effect))) (NN relationship)) (VP (VBD was) (VP (VBN established)))) (. .)))
(S1 (S (S (NP (NP (NNS Dosages)) (PP (IN of) (NP (ADJP (RB concomitantly) (VBN administered)) (NN drug1)))) (VP (MD should) (VP (VB be) (VP (VBN reduced) (PP (IN by) (NP (RB approximately) (NN half))) (, ,) (SBAR (IN because) (S (NP (NN drug2)) (VP (VBZ amplifies) (NP (NP (NP (DT the) (JJ therapeutic) (NNS actions)) (CC and) (NP (NNS side-effects))) (PP (IN of) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Combination)) (PP (IN with) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NNS seizures)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Additive) (JJ sedative) (NNS effects)) (CC and) (NP (JJ confusional) (NNS states))) (VP (MD may) (VP (VB emerge) (SBAR (IN if) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN given) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB be) (VP (VBN avoided) (PP (IN by) (S (VP (VBG using) (NP (NP (DT the) (JJS lowest) (NN dose)) (ADJP (JJ possible) (PP (IN with) (NP (NP (DT the) (NNS substances)) (PP (IN in) (NP (NN question)))))))))))))) (. .)))
(S1 (S (S (VP (VBP Exert) (NP (JJ particular) (NN caution)) (PP (IN in) (S (VP (VBG combining) (NP (NN drug1)) (PP (IN with) (NP (NP (JJ other) (NNS drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))) (-RRB- -RRB-))))))))) (: :) (S (NP (RB Particularly) (DT the) (JJ elderly)) (VP (MD may) (VP (VB develop) (NP (NP (NN delirium)) (, ,) (NP (JJ high) (NN fever)) (, ,) (NP (JJ severe) (NN obstipation)) (, ,) (NP (JJ even) (NN ileus)) (CC and) (NP (NN glaucoma)))))) (. .)))
(S1 (S (S (VP (VBP Reduce) (NP (CC both) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NN drug1)))) (CC and) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (JJ other) (NN drug))))))) (. .)))
(S1 (S (S (SBAR (IN If) (FRAG (JJ possible))) (, ,) (VP (VB avoid) (NP (JJ such) (NNS combinations)))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (CC and/or) (NP (NN stimulantes))) (PP (IN of) (NP (DT the) (NN drug2) (: /) (NN drug3) (NN type)))) (VP (MD may) (VP (VB counteract) (NP (NP (DT the) (JJ specific) (NNS actions)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concomitant) (NN use)) (PP (IN of) (NP (DT these) (NNS substances)))) (VP (MD should) (VP (VB be) (VP (VBN avoided))))) (. .)))
(S1 (S (S (NP (NP (NN Coffee)) (CC and) (NP (JJ black) (NN tea))) (VP (MD should) (VP (VB be) (VP (VBN avoided) (SBAR (IN because) (S (NP (PRP they)) (VP (VBP decrease) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NN drug1)))) (ADVP (RB considerably))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ same)) (VP (VBZ is) (ADJP (JJ true) (PP (IN for) (NP (NN drug1)))))) (: ;)))
(S1 (S (S (NP (DT these)) (VP (MD should) (VP (VB be) (VP (VBN given) (NP (QP (CD 1) (TO to) (CD 2)) (NNS hours)) (PP (PP (IN before)) (CC or) (PP (IN after) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NN drug1)))))))))) (. .)))
(S1 (S (NP (NP (NP (NN Usage)) (PP (IN with) (NP (NN drug1)))) (: :) (S (PP (JJ Due) (TO to) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (VBN increased) (NN CNS) (NN depressants) (NNS effects))))) (, ,) (NP (NN drug2)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NP (NN caution)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP are) (ADVP (RB currently)) (VP (VBG receiving) (NP (NN drug3)))))))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN CNS) (NN depressant) (NNS effects)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (ADJP (JJ additive) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (JJ other) (NNS drug2)))))))) (. .)) (. .)))
(S1 (S (S (NP (JJ Limited) (NN evidence)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB influence) (NP (NP (DT the) (NP (NN intensity)) (CC and) (NP (NN duration))) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (NN drug2)))))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (JJ multiple-dose) (NN study)) (PP (IN in) (NP (CD 30) (JJ normal) (NN weight) (NNS subjects))))) (, ,) (NP (NP (NN coadministration)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NP (NP (CD 40) (NNS grams)) (PP (IN of) (NP (NN drug3)))) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NP (QP (RB approximately) (CD 3)) (NNS glasses)) (PP (IN of) (NP (NN wine)))) (-RRB- -RRB-)))))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (NN alteration)) (PP (IN of) (NP (NP (NN drug4) (NNS pharmacokinetics)) (, ,) (NP (NP (NN drug5) (NNS pharmacodynamics)) (PRN (-LRB- -LRB-) (NP (JJ fecal) (JJ fat) (NN excretion)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (JJ systemic) (NN exposure)) (PP (TO to) (NP (NN drug6))))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Preliminary) (NNS data)) (PP (IN from) (NP (DT a) (NN drug2) (CC and) (NN drug3) (NN drug) (NN interaction) (NN study)))) (VP (VBP indicate) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN drug4) (NN plasma) (NNS levels))) (SBAR (WHADVP (WRB when)) (S (NP (NN drug5)) (VP (VBD was) (VP (VBN coadministered) (PP (IN with) (NP (NN drug6)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (CD 12) (JJ normal-weight) (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug2) (CD 120) (NN mg) (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 6) (NNS days)))))))) (, ,) (NP (NN drug3)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN dose)) (PP (IN of) (NP (NN drug4))))))))) (. .))))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NNS Analogues))) (: :) (S (NP (DT A) (JJ pharmacokinetic) (NN interaction) (NN study)) (VP (VBD showed) (NP (NP (DT a) (CD 30) (NN %) (NN reduction)) (PP (IN in) (NP (JJ drug2) (NN supplement) (NN absorption)))) (SBAR (WHADVP (WRB when)) (S (ADVP (RB concomitantly)) (VP (VBN administered) (PP (IN with) (NP (NN drug3)))))))) (. .))))
(S1 (S (S (NP (NN drug1)) (VP (VBD inhibited) (NP (NP (NN absorption)) (PP (IN of) (NP (DT a) (NN drug2) (NN supplement)))) (PP (IN by) (NP (QP (RB approximately) (CD 60)) (NN %))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN effect)) (PP (IN of) (NP (NN drug1))) (PP (IN on) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (JJ supplemental) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (JJ nutritionally-derived) (NNS drug4))))))) (VP (VBZ is) (RB not) (VP (VBN known) (PP (IN at) (NP (DT this) (NN time)))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (: :)) (PP (IN In) (NP (NP (CD 12) (JJ normal-weight) (NNS subjects)) (VP (VBG receiving) (NP (NP (NP (NN drug2) (CD 80) (NN mg)) (NP (NP (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 5) (NNS days)))))) (, ,) (NP (NN drug3))))))) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (NP (DT the) (NP (NNS pharmacokinetics)) (CC or) (NP (NNS pharmacodynamics))) (PRN (-LRB- -LRB-) (ADJP (NN blood) (JJ glucose-lowering)) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN extended-release) (NNS tablets)) (-RRB- -RRB-))) (: :) (S (PP (IN In) (NP (NP (CD 17) (JJ normal-weight) (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug2) (CD 120) (NN mg) (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 6) (NNS days)))))))) (, ,) (NP (NN drug3)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NP (NNS drug4)) (PRN (-LRB- -LRB-) (NP (NN extended-release) (NNS tablets)) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (NP (NP (JJ Oral) (NN drug1)) (: :) (S (PP (IN In) (NP (CD 20) (JJ normal-weight) (JJ female) (NNS subjects))) (, ,) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN drug2) (CD 120) (NN mg) (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 23) (NNS days))))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT no) (NNS changes)) (PP (IN in) (NP (NP (DT the) (JJ ovulation-suppressing) (NN action)) (PP (IN of) (NP (JJ oral) (NN drug3))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (CD 12) (JJ normal-weight) (NNS subjects)) (VP (VBG receiving) (NP (NP (NN drug2) (CD 120) (NN mg) (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 7) (NNS days)))))))) (, ,) (NP (NN drug3)) (VP (VBD did) (RB not) (VP (VB alter) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NP (DT a) (JJ single) (NN 300-mg) (NN dose)) (PP (IN of) (NP (NN drug4))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (NP (DT a) (JJ 2-way) (NN crossover) (NN study)) (PP (IN of) (NP (NP (CD 24) (ADJP (ADJP (JJ normal-weight)) (, ,) (ADJP (RB mildly) (JJ hypercholesterolemic))) (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2) (CD 120) (NN mg) (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 6) (NNS days)))))))))) (, ,) (NP (NN drug3)) (VP (VBD did) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug4))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN In) (NP (CD 12) (JJ normal-weight) (NNS subjects))) (, ,) (NP (NP (NN administration)) (PP (IN of) (NP (NP (NN drug2) (CD 120) (NN mg) (CD three) (NNS times)) (NP (NP (DT a) (NN day)) (PP (IN for) (NP (CD 16) (NNS days))))))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (NP (DT any) (NN change)) (PP (IN in) (NP (CC either) (NP (NP (NN drug3) (NNS pharmacokinetics)) (PRN (-LRB- -LRB-) (NP (CC both) (NP (NN R-)) (CC and) (NP (NN S-enantiomers))) (-RRB- -RRB-))) (CC or) (NP (NP (NNS pharmacodynamics)) (PRN (-LRB- -LRB-) (NP (NP (NN prothrombin) (NN time)) (CC and) (NP (NN serum) (NN Factor) (NN VII))) (-RRB- -RRB-)))))))))) (. .))))
(S1 (S (SBAR (IN Although) (S (NP (NP (JJ undercarboxylated) (NN osteocalcin)) (, ,) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (NN vitamin) (NN K) (JJ nutritional) (NN status)))) (, ,)) (VP (VBD was) (ADJP (JJ unaltered)) (PP (IN with) (NP (NN drug1) (NN administration)))))) (, ,) (NP (NN vitamin) (NN K) (NNS levels)) (VP (VBD tended) (PP (TO to) (NP (NN decline))) (PP (IN in) (NP (NP (NNS subjects)) (VP (VBG taking) (NP (NN drug2)))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN as) (S (NP (NN drug1) (NN absorption)) (VP (MD may) (VP (VB be) (VP (VBN decreased) (PP (IN with) (NP (NN drug2)))))))) (, ,) (NP (NP (NNS patients)) (PP (IN on) (NP (NP (JJ chronic) (JJ stable) (NNS doses)) (PP (IN of) (NP (NN drug3))))) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBN prescribed) (NP (NN drug4))))))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB closely)) (PP (IN for) (NP (NP (NNS changes)) (PP (IN in) (NP (NN coagulation) (NNS parameters))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ competes) (PP (IN with) (NP (NN drug2))) (PP (IN for) (NP (JJ active) (JJ tubular) (NN secretion)))) (CC and) (VP (ADVP (RB thus)) (VBZ inhibits) (NP (NP (DT the) (JJ renal) (NN excretion)) (PP (IN of) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBD led) (PP (TO to) (NP (NP (ADJP (RB statistically) (JJ significant)) (NNS increases)) (PP (PP (IN in) (NP (NP (DT the) (NN elimination) (NN half-life)) (PRN (-LRB- -LRB-) (NP (CD 38) (NN %)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (JJ systemic) (NN exposure)) (PRN (-LRB- -LRB-) (NP (CD 56) (NN %)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NP (DT the) (NN coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBZ is) (NP (NN evidence) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD may) (VP (VB reduce) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (NN drug2)))) (PP (TO to) (NP (NP (JJ subtherapeutic) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NP (JJ therapeutic) (NN range)) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (NP (QP (CD 50) (TO to) (CD 100)) (NN g/mL) (JJ total) (NN drug3))))))) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (NP (NP (PRP itself)) (VP (VBP appear) (S (VP (TO to) (VP (VP (VB induce)) (CC or) (VP (VB inhibit) (NP (NP (DT the) (NP (NN cytochrome) (NN P-450)) (NN drug-metabolizing) (NN enzyme) (NN system)) (PP (IN of) (NP (DT the) (NN liver)))))))))))) (. .)))
(S1 (S (SBAR (IN Because) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (NP (JJ hepatic) (NN cytochrome) (NN P-450) (JJ drug-metabolizing) (NNS enzymes)) (PRN (-LRB- -LRB-) (NP (NP (NN CYP3A4)) (, ,) (NP (NN CYP2D6)) (, ,) (NP (NN CYP1A2))) (-RRB- -RRB-)))))))) (, ,) (NP (NP (NP (NNS inducers)) (CC or) (NP (NNS inhibitors))) (PP (IN of) (NP (DT these) (NNS enzymes)))) (VP (MD may) (VP (VB change) (NP (NP (DT the) (NN clearance)) (CC and) (, ,) (ADVP (RB hence)) (, ,) (NP (NP (DT the) (NN half-life)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (PP (IN On) (DT the) (NN basis) (IN of) (NP (JJ limited) (JJ available) (NNS data))) (, ,) (NP (DT no) (JJ dosage) (NN adjustment)) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NNS patients)) (PP (IN on) (NP (DT these) (NNS drugs)))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (: :) (S (PP (IN In) (NP (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NP (JJ potent) (NNS inducers)) (PP (IN of) (NP (NN CYP3A4))))))) (PRN (-LRB- -LRB-) (PP (FW i.e.) (, ,) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))) (-RRB- -RRB-)))) (, ,) (S (NP (NP (DT the) (NN clearance)) (PP (IN of) (NP (NN drug7)))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN increased)))) (CC and) (S (NP (NN drug8) (NN blood) (NNS concentrations)) (VP (VBD were) (VP (VBN decreased))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (PP (IN on) (DT the) (NN basis) (IN of) (NP (JJ available) (NNS data))) (, ,) (NP (NP (DT no) (JJ dosage) (NN adjustment)) (PP (IN for) (NP (NN drug1)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN for) (NP (NP (NNS patients)) (PP (IN on) (NP (DT these) (JJ drugs.1,3) (NNS drug2)))))))) (: :) (S (SBAR (IN Although) (S (NP (NP (DT no) (JJ pharmacokinetic) (NN drug) (NN interaction)) (PP (IN between) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (VP (VBZ has) (VP (VBN been) (VP (VBN observed)))))) (, ,) (NP (NP (NNS data)) (PP (IN from) (NP (CD 2) (JJ small) (NNS studies)))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN drug5)) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (ADJP (NN patient) (JJ controlled)) (NN administration)) (PP (IN of) (NP (NN drug6) (CD .4) (, ,) (CD 5) (NN Chemotherapy)))))))))))))) (: :) (S (NP (NP (NN Tumor) (NN response)) (PP (TO to) (NP (NN chemotherapy))) (PP (IN in) (NP (DT the) (NN P) (CD 388) (NN mouse) (NN leukemia) (NN model)))) (VP (VBZ is) (RB not) (VP (VBN affected) (PP (IN by) (NP (NN drug7)))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NNS humans))) (, ,) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (VP (VBP do) (RB not) (VP (VB affect) (NP (NP (DT the) (NNS pharmacokinetics)) (PP (IN of) (NP (NN drug4))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ crossover) (NN study)) (PP (IN in) (NP (CD 76) (JJ pediatric) (NNS patients))))) (, ,) (NP (NN I.V.))))
(S1 (S (S (NP (NN drug1)) (VP (VBD did) (RB not) (VP (VB increase) (NP (NP (NN blood) (NNS levels)) (PP (IN of) (NP (JJ high-dose) (NN drug2))))))) (. .)))
(S1 (S (NP (NP (JJ CYP3A4) (NNS Inhibitors)) (: :) (S (NP (NP (NN drug1)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (DT the) (NN drug) (NN metabolizing) (NN enzyme) (NN CYP3A4)))) (, ,)) (ADVP (RB significantly)) (VP (VBD increased) (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug2)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (TO to) (NP (NP (NNS subjects)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (NP (JJ poor) (NNS metabolizers)) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NP (JJ CLINICAL) (NN PHARMACOLOGY)) (, ,) (NP (NP (NN Variability)) (PP (IN in) (NP (NN Metabolism)))) (CC and) (NP (JJ Drug-Drug) (NNS Interactions))))) (-RRB- -RRB-)))))))))))) (. .))))
(S1 (S (PP (IN For) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC or) (NP (NP (JJ other) (JJ potent) (JJ CYP3A4) (NNS inhibitors)) (PP (JJ such) (IN as) (NP (NP (NP (NP (JJ other) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN eg)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7))) (-RRB- -RRB-)))) (CC or) (NP (NP (NN drug8)) (CC or) (NP (NN drug9)))))))))) (, ,) (NP (NP (DT the) (VBN recommended) (NN dose)) (PP (IN of) (NP (NN drug10)))) (VP (VBZ is) (NP (NP (CD 2) (NN mg)) (ADVP (RB daily)))) (. .)))
(S1 (S (S (NP (NP (JJ Drug-Laboratory-Test) (NNS Interactions) (NNS Interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NN laboratory) (NNS tests))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN metabolized) (PP (IN by) (NP (DT a) (NN P450) (NN enzyme) (NN system))))))) (, ,) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP induce)) (CC or) (VP (VBP inhibit) (NP (DT this) (NN drug) (NN metabolizing) (NN enzyme) (NN system))))))) (VP (MD may) (VP (VB elicit) (NP (NP (JJ important) (JJ drug-drug) (NNS interactions)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB alter) (NP (NN drug2) (NN plasma) (NNS concentrations)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Agents)) (SBAR (WHNP (WDT that)) (S (VP (MD might) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug1)) (PP (IN in) (NP (NN AIDS) (NNS patients))) (PP (IN for) (NP (NP (JJ other) (NNS indications)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB elicit) (NP (DT this) (NN activity)))))))))))))))) (VP (VBP include) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6))))) (. .)))
(S1 (S (S (NP (NP (ADJP (FW In) (FW vitro)) (NN perfusion)) (PP (IN of) (NP (VBN isolated) (NN rat) (NN liver)))) (VP (VBZ has) (VP (VBN shown) (SBAR (SBAR (IN that) (S (NP (NN drug1)) (VP (VBD caused) (NP (NP (DT a) (JJ significant) (NN reduction)) (PP (IN in) (NP (NN drug2) (NN metabolism))))))) (CC and) (SBAR (IN that) (S (NP (NN drug3)) (VP (VBD altered) (NP (NP (DT the) (JJ relative) (NN concentration)) (PP (IN of) (NP (NN trimetrexate) (NNS metabolites)))) (PP (ADVP (RB possibly)) (IN by) (S (VP (VBG competing) (PP (IN for) (NP (NN sulfate) (NNS metabolites))))))))))))) (. .)))
(S1 (S (S (PP (VBN Based) (PP (IN on) (NP (DT an) (ADJP (FW in) (FW vitro)) (NN rat) (NN liver) (NN model)))) (, ,) (NP (NP (NN nitrogen) (VBN substituted) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4))) (-RRB- -RRB-))) (VP (VBD were) (NP (NP (ADJP (ADJP (JJ potent)) (, ,) (ADJP (JJ non-competitive))) (NNS inhibitors)) (PP (IN of) (NP (NN drug5) (NN metabolism)))))) (. .)))
(S1 (S (S (NP (NP (NP (NNS Patients)) (VP (VBN medicated) (PP (IN with) (NP (DT these) (NNS drugs))))) (CC and) (NP (NN drug1))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NN Prolongation)) (PP (IN of) (NP (NP (NP (NN prothrombin) (NN time)) (PRN (-LRB- -LRB-) (NP (NN PT)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NNP International)) (VBN Normalized) (NN Ratio)) (PRN (-LRB- -LRB-) (NP (NN INR)) (-RRB- -RRB-)))))) (VP (VBD were) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)) (PP (ADVP (RB concomitantly)) (IN with) (NP (NN drug3))))))))) (. .))))
(S1 (S (S (NP (NNS Physicians)) (VP (MD should) (ADVP (RB carefully)) (VP (VB monitor) (NP (NP (NP (NN PT)) (CC and) (NP (NN INR))) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concurrently)) (VBN administered) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NN drug1) (JJ Severe) (NN thrombocytopenia)) (CC and) (NP (JJ gastrointestinal) (JJ bleeding))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN with) (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NP (JJ other) (NNS drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.)) (, ,) (NP (NNS drug4)) (-RRB- -RRB-))))))))))) (. .)))
(S1 (S (S (NP (NN Monitor) (NN platelet) (NN count)) (VP (NP (DT every) (CD 2) (NNS weeks)) (PP (IN for) (NP (DT the) (JJ first) (CD 2) (NNS months))))) (. .)))
(S1 (S (S (NP (NP (JJ Nasal) (NN Spray) (: :) (JJ Formal) (NNS studies)) (VP (VBN designed) (S (VP (TO to) (VP (VB evaluate) (NP (NP (NN drug) (NNS interactions)) (PP (IN with) (NP (NN drug1))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN done))))) (. .)))
(S1 (S (S (NP (DT No) (NN drug) (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed) (PP (IN with) (NP (NN drug1) (JJ nasal) (NN spray) (NNS ingredients))))))) (. .)))
(S1 (S (S (ADVP (RB Currently)) (, ,) (NP (NP (DT no) (NN drug) (NNS interactions)) (PP (IN with) (NP (NN drug1)))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (JJ prior) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (JJ postmenopausal) (NN osteoporosis) (NNS patients)))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN assessed))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN Paget) (POS 's) (NN Disease))))) (NP (JJ prior) (NN drug1) (NN use)) (VP (VBZ appears) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (JJ anti-resorptive) (NN response)) (PP (TO to) (NP (NN drug2) (JJ nasal) (NN spray))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN absorption)) (PP (IN of) (NP (JJ oral) (NNS medications)))) (VP (MD may) (VP (VB be) (VP (VBN decreased) (PP (IN during) (NP (NP (DT the) (JJ concurrent) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN because) (PP (IN of) (NP (NP (VBN decreased) (JJ gastric) (NN motility)) (CC and) (NP (VBN delayed) (JJ gastric) (NN emptying))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD should) (VP (VB be) (VP (VBN used) (PP (IN with) (NP (NN care))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking) (NP (NP (JJ other) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG causing) (NP (NP (NN CNS) (NNS effects)) (PP (JJ such) (IN as) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (NN drug4)))))))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Special) (NN attention)) (VP (MD should) (VP (VB be) (ADJP (JJ paid) (PP (TO to) (NP (NP (JJ potential) (NNS interactions)) (PP (IN with) (NP (NP (NNS drugs)) (VP (VBG having) (NP (JJ anticholinergic) (NNS properties))))))))))) (: ;)))
(S1 (S (S (ADVP (FW e.g.)) (, ,) (NP (NP (JJ other) (NN drug1)) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (PP (VBG including) (NP (NN drug3))) (-RRB- -RRB-))) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5)))) (. .)))
(S1 (S (S (NP (NN Laboratory) (NN Test) (NNS Interactions) (NP (NN drug1))) (VP (MD will) (VP (VB interfere) (PP (IN with) (NP (DT the) (JJ gastric) (NN secretion) (NN test)))))) (. .)))
(S1 (S (S (NP (NP (JJ Formal) (NN interaction) (NNS studies)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drugs)))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN performed))))) (. .)))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBN studied) (PP (IN in) (NP (NP (JJ clinical) (NNS trials)) (PP (IN of) (NP (NN drug1))))))) (VP (VBD were) (ADVP (RB routinely)) (VP (VBN treated) (PP (IN with) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP alter) (NP (NN platelet) (NN function)))))) (PRN (-LRB- -LRB-) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN GP) (NN IIb/IIIa) (NNS inhibitors))))) (-RRB- -RRB-)))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ bleeding)) (SBAR (IN if) (S (VP (VBN administered) (ADVP (ADVP (RB prior)) (PP (TO to))))))))) (, ,) (PP (PP (IN during)) (, ,) (CC or) (PP (IN after) (NP (NN drug6) (NN therapy))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (PP (IN During) (NP (NN drug1) (NN therapy)))) (, ,) (NP (NP (NNS results)) (PP (IN of) (NP (NN coagulation) (NNS tests)))) (CC and/or) (NP (NP (NNS measures)) (PP (IN of) (NP (JJ fibrinolytic) (NN activity))))) (VP (MD may) (VP (VB be) (ADJP (JJ unreliable)) (SBAR (IN unless) (S (NP (JJ specific) (NNS precautions)) (VP (VBP are) (VP (VBN taken) (S (VP (TO to) (VP (VB prevent) (NP (ADJP (FW in) (FW vitro)) (NNS artifacts)))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (NP (NP (DT an) (NN enzyme)) (SBAR (WHNP (WDT that)) (S (, ,) (SBAR (WHADVP (WRB when)) (S (ADJP (JJ present) (PP (IN in) (NP (NP (NN blood)) (PP (IN in) (NP (JJ pharmacologic) (NNS concentrations)))))))) (, ,) (VP (VBZ remains) (ADJP (JJ active)) (PP (IN under) (NP (ADJP (FW in) (FW vitro)) (NNS conditions))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD can) (VP (VB lead) (PP (TO to) (NP (NP (NN degradation)) (PP (IN of) (NP (NN fibrinogen))) (PP (IN in) (NP (NP (NN blood) (NNS samples)) (VP (VBN removed) (PP (IN for) (NP (NN analysis))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (VP (VB interact) (PP (IN with) (NP (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (-LRB- -LRB-) (VP (VBG causing) (NP (NP (RB too) (JJ great) (DT a) (NN decrease)) (PP (IN in) (NP (JJ adrenal) (NN function))))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN mixture)) (PP (IN of) (NP (CD three) (NNS stereoisomers)))) (-RRB- -RRB-))) (VP (VBZ has) (VP (VBN been) (VP (VBN administered) (ADVP (RB safely)) (S (VP (VBG following) (NP (JJ succinylcholine-facilitated) (NN tracheal) (NN intubation))))))))) (, ,) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB systematically)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (JJ Prior) (NN administration)) (PP (IN of) (NP (NN drug1)))) (VP (MD can) (VP (VB potentiate) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NNS effects)) (PP (IN of) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (NP (NN Evidence)) (PP (IN of) (NP (NP (JJ spontaneous) (NN recovery)) (PP (IN from) (NP (NN drug1)))))) (VP (MD should) (VP (VB be) (VP (VBN observed) (PP (IN before) (NP (NP (DT the) (NN administration)) (PP (IN of) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN before) (NP (NN drug2))))) (S (VP (TO to) (VP (VB attenuate) (NP (NP (DT some)) (PP (IN of) (NP (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (NNS drug3)))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBP are) (NP (NP (DT no) (JJ clinical) (NNS data)) (PP (IN on) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (JJ other) (NNS drug2)))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (-LRB- -LRB-) (VP (VBN administered) (PP (IN with) (NP (NN drug3)))) (: /) (NP (NP (NN drug4)) (VP (TO to) (VP (VB achieve) (NP (CD 1.25) (NNP M.C.))))))))
(S1 (S (S (VP (VBP decrease) (NP (NP (DT the) (NN ED50)) (PP (IN of) (NP (NN drug1)))) (PP (IN by) (NP (QP (RB as) (JJ much) (IN as) (CD 25)) (NN %))) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NP (JJ CLINICAL) (NN PHARMACOLOGY)) (: :) (NP (NP (NP (NNS Pharmacodynamics)) (CC and) (NP (NN Individualization))) (PP (IN of) (NP (NNS Dosages))))))) (-RRB- -RRB-)))) (. .)))
(S1 (S (S (NP (DT These) (NNS agents)) (VP (MD may) (ADVP (RB also)) (VP (VP (VB prolong) (NP (NP (DT the) (ADJP (RB clinically) (JJ effective)) (NN duration)) (PP (IN of) (NP (NN action))))) (CC and) (VP (VB decrease) (NP (NP (DT the) (JJ average) (NN infusion) (NN requirement)) (PP (IN of) (NP (NN drug1)))) (PP (IN by) (NP (QP (RB as) (JJ much) (IN as) (CD 35)) (NN %))) (PP (TO to) (NP (CD 40) (NN %))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJR greater) (NN potentiation)) (PP (IN of) (NP (NP (DT the) (JJ neuromuscular) (NN blocking) (NNS effects)) (PP (IN of) (NP (NN drug1)))))) (VP (MD may) (VP (VB be) (VP (VBN expected) (PP (IN with) (NP (NP (JJR higher) (NNS concentrations)) (PP (IN of) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ has) (NP (NP (ADJP (JJ little))) (CC or) (NP (DT no)) (NP (NN effect))) (PP (IN on) (NP (DT the) (NN ED50)))) (, ,) (CC but) (VP (MD may) (VP (VP (VB prolong) (NP (NP (DT the) (NN duration)) (PP (IN of) (NP (NN action))))) (CC and) (VP (VB decrease) (NP (NP (DT the) (JJ average) (NN infusion) (NN requirement)) (PP (IN by) (NP (QP (RB as) (JJ much) (IN as) (CD 20)) (NN %))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Other) (NNS drugs)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB enhance) (NP (NP (DT the) (JJ neuromuscular) (VBG blocking) (NN action)) (PP (IN of) (NP (NP (NN drug1)) (PP (JJ such) (IN as) (NP (NN drug2))))))))))) (VP (VBP include) (NP (NP (NP (JJ certain) (NN drug3)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (CC and) (NP (NN drug11)))) (-RRB- -RRB-))) (, ,) (NP (NN drug12) (NNS salts)) (, ,) (NP (NN drug13)) (, ,) (NP (JJ local) (NN drug14)) (, ,) (NP (NN drug15)) (, ,) (CC and) (NP (NN drug16))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ neuromuscular) (NN blocking) (NN effect)) (PP (IN of) (NP (NN drug1)))) (VP (MD may) (VP (VB be) (VP (VBN enhanced) (PP (PP (IN by) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP reduce) (NP (NP (NP (NN plasma) (NN cholinesterase)) (NN activity)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (ADJP (RB chronically) (VBN administered)) (JJ oral) (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC or) (NP (JJ certain) (NNS drug4)))) (-RRB- -RRB-)))))))) (CC or) (PP (IN by) (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (ADVP (RB irreversibly)) (VP (VBP inhibit) (NP (NN plasma) (NN cholinesterase))))))))))) (. .)) (S (NP (NP (NN Resistance)) (PP (TO to) (NP (NP (DT the) (JJ neuromuscular) (VBG blocking) (NN action)) (PP (IN of) (NP (JJ nondepolarizing) (NN drug5)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB chronically)) (VBN administered) (NP (NP (NN drug6)) (CC or) (NP (NN drug7)))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ chronic) (NN drug1)) (CC or) (NP (JJ drug2) (NN therapy)))) (PP (IN on) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN drug3)))))) (VP (VBP are) (ADJP (JJ unknown))))) (, ,) (S (NP (NP (ADJP (RB slightly) (JJR shorter)) (NNS durations)) (PP (IN of) (NP (JJ neuromuscular) (NN block)))) (VP (MD may) (VP (VB be) (VP (VBN anticipated))))) (CC and) (S (NP (NN infusion) (NN rate) (NNS requirements)) (VP (MD may) (VP (VB be) (ADJP (JJR higher)))))) (. .)))
(S1 (S (S (NP (DT Some) (NN drug) (NNS interactions)) (VP (VBP are) (: :) (NP (CC -) (NP (NN birth) (NN control) (NNS pills)) (CC -) (NP (NN drug1))))) (: -) (NP (NP (NP (NP (NP (NP (NNS medicines)) (PP (IN for) (NP (NP (NN angina)) (CC or) (NP (JJ high) (NN blood) (NN pressure))))) (CC -) (NP (NNS medicines))) (PP (IN for) (NP (NP (NP (NP (NP (NN pain)) (CC -) (NP (NNS medicines))) (PP (TO to) (NP (NP (NN control) (NNS seizures)) (PP (JJ such) (IN as) (NP (NP (NP (NP (NN drug2)) (CC or) (NP (NN drug3))) (CC -) (NP (JJ certain) (NN drug4))) (VP (VBN given) (PP (IN by) (NP (NP (NP (NN injection)) (CC -) (NP (NN drug5))) (CC -) (NP (NP (NN drug6)) (CC -) (NP (NN drug7))))))))))) (CC -) (NP (NN drug8))) (CC or) (NP (NN drug9))))) (CC -) (NP (JJ local) (NN drug10))) (ADJP (JJ such) (PP (IN as) (NP (NP (NN drug11)) (CC -) (NP (JJ general) (NN drug12)))))) (: -) (NP (NP (NN drug13)) (CC or) (NP (JJ other) (NN drug14)))))
(S1 (S (S (NP (NP (ADJP (RB Clinically) (CC or) (ADJP (RB potentially) (JJ significant))) (NN drug) (NNS interactions)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (DT the) (JJ following) (NNS agents/classes))))) (VP (VBP have) (VP (VBN been) (VP (VBN observed))))) (. .)))
(S1 (S (S (S (NP (DT These)) (VP (VBP are) (VP (VBN described) (PP (IN in) (NP (JJR greater) (NN detail))) (PP (IN below) (: :) (NP (NN drug1)))))) (CC and) (S (NP (DT the) (JJ following) (NNS agents/classes)) (VP (VBP have) (VP (VBN been) (VP (VBN observed)))))) (. .)))
(S1 (S (S (NP (DT These)) (VP (VBP are) (VP (VBN described) (PP (IN in) (NP (JJR greater) (NN detail))) (PP (IN below) (: :) (NP (NP (JJ Oral) (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (, ,) (NP (NN drug9)) (, ,) (NP (NN drug10)) (, ,) (NP (NN drug11)) (, ,) (NP (NN drug12)) (, ,) (NP (JJ Oral) (NN drug13))))))) (: :) (S (NP (ADJP (RB Clinically) (JJ significant)) (NN hypoglycemia)) (VP (MD may) (VP (VB be) (ADJP (JJ precipitated) (PP (IN by) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug14))) (PP (IN with) (NP (JJ oral) (NN drug15))))))))) (: ;)))
(S1 (S (S (NP (NN one) (CD fatality)) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (PP (IN from) (NP (NN hypoglycemia))) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (JJ combined) (NN drug1)) (CC and) (NP (NN drug2) (NN use)))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (VBZ reduces) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4)))))) (CC and) (VP (VBZ increases) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (DT these) (NNS agents))))))) (. .)))
(S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (ADVP (RB concomitantly)) (PP (IN with) (NP (NP (DT these)) (CC or) (NP (JJ other)) (NP (NNS drug2)))))))) (, ,) (S (S (NP (NN blood) (NN glucose) (NNS concentrations)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (CC and) (S (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (NN drug3)))) (VP (MD should) (VP (VB be) (VP (VBN adjusted) (PP (IN as) (ADJP (JJ necessary))))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN Prothrombin) (NN time))) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (JJ concomitant) (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (PP (IN In) (NP (JJ post-marketing) (VBP experience))) (, ,) (PP (IN as) (PP (IN with) (NP (JJ other) (NN drug1)))) (, ,) (NP (NP (JJ bleeding) (NNS events)) (PRN (-LRB- -LRB-) (NP (NP (NN bruising)) (, ,) (NP (NNS epistaxis)) (, ,) (NP (JJ gastrointestinal) (JJ bleeding)) (, ,) (NP (NN hematuria)) (, ,) (CC and) (NP (NN melena))) (-RRB- -RRB-))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NN association)) (PP (IN with) (NP (NP (NNS increases)) (PP (IN in) (NP (NP (NN prothrombin) (NN time)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)) (PP (ADVP (RB concurrently)) (IN with) (NP (NN drug3))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Careful) (NN monitoring)) (PP (IN of) (NP (NN prothrombin) (NN time))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (-LRB- -LRB-) (VP (VB See) (NP (NP (NN &lt)) (: ;) (NP (DT a) (JJ href=) (NN &quot)) (: ;) (NP (NN flucon_cp.htm) (NN #) (NN CP&quot)) (: ;) (NP (NN >CLINICAL) (NN PHARMACOLOGY)) (: :) (NP (NN Drug) (NN Interaction) (NNS Studies)) (. .))) (-RRB- -RRB-)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ increases) (NP (NP (DT the) (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (JJ Careful) (NN monitoring)) (PP (IN of) (NP (NN drug1) (NNS concentrations))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (-LRB- -LRB-) (VP (VB See) (NP (NP (NN &lt)) (: ;) (NP (DT a) (JJ href=) (NN &quot)) (: ;) (NP (NN flucon_cp.htm) (NN #) (NN CP&quot)) (: ;) (NP (NN >CLINICAL) (NN PHARMACOLOGY)) (: :) (NP (NN Drug) (NN Interaction) (NNS Studies)) (. .))) (-RRB- -RRB-)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NN drug2)) (VP (MD may) (ADVP (RB significantly)) (VP (VB increase) (NP (NN drug3) (NNS levels)) (PP (IN in) (NP (NP (JJ renal) (NN transplant) (NNS patients)) (PP (PP (IN with)) (CC or) (PP (IN without) (NP (JJ renal) (NN impairment))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Careful) (NN monitoring)) (PP (IN of) (NP (NP (NN drug1) (NNS concentrations)) (CC and) (NP (NN serum) (NN creatinine))))) (VP (VBZ is) (VP (VBN recommended) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))) (. .)))
(S1 (S (S (-LRB- -LRB-) (VP (VB See) (NP (JJ CLINICAL) (NN PHARMACOLOGY)))) (: :) (NP (NN Drug) (NN Interaction) (NNS Studies)) (. .) (-RRB- -RRB-)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ enhances) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (ADJP (RB concurrently) (VBN administered)) (NN drug3)))))) (. .)))
(S1 (S (S (PP (VBG Depending) (PP (IN on) (NP (JJ clinical) (NNS circumstances)))) (, ,) (NP (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (S (VP (VBG increasing) (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (NP (NN drug1)) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN administered) (PP (IN with) (NP (NN drug2))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (VBZ increases) (NP (NP (DT the) (NN serum) (NNS concentrations)) (PP (IN of) (NP (NN drug3)))))) (. .)))
(S1 (S (S (NP (NP (JJ Careful) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug1) (NNS concentrations))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))) (VP (VBZ is) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (PP (IN Because) (PP (IN of) (NP (NP (DT the) (NN occurrence)) (PP (IN of) (NP (NP (JJ serious) (JJ cardiac) (NNS dysrhythmias)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (NN prolongation)) (PP (IN of) (NP (DT the) (NN QTc) (NN interval))) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (NN drug2)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN drug3)))))))))))))))) (, ,) (NP (NN interaction) (NNS studies)) (VP (VBP have) (VP (VBN been) (VP (VBN performed))))) (. .))))
(S1 (S (S (NP (NP (CD One) (NN study)) (PP (IN at) (NP (NP (DT a) (JJ 200-mg) (JJ daily) (NN dose)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD failed) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (DT a) (NN prolongation)) (PP (IN in) (NP (NN QTc) (NN interval))))))))) (. .)))
(S1 (S (S (NP (NP (DT Another) (NN study)) (PP (IN at) (NP (NP (DT a) (ADJP (ADJP (JJ 400-mg)) (CC and) (ADJP (JJ 800-mg))) (JJ daily) (NN dose)) (PP (IN of) (NP (NN drug1)))))) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (NN drug2)) (VP (VBN taken) (PP (IN in) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 400) (NN mg)) (PP (IN per) (NP (NP (NN day)) (CC or) (NP (JJR greater)))))))))) (ADVP (RB significantly)) (VP (VBZ increases) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NN drug3)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (ADVP (RB concomitantly)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ combined) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (NP (CD 400) (NN mg) (QP (CC or) (JJR greater))) (PP (IN with) (NP (NN drug2)))))))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN coadministration)) (PP (IN of) (NP (NP (NN drug1)) (PP (IN at) (NP (NP (NNS doses)) (ADJP (JJR lower) (PP (IN than) (NP (NP (CD 400) (NN mg/day)) (PP (IN with) (NP (NN drug2))))))))))) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NP (JJ cardiac) (NNS events)) (, ,) (PP (VBG including) (NP (NP (NN torsade) (NN de) (NNS pointes)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHPP (TO to) (WHNP (WP whom))) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (VP (VBN coadministered))))))))))))))) (. .))))
(S1 (S (S (NP (DT A) (JJ controlled) (NN study)) (VP (VBD found) (SBAR (IN that) (S (NP (NP (NP (JJ concomitant) (NN drug1) (CD 200) (NN mg)) (ADVP (RB once) (RB daily))) (CC and) (NP (NP (NN drug2) (CD 20) (NN mg)) (NP (CD four) (NNS times) (NP (DT a) (NN day))))) (VP (VBD yielded) (NP (NP (NP (DT a) (JJ significant) (NN increase)) (PP (IN in) (NP (NN drug3) (NN plasma) (NNS levels)))) (CC and) (NP (NP (NN prolongation)) (PP (IN of) (NP (NN QTc) (NN interval)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ combined) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (VP (VBZ is) (VP (VBN contraindicated)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NN drug2))) (PP (IN in) (NP (NP (NNS patients)) (VP (ADVP (RB concurrently)) (VBG taking) (NP (NP (NP (NN drug3)) (CC or) (NP (JJ other) (NNS drugs))) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system))))))))) (VP (MD may) (VP (VB be) (VP (VBN associated) (PP (IN with) (NP (NP (NNS elevations)) (PP (IN in) (NP (NP (NN serum) (NNS levels)) (PP (IN of) (NP (DT these) (NNS drugs))))))))))) (. .))))
(S1 (S (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ definitive) (NN information))))) (, ,) (NP (NN caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (VP (VBG coadministering) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NN uveitis)))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHPP (TO to) (WHNP (WP whom))) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (VP (VBN coadministered)))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (ADVP (RB concomitantly)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (EX There)) (VP (VBP have) (VP (VBN been) (NP (NP (NNS reports)) (PP (IN of) (NP (NN nephrotoxicity)))) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHPP (TO to) (WHNP (WP whom))) (S (NP (NP (NN drug2)) (CC and) (NP (NN drug3))) (VP (VBD were) (VP (VBN coadministered)))))))))) (. .))))
(S1 (S (S (NP (NP (NNS Patients)) (VP (VBG receiving) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (ADVP (RB concomitantly)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Following) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NN drug2)) (, ,) (NP (NN drug3))))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ substantial) (NNS increases)) (PP (IN in) (NP (NP (NN drug4) (NNS concentrations)) (CC and) (NP (NN psychomotor) (NNS effects)))))))) (. .))))
(S1 (S (S (NP (NP (DT This) (NN effect)) (PP (IN on) (NP (NN drug1)))) (VP (VBZ appears) (S (VP (TO to) (VP (VB be) (ADJP (RBR more) (JJ pronounced) (PP (VBG following) (NP (NP (JJ oral) (NN administration)) (PP (IN of) (NP (NN drug2))) (PP (IN than) (PP (IN with) (NP (NP (NN drug3)) (VP (VBN administered) (ADVP (RB intravenously)))))))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (NP (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN metabolized) (PP (IN by) (NP (DT the) (NN cytochrome) (NN P450) (NN system))))))) (, ,)) (VP (VBP are) (ADVP (RB concomitantly)) (VP (VBN administered) (PP (IN with) (NP (NN drug2))))))) (, ,) (S (S (NP (NN consideration)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (TO to) (S (VP (VBG decreasing) (NP (DT the) (NN drug3) (NN dosage))))))))) (, ,) (CC and) (S (NP (DT the) (NNS patients)) (VP (MD should) (VP (VB be) (ADVP (RB appropriately)) (VP (VBN monitored))))) (. .))))
(S1 (S (S (NP (NP (NN drug1) (NNS tablets)) (VP (VBN coadministered) (PP (IN with) (NP (NP (NN drug2)) (: -) (CC and) (NP (NN drug3)) (NP (JJ -containing) (JJ oral) (NNS drug4)))))) (VP (VBD produced) (NP (NP (DT an) (JJ overall) (NN mean) (NN increase)) (PP (IN in) (NP (NP (NN drug5)) (CC and) (NP (NN drug6) (NNS levels))))))) (: ;)))
(S1 (S (S (ADVP (RB however)) (, ,) (PP (IN in) (NP (DT some) (NNS patients))) (NP (EX there)) (VP (VBD were) (NP (NP (NNS decreases)) (PP (RP up) (TO to) (NP (NP (NP (CD 47) (NN %)) (CC and) (NP (CD 33) (NN %))) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2) (NNS levels))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS data)) (ADJP (RB presently) (JJ available))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NNS decreases)) (PP (IN in) (NP (NP (NP (DT some) (JJ individual) (NN drug1)) (CC and) (NP (NN drug2) (NN AUC) (NNS values))) (PP (IN with) (NP (NN drug3) (NN treatment)))))) (VP (VBP are) (ADVP (RB likely)) (NP (NP (DT the) (NN result)) (PP (IN of) (NP (JJ random) (NN variation))))))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (NP (EX there)) (VP (VBZ is) (NP (NN evidence) (SBAR (IN that) (S (NP (NN drug1)) (VP (MD can) (VP (VB inhibit) (NP (NP (DT the) (NN metabolism)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))))))))))) (, ,) (NP (EX there)) (VP (VBZ is) (NP (DT no) (NN evidence) (SBAR (IN that) (S (NP (NN drug4)) (VP (VBZ is) (NP (NP (DT a) (JJ net) (NN inducer)) (PP (IN of) (NP (NP (NN drug5)) (CC or) (NP (NN drug6) (NN metabolism))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN significance)) (PP (IN of) (NP (DT these) (NNS effects)))) (VP (VBZ is) (ADVP (RB presently)) (ADJP (JJ unknown)))) (. .)))
(S1 (S (NP (NNS Physicians)) (VP (MD should) (VP (VB be) (NP (NN aware)) (SBAR (IN that) (S (S (NP (NP (NN interaction) (NNS studies)) (PP (IN with) (NP (NP (NNS medications)) (ADJP (JJ other) (PP (IN than) (NP (NP (DT those)) (VP (VBN listed) (PP (IN in) (NP (NP (DT the) (NN &lt)) (: ;) (NP (DT a) (NN href=) (NN &quot)) (: ;) (NP (NN flucon_cp.htm) (NN #) (NN CP&quot)) (: ;) (NP (NN &gt)) (: ;) (NP (JJ CLINICAL) (NN PHARMACOLOGY) (NN section))))))))))) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN conducted))))) (, ,) (CC but) (S (NP (JJ such) (NNS interactions)) (VP (MD may) (VP (VB occur)))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN interaction)) (PP (IN of) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,))) (PP (IN with) (NP (JJ other) (NNS drugs)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB well)) (VP (VBN studied))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (: --) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (UCP (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NP (NN drug5)) (CC and) (NP (NN drug6)))))) (, ,))) (VP (MD may) (VP (VB cause) (NP (JJ bleeding) (NNS complications))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (JJ careful) (NN monitoring)) (VP (VBZ is) (ADJP (JJ advised)))) (. .)))
(S1 (S (S (PP (IN In) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ acute) (NNS MI))))) (, ,) (NP (NN drug1)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (RB not) (ADVP (RB otherwise)) (VBN contraindicated)))) (, ,) (VP (MD should) (VP (VB be) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (VP (VB see) (PP (IN below))) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (NP (NP (NP (NP (NN Anticoagulation)) (CC and) (NP (NN drug1))) (PP (IN After) (NP (NN Treatment))) (PP (IN for) (NP (JJ Myocardial) (NN Infarction)))) (: --) (S (PP (IN In) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (JJ acute) (JJ myocardial) (NN infarction))))) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN drug2)))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NP (NN reinfarction)) (CC and) (NP (NN stroke)))))))))))) (. .))))
(S1 (S (NP (NP (DT The) (NN addition)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NN drug2)))) (VP (VP (VBZ causes) (NP (NP (DT a) (JJ minimal) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NP (JJ minor) (JJ bleeding)) (PRN (-LRB- -LRB-) (NP (NP (CD 3.9) (NN %)) (CC vs.) (NP (CD 3.1) (NN %))) (-RRB- -RRB-)))))))) (, ,) (CC but) (VP (VBZ does) (RB not) (VP (VB appear) (S (VP (TO to) (VP (VB increase) (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (JJ major) (JJ bleeding)))) (PRN (-LRB- -LRB-) (NP (VB see)))))))))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN drug1)) (VP (VBZ is) (VP (VBN used) (PP (IN with) (NP (JJ other) (NN drug2))))))) (, ,) (NP (NP (NN potentiation)) (PP (IN of) (NP (JJ antihypertensive) (NN effect)))) (VP (MD may) (VP (VB occur)))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD should) (VP (VB be) (VP (VBN followed) (ADVP (RB carefully)) (S (VP (TO to) (VP (VB detect) (NP (NP (NP (JJ side) (NNS reactions)) (CC or) (NP (JJ unusual) (NNS manifestations))) (PP (IN of) (NP (NN drug) (NN idiosyncrasy))))))))))) (. .)))
(S1 (S (S (NP (NNS Patients)) (VP (MD may) (VP (VB require) (NP (NP (VBN reduced) (NNS doses)) (PP (IN of) (NP (NN drug1)))) (ADVP (WRB when)) (PP (IN on) (NP (NN drug2)))))) (. .)))
(S1 (S (S (SBAR (IN If) (S (NP (NN hypotension)) (VP (VBZ does) (VP (VB occur) (PP (IN during) (NP (NN anesthesia))))))) (, ,) (NP (PRP it)) (ADVP (RB usually)) (VP (MD can) (VP (VB be) (VP (VBN controlled) (PP (IN by) (NP (NN drug1))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ adrenergic) (NNS receptors)) (VP (VBP remain) (ADJP (JJ sensitive)) (PP (IN during) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug1))))))) (. .)))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (VP (VBP are) (VP (VBN given) (ADVP (RB concomitantly)))))) (NP (DT the) (NN patient)) (VP (MD should) (VP (VB be) (ADVP (RB carefully)) (VP (VBN monitored) (PP (IN for) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN drug3) (NN toxicity))))))))) (. .)))
(S1 (S (S (VP (VBN Read) (NP (NP (DT the) (JJ circular)) (PP (IN for) (NP (NN drug1) (NNS preparations)))))) (. .)))
(S1 (S (S (NP (JJ Several) (NNS studies)) (VP (VBP demonstrate) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (DT the) (NN bioavailability)) (PP (IN of) (NP (NN drug1)))))) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN ingested) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (ADVP (RB adversely)) (VP (VBP affect) (NP (NN blood) (NN pressure) (NN control)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBN treated) (PP (IN with) (NP (NN drug1))))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (CC or) (NP (NN drug3))))) (VP (VBZ is) (RB not) (VP (VBN recommended)))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (VP (VB See) (NP (NNS CONTRAINDICATIONS)))) (. .))))
(S1 (S (NP (JJ Drug/Laboratory) (NN Test) (NNS Interactions)) (ADVP (RB drug1)) (VP (MD may) (VP (VB interfere) (PP (IN with) (NP (NP (NN measurement)) (PP (IN of) (: :) (NP (NP (NP (JJ urinary) (JJ uric) (NN acid)) (PP (IN by) (NP (DT the) (NN phosphotungstate) (NN method)))) (, ,) (NP (NP (NN serum) (NN creatinine)) (PP (IN by) (NP (DT the) (NN alkaline) (NN picrate) (NN method)))) (, ,) (CC and) (NP (NP (NN SGOT)) (PP (IN by) (NP (JJ colorimetric) (NNS methods)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Interference)) (PP (IN with) (NP (JJ spectrophotometric) (NNS methods))) (PP (IN for) (NP (NN SGOT) (NN analysis)))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN reported))))) (. .)))
(S1 (S (S (SBAR (IN Since) (S (NP (NN drug1)) (VP (VBZ causes) (NP (NP (NN fluorescence)) (PP (IN in) (NP (NN urine) (NNS samples))) (PP (IN at) (NP (DT the) (JJ same) (NN wave) (NNS lengths)))) (PP (IN as) (NP (NNS catecholamines)))))) (, ,) (NP (NP (ADJP (RB falsely) (JJ high)) (NNS levels)) (PP (IN of) (NP (JJ urinary) (NNS catecholamines)))) (VP (MD may) (VP (VB be) (VP (VBN reported))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD will) (VP (VB interfere) (PP (IN with) (NP (NP (DT the) (NN diagnosis)) (PP (IN of) (NP (NN pheochromocytoma)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB recognize) (NP (DT this) (NN phenomenon)) (PP (IN before) (NP (NP (DT a) (NN patient)) (PP (IN with) (NP (NP (DT a) (JJ possible) (NN pheochromocytoma)) (VP (VBZ is) (VP (VBN subjected) (PP (TO to) (NP (NN surgery)))))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ does) (RB not) (VP (VB interfere) (PP (IN with) (NP (NP (NN measurement)) (PP (IN of) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-))) (, ,) (NP (NP (DT a) (NN test)) (PP (IN for) (NP (NN pheochromocytoma)))) (, ,))))) (PP (IN by) (NP (NP (DT those) (NNS methods)) (SBAR (WHNP (WDT which)) (S (VP (VBP convert) (NP (NN drug4)) (PP (TO to) (NP (NN drug5))))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN recommended) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN pheochromocytoma)))))))))) (. .)))
(S1 (S (S (ADVP (RB Rarely)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NN urine)) (VP (VBZ is) (VP (VBN exposed) (PP (TO to) (NP (NN air))) (PP (IN after) (NP (NN voiding))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB darken) (PP (IN because) (IN of) (NP (NP (NN breakdown)) (PP (IN of) (NP (NP (NN drug1)) (CC or) (NP (PRP$ its) (NNS metabolites))))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (VBN increased) (JJ systemic) (NN toxicity))) (SBAR (IN since) (S (NP (NNS drug4)) (VP (VBP inhibit) (NP (NP (DT the) (NN breakdown)) (PP (IN of) (NP (NN drug5)))))))))) (. .))))
(S1 (S (S (NP (NP (NN Antimyasthenics) (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug1)) (CC and) (NP (NN antimyasthenics))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NN loss)) (PP (IN of) (NP (NP (NN control)) (PP (IN of) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NP (JJ myasthenia) (NNS gravis)) (ADJP (JJ due) (PP (TO to) (NP (NP (NN antagonism)) (PP (IN of) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NNS antimyasthenics))) (PP (IN on) (NP (JJ skeletal) (NN muscle))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Temporary) (NN dosage) (NN adjustment)) (PP (IN of) (NP (NNS antimyasthenics)))) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (ADVP (RB Also)) (NP (NN antimyasthenics)) (VP (MD may) (VP (VB have) (NP (NN anticholinesterase) (NN activity))))) (. .)))
(S1 (S (NP (NP (JJ drug1) (NNS medications)) (: :) (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (JJ additive) (NN depressant) (NNS effects)))))) (. .))))
(S1 (S (S (NP (NP (NN drug1)) (: :) (NP (NN drug2))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NN diffusion) (NN rate)) (PP (IN of) (NP (NN drug3)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NP (DT a) (VBN decreased) (NN time)) (PP (IN of) (NP (NN onset)))) (, ,) (CC but) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (JJ systemic) (NN toxicity))))))))))) (. .)))
(S1 (S (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (CONJP (JJ such) (IN as)) (NP (NN drug2)) (-RRB- -RRB-))) (: :) (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN drug4))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NP (NN prolongation)) (CC or) (NP (NN enhancement))) (PP (IN of) (NP (DT the) (JJ neuromuscular) (NN blockade)))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (NP (DT the) (JJ antibacterial) (NN action)) (PP (IN of) (NP (DT the) (NN drug4)))))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (JJ Concurrent) (NN use)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN drug3))))) (VP (MD may) (VP (VB extend) (NP (NP (DT the) (NN plasma) (NN half-life)) (PP (IN of) (NP (NN drug4))))))) (. .))))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (NP (NNS Patients)) (PP (IN on) (NP (NN drug2)))) (, ,) (CONJP (CC and) (RB especially)) (NP (NP (DT those)) (VP (VBN started) (ADVP (RB recently)))) (, ,)) (VP (MD may) (ADVP (RB occasionally)) (VP (VBP experience) (NP (NP (DT an) (JJ excessive) (NN reduction)) (PP (IN of) (NP (NN blood) (NN pressure))) (PP (IN after) (NP (NP (NN initiation)) (PP (IN of) (NP (CD drug3) (NNS Tablets) (NN therapy))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (NN possibility)) (PP (IN of) (NP (JJ hypotensive) (NNS effects)))) (VP (MD can) (VP (VB be) (VP (VBN minimized) (PP (IN by) (S (VP (CC either) (VP (VBG discontinuing) (NP (DT the) (NN drug1))) (CC or) (VP (VBG increasing) (NP (NP (DT the) (NN salt) (NN intake)) (ADJP (JJ prior) (PP (TO to) (NP (NP (NN initiation)) (PP (IN of) (NP (NP (NN treatment)) (PP (IN with) (NP (NN drug2))))))))))))))))) (. .)))
(S1 (S (SBAR (IN If) (S (NP (NN drug1) (NNS cannot)) (VP (VB be) (VP (VBN interrupted))))) (, ,) (NP (JJ close) (JJ medical) (NN supervision)) (VP (VP (MD should) (VP (VB be) (VP (VBN provided) (PP (IN with) (NP (NP (DT the) (JJ first) (NN dose)) (PP (IN of) (NP (NN drug2) (NNS Tablets))))) (, ,) (PP (IN for) (NP (QP (IN at) (JJS least) (CD two)) (NNS hours)))))) (CC and) (PP (IN until) (NP (NN blood) (NN pressure))) (VP (VBZ has) (VP (VBN stabilized) (PP (IN for) (NP (DT another) (NN hour)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NN rate)) (CC and) (NP (NN extent))) (PP (IN of) (NP (NN drug1) (NP (NP (NN absorption)) (CC and) (NP (NN elimination)))))) (VP (VBP are) (RB not) (VP (VBN affected) (PP (IN by) (NP (JJ concomitant) (NN drug2)))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NN bioavailability)) (PP (IN of) (NP (NN drug1)))) (VP (VBD was) (VP (VBN reduced) (PP (IN by) (NP (NN drug2))) (, ,) (ADVP (RB however))))) (, ,) (CC and) (S (NP (DT this)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NN plasma) (NN ACE) (NN inhibition))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug1) (NNS Supplements)) (CC and) (NP (NN drug2) (: :) (NN drug3) (NNS Tablets))) (VP (MD may) (VP (VB increase) (NP (NN serum) (NN potassium)) (PP (IN because) (IN of) (NP (PRP$ its) (NN potential) (S (VP (TO to) (VP (VB decrease) (NP (NN aldosterone) (NN production)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (CC and) (NP (NNS others))) (-RRB- -RRB-))) (, ,) (NP (NN drug5) (NNS supplements)) (CC or) (NP (NP (JJ other) (NNS drugs)) (ADJP (JJ capable) (PP (IN of) (S (VP (VBG increasing) (NP (NP (NN serum) (NN potassium)) (PRN (-LRB- -LRB-) (NP (NP (NN drug6)) (, ,) (NP (NN drug7)) (, ,) (NP (NN drug8)) (CC and) (NP (NNS others))) (-RRB- -RRB-))))))))))) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN hyperkalemia))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (SBAR (IN if) (S (NP (NP (JJ concomitant) (NN use)) (PP (IN of) (NP (JJ such) (NNS agents)))) (VP (VBZ is) (VP (VBN indicated))))) (, ,) (S (NP (PRP they)) (VP (MD should) (VP (VB be) (VP (VBN given) (PP (IN with) (NP (NN caution))))))) (CC and) (S (NP (NP (DT the) (NN patient) (POS 's)) (NN serum) (NN potassium)) (VP (MD should) (VP (VB be) (VP (VBN monitored) (ADVP (RB frequently))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (NP (NP (VBN Increased) (NN serum) (NN drug2)) (CC and) (NP (NP (NNS symptoms)) (PP (IN of) (NP (NN drug3) (NN toxicity))))) (VP (VBP have) (VP (VBN been) (VP (VBN reported) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (JJ concomitant) (NN drug4) (CC and) (NN ACE) (NN inhibitor) (NN therapy))))))))) (. .))))
(S1 (S (S (S (NP (DT These) (NNS drugs)) (VP (MD should) (VP (VB be) (VP (VBN coadministered) (PP (IN with) (NP (NN caution))))))) (CC and) (S (NP (NP (JJ frequent) (NN monitoring)) (PP (IN of) (NP (NN serum) (NN drug1) (NN concentration)))) (VP (VBZ is) (VP (VBN recommended))))) (. .)))
(S1 (S (S (NP (NP (NN Use)) (PP (IN of) (NP (DT a) (NN drug1)))) (VP (MD may) (ADVP (RB further)) (VP (VB increase) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN toxicity))))))) (. .)))
(S1 (S (NP (NP (NN drug1)) (: :) (S (S (NP (DT A) (JJ controlled) (JJ pharmacokinetic) (NN study)) (VP (VBZ has) (VP (VBN shown) (NP (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (NN plasma) (NN drug2) (NNS concentrations)) (SBAR (WHADVP (WRB when)) (S (VP (VBN coadministered) (PP (IN with) (NP (NN drug3) (NNS Tablets)))))))))))) (, ,) (CC but) (S (NP (NP (DT an) (NN effect)) (PP (IN of) (NP (NN drug4))) (PP (IN on) (NP (NP (DT the) (NN plasma) (NN concentration)) (PP (IN of) (NP (NN drug5) (: /) (NN drug6)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN excluded)))))) (. .))))
(S1 (S (S (NP (NN drug1) (: :) (NN Animal) (NNS data)) (VP (VBP have) (VP (VBN suggested) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (NN interaction)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT this)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN investigated) (PP (IN in) (NP (JJ human) (NNS studies))))))) (. .)))
(S1 (S (S (NP (NP (NN Coadministration)) (PP (IN of) (NP (DT both) (NNS drugs)))) (VP (MD should) (VP (VB proceed) (PP (IN with) (NP (NN caution)))))) (. .)))
(S1 (S (NP (NP (NN Food) (NN Interaction)) (: :) (S (NP (NP (JJ Oral) (NN administration)) (PP (IN of) (NP (NN drug1) (NNS Tablets))) (PP (IN with) (NP (NN food)))) (VP (VBZ does) (RB not) (NP (NP (ADJP (RB significantly) (JJR lower)) (NP (DT the) (NP (NN rate)) (CC or) (NP (NN extent)))) (PP (IN of) (NP (NP (NN drug2) (NN absorption)) (ADJP (JJ relative) (PP (TO to) (NP (DT the) (JJ fasted) (NN state))))))))) (. .))))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (NN biotransformation)) (PP (IN of) (NP (NN drug1))) (PP (TO to) (NP (NP (DT the) (JJ active) (NN metabolite)) (, ,) (NP (NN drug2)) (, ,)))))) (VP (VBZ is) (VP (VBN reduced) (NP (NP (QP (RB approximately) (CD 43)) (NN %)) (, ,) (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT the) (NN plasma) (NN ACE) (NN inhibition) (NN curve)) (PP (IN of) (NP (QP (RB approximately) (CD 20)) (NN %))))))) (, ,) (ADVP (RB probably)) (ADJP (RB clinically) (JJ insignificant))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (JJ clinical) (NNS trials))) (, ,) (NP (NN drug1)) (VP (VBD was) (ADVP (RB generally)) (VP (VBN administered) (PP (IN in) (NP (DT a) (JJ non-fasting) (NN state)))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VP (MD can) (VP (VB interact) (PP (IN with) (NP (NP (NP (DT the) (NNS drugs)) (PP (IN of) (NP (DT the) (JJ following) (NNS categories))) (: :)) (: -) (NP (NP (NP (NN Blood) (NN dyscrasia)) (: :) (S (VP (MD can) (VP (VB cause) (NP (JJ unpredictable) (NN myelotoxicity))))) (: -) (NP (NN Bone) (NN marrow) (NNS depressants)) (: :) (S (VP (MD can) (VP (VB cause) (NP (DT a) (JJ predictable) (JJ dose-related) (NN myelotoxicity))))) (: -) (NP (NN Radiation) (NN therapy)) (: :) (S (VP (MD may) (VP (VB cause) (NP (NN marrow) (NN depression))))) (: -) (NP (JJ Neurotoxic) (NNS medications)) (: :) (S (VP (MD can) (VP (VB cause) (NP (JJ neurologic) (NN toxicity))))) (: -) (NP (NN drug2)) (: :) (VP (MD can) (VP (VB increase) (NP (JJ seizure) (NN activity))))) (: -) (NP (NN drug3))))))) (: :) (VP (MD may) (VP (VB potentiate) (NP (DT the) (NN replication)) (PP (IN of) (NP (DT the) (NN drug4) (NN virus))))) (, ,) (VP (MD may) (VP (VB increase) (NP (DT the) (JJ side) (NNS effects)) (PP (IN of) (NP (DT the) (NN vaccination))))) (, ,) (CC and) (VP (VB decrease) (NP (NP (NN patient) (POS 's) (NN response)) (PP (TO to) (NP (DT the) (NN vaccine))))))) (: -) (S (NP (NP (NN drug5)) (: :) (S (VP (MD may) (VP (VB cause) (NP (NN shortness)) (PP (IN of) (NP (NP (NN breath)) (CC and) (NP (NN bronchospasm))))))) (: -) (NP (NN drug6)) (: :)) (VP (MD may) (VP (VB decrease) (NP (NN patient) (POS 's) (NN response)) (PP (TO to) (NP (DT the) (NN drug7))))))))
(S1 (S (S (NP (NN drug1)) (VP (VBZ inhibits) (NP (NP (NP (DT some)) (PP (IN of) (NP (DT the) (NN liver) (POS 's) (NN ability) (S (VP (TO to) (VP (VB metabolize) (NP (DT some) (JJ other) (NNS drugs)))))))) (: -) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (CC and) (NP (NN drug6)))))) (. .)))
(S1 (S (S (S (ADVP (RB Thus)) (NP (NP (DT the) (NNS concentrations)) (PP (IN of) (NP (DT these) (NNS drugs)))) (VP (MD would) (VP (VB increase) (NP (NN meaning))))) (S (NP (JJ side) (NNS effects)) (VP (MD may) (VP (VB be) (VP (VBN seen)))))) (. .)))
(S1 (S (S (NP (DT A) (NN dose) (NN adjustment)) (VP (MD may) (VP (VB be) (VP (VBN required))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ concomitant) (NN use)) (PP (IN of) (NP (NN drug1))) (PP (PP (IN with) (NP (JJ other) (NN drug2))) (CC or) (PP (IN with) (NP (NP (JJ other) (NNS agents)) (SBAR (WHNP (WDT which)) (S (VP (VBP produce) (NP (JJ dry) (NP (NP (NN mouth)) (, ,) (NP (NN constipation)) (, ,) (NP (NP (NN somnolence)) (PRN (-LRB- -LRB-) (NP (NN drowsiness)) (-RRB- -RRB-))) (, ,) (CC and/or) (NP (JJ other) (JJ anticholinergic-like) (NNS effects))))))))))) (VP (MD may) (VP (VB increase) (NP (NP (DT the) (NP (NN frequency)) (CC and/or) (NP (NN severity))) (PP (IN of) (NP (JJ such) (NNS effects))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (MD may) (ADVP (RB potentially)) (VP (VB alter) (NP (NP (DT the) (NN absorption)) (PP (IN of) (NP (NP (DT some) (ADJP (RB concomitantly) (VBN administered)) (NNS drugs)) (ADJP (JJ due) (PP (TO to) (NP (NP (JJ anticholinergic) (NNS effects)) (PP (IN on) (NP (JJ gastrointestinal) (NN motility)))))))))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (MD may) (VP (VB be) (PP (IN of) (NP (NN concern))) (PP (IN for) (NP (NP (NNS drugs)) (PP (IN with) (NP (DT a) (JJ narrow) (JJ therapeutic) (NN index)))))))) (. .)))
(S1 (S (S (NP (JJ Mean) (NN drug1) (NN plasma) (NNS concentrations)) (VP (VBD were) (ADJP (NP (QP (RB approximately) (CD 2)) (NN fold)) (JJR higher)) (SBAR (WHADVP (WRB when)) (S (NP (NN drug2)) (VP (VBD was) (VP (VBN administered) (PP (IN with) (NP (NP (NN drug3)) (, ,) (NP (DT a) (JJ potent) (NN CYP3A4) (NN inhibitor)))))))))) (. .)))
(S1 (S (NP (NP (JJ Other) (NNS inhibitors)) (PP (IN of) (NP (DT the) (NP (NN cytochrome) (NN P450) (NN 3A4)) (NN enzyme) (NN system))) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug2)) (CC and) (NP (NN drug3)))) (-RRB- -RRB-))) (CC or) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NN drug5)) (CC and) (NP (NN drug6)))) (-RRB- -RRB-))))) (, ,)) (VP (MD may) (VP (VB alter) (NP (NP (NN drug7) (NN mean) (JJ pharmacokinetic) (NNS parameters)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (, ,) (NP (NP (NN Cmax)) (CC and) (NP (NN AUC))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ clinical) (NN relevance)) (PP (IN of) (NP (JJ such) (JJ potential) (NNS interactions)))) (VP (VBZ is) (RB not) (VP (VBN known)))) (. .)))
(S1 (S (S (NP (NN Caution)) (VP (MD should) (VP (VB be) (VP (VBN used))) (SBAR (WHADVP (WRB when)) (S (NP (JJ such) (NNS drugs)) (VP (VBP are) (NP (NN co-administered))))))) (. .)))
(S1 (S (S (NP (NP (JJ Concurrent) (NN ingestion)) (PP (IN of) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NP (CD 20) (NN mL)) (PP (IN of) (NP (NP (NNS drug2)) (VP (VBG containing) (NP (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN drug5))))))) (-RRB- -RRB-))))) (VP (VBD did) (RB not) (ADVP (RB significantly)) (VP (VB affect) (NP (NP (DT the) (NN exposure)) (PP (IN of) (NP (NP (NN drug6)) (CC or) (NP (NN drug7)))))))) (. .)))
